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In the following dissertation I examine two of my primary studies that highlight the 
importance of opioid balance in itch and pain. In particular, these two studies focus on neurons 
that participate in kappa-opioid receptor signaling. In Part I, I describe the role of dynorphin 
spinal cord neurons in the modulation of itch. In Part II, I focus on neurons in the brainstem 
containing the kappa-opioid receptor and their role in the modulation of itch and pain. 
In Part I, I discuss the role of neurons in the spinal cord that participate in kappa signaling 
that are modulated by mu agonists such as morphine. For this study, we used animal models and 
found that neuraxial morphine causes itch through spinal neurons and not mast cells. In 
particular, we found that spinal dynorphin (Pdyn) neurons are both necessary and sufficient for 
morphine-induced itch in mice. Agonism of the kappa-opioid receptor alleviated morphine-
induced itch in mice and nonhuman primates. Thus, our work revealed that morphine causes itch 
through a mechanism of disinhibition of a kappa-sensitive pathway within the spinal cord. This 
mechanism, in which a mu agonist reduces the impact of endogenous dynorphin, is illustrative of 
the delicate balance between mu and kappa tone that, when accidentally disrupted, elicits 
abnormal itch sensations. 
In Part II, I describe a cellular circuit involving brainstem neurons containing the kappa-
opioid receptor that inhibits pain and itch in mice. Using a combination of molecular, tracing, 
and behavioral approaches, we found that spinally-projecting neurons in the medulla containing 
the kappa-opioid receptor inhibit itch and pain. With chemogenetic inhibition, we determined 
v 
that these neurons are required for stress-induced analgesia. Furthermore, we found a 
dynorphinergic pathway arising from the midbrain that modulates nociception within the 
medulla. These discoveries highlight the role of kappa signaling in the brainstem modulate itch 
and pain. 
Thus, both investigations, centered in the brainstem and in the spinal cord, emphasize the 
importance the balance between endogenous opioids in normal somatosensory functions. 
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This dissertation covers two major projects that I have worked on as a student. In my 
eyes, they have both challenged me and are equally interesting. Having divided my time across 
both projects throughout the duration of my studies, I believe it is worthwhile to dedicate space 
for them both in this dissertation. Initially, I viewed these two projects, one focused on a 
brainstem structure, the other on a specific population of spinal neurons, as distinct and separate 
questions. However, I now appreciate their similarities and how they both harmonize the idea 
that opioid homeostasis is integral to normal somatosensory functions. In both the brainstem and 
in the spinal cord, an imbalance between opioid signaling can engender itch pathology. The 
neuronal underpinnings of these disorders have formed the basis of my investigations. Together, 
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1.0 Introduction to morphine-induced itch 
Opioids have been used to control pain for millennia. Today, they are used for numerous 
types of pain, including acute, chronic, pre-, peri-, and post- operative, and cancer pain. 
Unfortunately, the use of opioids is not without side effects. These side effects range from 
debilitating, such as constipation and nausea, to deadly, such as sedation and respiratory 
depression (Colvin, Bull, and Hales 2019; Els et al. 2017; Baldini, Von Korff, and Lin 2012; 
Dahan et al. 2004; Dahan, Aarts, and Smith 2010). Additionally, opioid medications are 
extremely addictive and have contributed to the world-wide opioid epidemic (Alam and Juurlink 
2016). Thus, clinical efforts to reduce the use and abuse of these drugs have spurred research into 
alternative treatments and well as alternative routes for the administration of opioid drugs (E. C. 
Sun et al. 2016; Mudumbai et al. 2016). 
One attempt to circumvent these adverse side effects has been the neuraxial (epidural and 
intrathecal) route of administration of opioids. The neuraxial route of administration is often 
preferred due to a decreased risk of constipation, nausea, respiratory depression, and dependence 
(de Leon-Casasola, Karabella, and Lema 1996; C. L. Wu et al. 2004; Niiyama et al. 2005; 
Bujedo 2012; Bujedo 2014). Moreover, because a catheter can be placed directly into the 
neuraxis, a smaller dose of opioid analgesics can be used for rapid and effective pain 
management (Fassoulaki et al. 2004; Chadwick and Ready 1988; Chestnut 2005). Compared 
with parenteral opioid administration, such as through an intravenous (IV), intramuscular (IM), 
or subcutaneous (SC) route, the intrathecal (IT) route of administration uses a fraction of the 
dose required due to its improved bioavailability (Stevens and Ghazi 2000).  
2 
1.1 Clinical indications for neuraxial opioid drug use 
Neuraxial opioids are frequently administered for abdominal and lower extremity 
surgeries (Sarma and Boström 1993; Fassoulaki et al. 2004; Dualé et al. 2003; Chadwick and 
Ready 1988; Grant and Checketts 2008). For these procedures, the use of neuraxial analgesia, 
rather than parenteral analgesia, has been associated with improved postoperative outcomes such 
decreased length of hospital stay and reduced need for parenteral opioids postoperatively (de 
Leon-Casasola, Karabella, and Lema 1996; Jørgensen et al. 2000; Chestnut 2005). 
1.2 Epidemiology and burden of opioid-induced pruritus 
Although neuraxial opioids are frequently used in acute perioperative pain, they also have 
side effects. These side effects include pruritus (Ballantyne, Loach, and Carr 1988; Szarvas, 
Harmon, and Murphy 2003; Kumar and Singh 2013; Ganesh and Maxwell 2007), nausea (25%), 
sedation (17%), urinary retention (19%), and, very rarely, respiratory depression (3%) 
(Yurashevich and Habib 2019; Chestnut 2005; Mugabure Bujedo 2012). Although pruritus is 
occasionally observed with parenteral opioid use (Tarcatu et al. 2007; Jannuzzi 2016), it is an 
extremely common side effect of neuraxial opioids, with an incidence ranging from 30-85%, 
depending on the dose and lipophilicity of the opioid administered (Kumar and Singh 2013; Yeh 
et al. 2000; Shah, Sia, and Chong 2000). Dose-response relationships between spinal morphine, 
analgesic duration, and pruritus have indicated that escalating doses of morphine improve 
analgesia, but are correlated with higher incidences and severity of pruritus (Jiang et al. 1991; 
Sultan et al. 2016). This relationship suggests that the duration of analgesia of neuraxial 
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morphine can be improved with increased doses, but must be weighed against increasing side 
effects. 
Due to the widespread use of neuraxial opioids in the childbirth setting, opioid-induced 
pruritus is most frequently observed among obstetric patients (Tubog et al. 2018; Wells, Paech, 
and Evans 2004; Yurashevich and Habib 2019; S Charuluxananan et al. 2000) (Table 1), where it 
has an incidence of up to 85% (Yeh et al. 2000), and is primarily dose-dependent (Jiang et al. 
1991; Sultan et al. 2016). Pruritus is also frequently reported among orthopedic patients 
receiving neuraxial opioids (30-70%) (Kaye et al. 2019; Szarvas et al. 2003) for enhanced 
recovery after surgery (ERAS). The incidence of pruritus in patients receiving neuraxial 
morphine is more common among female patients (60-85%) (Tubog et al. 2018; Wells, Paech, 
and Evans 2004; Yurashevich and Habib 2019; Charuluxananan et al. 2000), which mirrors the 
incidence and burden of chronic pain that also disproportionately affects women. Differences in 
estrous cycle, which could affect the sensitivity of the mu-opioid receptor to opioid drugs 
(LaBella, Kim, and Templeton 1978), have been proposed to underlie these differences, yet the 
extent to which non-biological factors could also contribute to disparities in experiences of 
pruritus warrants further investigation.  
In contrast to the high frequency of neuraxial opioid-induced itch, parenteral opioid-
induced pruritus occurs in less than 10% of patients on long-term opioid therapy, such as patients 
receiving intravenous (IV) morphine for vaso-occlusive crisis in sickle cell disease (Krajnik and 
Zylicz 2001; Werawatganon and Charuluxanun 2005). Unlike neuraxial opioid-induced pruritus, 
which is observed following a single dose of opioids, parenteral opioid-induced pruritus is 
mostly observed among patient populations on chronic opioid use (Werawatganon and 
Charuluxanun 2005; Hong, Flood, and Diaz 2008). In addition to patients with sickle cell 
4 
disease, these groups include individuals who chronically take oral and parenteral opioids for 
pain, such as cancer patients and those with opioid dependence (Galloway and Yaster 2000; 
Watcha and White 1992; Koch et al. 2008). 
Among patients on continuous morphine infusion during vaso-occlusive crises in sickle 
cell disease, pruritus was the most common reason for switching medications to another opioid 
class: for example, from morphine to a semi-synthetic opioid such as hydromorphone (DiGiusto 
et al. 2014) In these settings, the development of pruritus may be associated with central 
sensitization to opioids that may occur independently of tolerance to opioid-induced analgesia 
(Schmelz and Paus 2007). Proposed mechanisms include sensitization of itch-responsive circuits 
within the spinal dorsal horn following chronic use (Ikoma et al. 2006). In particular, central, but 
not peripheral, mu-opioid receptors have recently been implicated in modulation of dermatitis 
and lymphoma-induced chronic itch (Wang et al. 2021). Further research is necessary to 
elucidate the contribution of these central pathways to chronic opioid-induced pruritus. Thus, 
while pruritus is most common following neuraxial opioid administration, it also poses a 
troublesome side effect for a small number of patients, such as those with sickle cell disease on 
parenteral opioids.  
Polymorphisms of OPRM1 on opioid-induced analgesia and pruritus 
Sequencing of the OPRM1 gene, which encodes the mu-opioid receptor, indicates that 
certain polymorphisms may be associated with protection against the side effect of pruritus (Tsai 
et al. 2010; Pettini et al. 2018). For example, genetic association studies have focused on the 
A118G polymorphism of OPRM1 (Tsai et al. 2010; Pettini et al. 2018). The recessive G allele in 
this polymorphism is associated with lower incidences of pruritus among obstetric patients 
receiving epidural (4.8%) and spinal (0-50%) morphine (Tsai et al. 2010; Pettini et al. 2018). 
5 
This variant is further associated with reduced sensitivity to the analgesic effects of opioids (Sia 
et al. 2008), suggesting that the A118G polymorphism may give rise to a mu-opioid receptor that 
is generally less responsive to opioid medications. However, given the heterogeneity among 
clinical populations receiving opioid analgesia and their self-reported experiences for both pain 
and itch, many of these studies are underpowered to provide definitive conclusions about these 
polymorphism relationships (Wong et al. 2010; Kung et al. 2018). In mice, distinct splice 
variants of the mu-opioid receptor, MOR1D and MOR1, have been shown to differentially 
modulate morphine-induced itch and morphine-induced analgesia, respectively (Liu et al. 2011). 
However, the contributions of these splice variants have not been characterized in humans. 
Additional large population genetic association studies are necessary to further assess the clinical 
significance and utility of identifying genetic variations on acute postoperative pain management 
and risk for opioid-related side effects. 
Differences in opioid medications and pruritus 
Opioid-induced pruritus is observed following the use of intrathecally administered 
hydrophilic opioids (such as morphine) and lipophilic opioids (such as fentanyl and sufentanil) 
(Mulroy, Larkin, and Siddiqui 2001; Gulhas et al. 2007). The high incidence of pruritus 
following morphine (60-85%) (Waxler et al. 2005; Jannuzzi 2016; Ganesh and Maxwell 2007; 
Szarvas, Harmon, and Murphy 2003; Ballantyne, Loach, and Carr 1988) and lipophilic opioids 
(60-90%) (Mulroy, Larkin, and Siddiqui 2001; Gulhas et al. 2007) suggests a common mu-
sensitive pathway modulates pruritus in response to these medications (Table 1). However, a key 
difference between these two classes of opioid drugs is the onset of pruritus; pruritus occurs 
within hours up to several days in patients receiving epidural and spinal morphine (Slappendel et 
al. 2000; Waxler et al. 2005), whereas with lipid-soluble opioids, the onset of pruritus can occur 
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as rapidly as within minutes of administration (Gulhas et al. 2007; Wells, Paech, and Evans 
2004). These differences reflect the pharmacokinetics of these intrathecally-administered opioid 
medications; microdialysis studies in pigs (Ummenhofer et al. 2000) (using equimolar doses of 
morphine, fentanyl, and sufentanil) have revealed that spinal exposure to morphine was greater 
than lipophilic opioids due to its low spinal cord distribution volume and slow clearance into the 
plasma. Fentanyl and sufentanil were found to rapidly clear into the plasma and epidural fat, 
respectively, reducing their spinal bioavailability (Ummenhofer et al. 2000). In a clinical study 
examining the clearance of opioid medications from the CSF, volunteers receiving an intrathecal 
injection of both morphine and fentanyl (50 μg each), the ratio of morphine to fentanyl in the 
CSF increased over time (reaching 4:1 within two hours) (Eisenach et al. 2003). These 
differences support the suitability of neuraxial morphine for acute postoperative pain, such as for 
ERAS (Tang et al. 2020) and in obstetric settings (Sutton and Carvalho 2017), due to its superior 
bioavailability, but its long elimination time must be considered against its delayed adverse 
effects, such as pruritus.  
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dependent) (Ennis et 
al. 1991; Philbin et al. 
1982; Baldo and 
Pham 2012) 
Neuraxial 
Morphine (1.5-5 mg epidural; 50-
200 μg IT) 
60-85% (Waxler et 
al. 2005; Jannuzzi 
2016; Ganesh and 
Maxwell 2007; 
Szarvas, Harmon, 
and Murphy 2003; 
Ballantyne, Loach, 
and Carr 1988) 
Hours to days 
(Slappendel et 
al. 2000; 
Waxler et al. 
2005) 
Central/spinal 
(Kumar and Singh 
2013; Wang et al. 
2021; Nguyen et al. 
2021) 
Neuraxial 
Lipid-soluble (fentanyl and 
sufentanil) (20-100 μg epidural; 




Gulhas et al. 2007) 
Rapid (within 
minutes to 4 
hours) (Gulhas 





(Kumar and Singh 
2013; Wang et al. 
2021; Nguyen et al. 
2021) 
1.3 Mechanisms for opioid-induced pruritus 
1.3.1 Role of mast cells 
It has been proposed that release of histamine underlies opioid-induced pruritus 
(Galloway and Yaster 2000), although route of administration might lead to differential impact 
of mast cells on pruritus (Figure 1). Intramuscular and subcutaneous morphine have been shown 
to evoke pruritus and vasodilation at the injection site (Melo et al. 2018). One study that 
performed in vivo microdialysis in human skin found that intradermal injections of morphine led 
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to dose-dependent increases in local histamine and itch sensations (Blunk et al. 2004). Similarly, 
examination of blood samples from patients with parenteral exposure to opioids has also 
revealed an elevation in histamine levels (Ennis et al. 1991; Philbin et al. 1982; Baldo and Pham 
2012). Lastly, in vitro studies in both human and rodent models have confirmed that opioids, 
such as morphine, act directly on mast cells to drive degranulation and histamine release (Lansu 
et al. 2017; Grosman 1981; Hermens et al. 1985). 
 
 
Figure 1. Proposed mechanisms of opioid-induced pruritus.  
Mechanisms by which opioids could drive pruritus in the skin, dorsal root ganglia (DRG), and spinal cord dorsal 
horn. In the skin, systemic opioids can cause mast cell degranulation through activation of Mas-Related G Protein-
Coupled Receptor-X2 (MRGPRX2) on mast cells. Neuraxial opioids are proposed to drive itch through spinal 
neurons containing the mu-opioid receptor (MOR) in the spinal cord dorsal horn. 
 
 
Only recently, however, has it become clear how opioids could directly activate mast cells. 
Morphine was recently found to induce mast cell degranulation through activation of mas-related 
G protein-coupled receptor X2 (MRGPRX2), a primate-exclusive G protein-coupled receptor 
(GPCR), rather than canonical opioid receptors (such as the mu-opioid receptor) (Lansu et al. 
2017). Binding of opioids to MRGPRX2 leads to increases in intracellular calcium in mast cells 
9 
(Lansu et al. 2017). This is thought to occur through the phospholipase C-beta pathway, which 
results in the release of mediators, such as histamine (Porebski et al. 2018) MRGPRX2 is 
implicated in itch and pain (Meixiong et al. 2019), and the restricted expression of MRGPRX2 on 
mast cells, which can be activated in the absence of atopy (Porebski et al. 2018), such as by direct 
binding of opioids (Lansu et al. 2017), establishes a mechanism for how opioids can directly act 
on mast cells to give rise to pruritus (Figure 2). The expression of MRGPRX2 on mast cells may 
also underlie anaphylaxis following opioid administration, which comprised 2.6% of all cases of 
anaphylaxis due to anesthetics (Laxenaire et al. 1990). For these reasons, MRGPRX2 should be 
considered a target for IgE-independent allergic reactions to perioperative drugs such as morphine 
administered subcutaneously and intravenously. 
However, for neuraxial opioids, the evidence that a mast cell-dependent mechanism 
underlies pruritus is less compelling. In humans, the neuraxial administration of fentanyl, a 
lipophilic and synthetic opioid, evokes pruritus even though fentanyl does not cause mast cell 
degranulation and histamine release as morphine does (Rosow et al. 1982; Hermens et al. 1985; 
Warner et al. 1991; Flacke et al. 1987). Furthermore, clinical plasma concentrations of morphine 
are orders of magnitude smaller than CSF concentrations following neuraxial morphine 
administration (<0.01%) (Sjöström et al. 1987; Bernards et al. 2003) and the concentration of 
morphine detected in the plasma is likely insufficient to cause mast cell degranulation, as 
suggested by in vitro studies (Figure 2) (Lansu et al. 2017; Grosman 1981; Hermens et al. 1985). 
Mast cell-mediated pruritus following the local injection of opioids, as seen following 
intradermal injections of morphine, is restricted to the site of injection (Blunk et al. 2004), and 
does not explain how neuraxial opioids, frequently administered into lumbar segments, evoke 
pruritus in other dermatomes, including those innervating facial regions (Ballantyne, Loach, and 
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Carr 1988; Szarvas, Harmon, and Murphy 2003; Ganesh and Maxwell 2007). Lastly, genetically 
modified mice lacking mast cells scratch at levels similar to controls in response to intrathecal 
morphine (Nguyen et al. 2021). Therefore, a mast cell-dependent mechanism does not explain 
the prevalence and spread of neuraxial opioid-induced pruritus.  
Taken together, although there is evidence that histamine release from mast cells may 
cause itch from peripheral (subcutaneous, oral, and intravenous) opioids, this process is unlikely 
to contribute to neuraxial opioid-induced pruritus. 
 
 
Figure 2. Systemic and neuraxial opioid-induced pruritus are separately modulated. 
Systemic (oral, subcutaneous, and parenteral) morphine may drive pruritus through the engagement of Mas-Related 
G Protein-Coupled Receptor-X2 (MRGPRX2) on mast cells. Neuraxial (epidural and intrathecal) opioid-induced 
pruritus, on the other hand, is likely driven by spinal neurons containing the mu-opioid receptor (MOR) because less 
than 0.01% of the peak concentration detected in the CSF is detected in the plasma following neuraxial opioid 
administration. 
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1.3.2 Central mechanisms of opioid-induced pruritus 
With neuraxial morphine-morphine induced itch, it has been proposed that the nervous 
system could be responsible for mediating the sensation of itch through the binding of opioids to 
the mu opioid receptor (Ko 2015; Kumar and Singh 2013) (Figure 2). The analgesic benefits of 
opioids are mediated through the nervous system (Pathan and Williams 2012; Pan, Hirakawa, 
and Fields 2000); therefore, it is plausible that pruritus, the unwanted sensory symptom, may 
also be neuronally-mediated. To add, although both intrathecal and epidural opioids cause 
pruritus (Ballantyne, Loach, and Carr 1988; Szarvas, Harmon, and Murphy 2003), pruritus 
occurs much more commonly with the intrathecal route of administration (Simmons et al. 2012). 
This observation suggests that the pruritus occurs due to a direct effect of the opioid within the 
neuraxis. 
Further evidence for a neuronal mechanism is the clinical observation that opioid 
lipophilicity is associated with the onset of pruritus among patients. For example, lipophilic 
opioids such as fentanyl, which more readily cross the blood brain barrier, are associated with a 
more rapid onset and shorter duration of pruritus than hydrophobic opioids such as morphine 
(Asokumar et al. 1998; Wells, Paech, and Evans 2004; Shah, Sia, and Chong 2000; Kumar and 
Singh 2013), consistent with a neural mechanism of action. These clinical observations further 
support the idea that two separate mechanisms underlie opioid-induced pruritus from different 
routes of administration. 
1.3.2.1 Opioid-induced pruritus mediated by primary afferents 
Primary sensory neurons respond directly to itch-inducing agents. For example, a class of 
TRPV1-containing C-fibers that innervate the skin expresses the histamine receptor (H1R), 
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which can be activated by histamine (Shim and Oh 2008; Davidson and Giesler 2010). Upon 
activation with histamine, these neurons transmit pruriceptive information to the superficial 
layers of the spinal cord and this information ascends through the spinothalamic tracts to target 
the primary sensory and cingulate cortices (Schmelz et al. 1997). Thus, if opioid-induced pruritus 
causes the release of histamine, then peripheral opioid-induced itch may occur through this 
pathway (Figure 1). Consistent with this view, intradermal injection of the mu-opioid receptor 
agonist, DAMGO, elicits itch in mice that is abrogated with the ablation of TRPV1-expressing 
fibers (Melo et al. 2018). Furthermore, the administration of capsaicin, a TRPV1 agonist, 
reduced scratching in response to intradermal DAMGO, but this was not observed following 
agonism of TRPA1, another channel expressed by primary afferents that has been implicated in 
acute and chronic itch (Melo et al. 2018; Wilson et al. 2013, 2011). These findings suggest that 
for subcutaneous, oral, and intravenous opioids, itch likely occurs through TRPV1 sensory 
neurons following the release of histamine from mast cells (Ennis et al. 1991; Philbin et al. 1982; 
Baldo and Pham 2012). However, given the weak association between neuraxial opioids and 
histamine release in the systemic circulation (Rosow et al. 1982; Hermens et al. 1985; Warner et 
al. 1991; Flacke et al. 1987), H1R-expressing sensory neurons are not likely to be involved in 
neuraxial opioid-induced pruritus. 
Presently, neuraxial opioids are not believed to act directly on mu-opioid receptor 
expressing sensory neurons to elicit itch. Conditional deletion of the mu-opioid receptor from 
TRPV1 and somatostatin neurons, which have been implicated in itch signaling, did not affect 
intrathecal morphine-induced itch in mice (Wang et al. 2021). In support of this view, other 
studies have suggested that rather than direct modulation of these peripheral sensory neurons, 
neuraxial opioids may influence pruriceptive processing centrally. One study, performed in rats, 
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identified that neuraxial morphine augmented the activity in trigeminothalamic tract neurons in 
response to itch stimuli (Moser and Giesler 2013). Trigeminothalamic tract neurons are 
analogous to spinothalamic tract neurons in the spinal cord, but relay information pertaining to 
the head and neck regions rather than the body. It was found that intrathecal morphine caused 
these neurons to increase their ongoing activity to pruritogens applied to the skin (Moser and 
Giesler 2013). Intrathecal morphine also enhanced responses to innocuous mechanical stimuli, 
suggesting that opioids may also cause sensitization to touch-evoked itch (Moser and Giesler 
2013). Another study in mice also examined the role of TRPV1 antagonists and neuraxial 
morphine-induced itch (Sakakibara et al. 2019). In this study, it was observed that the intrathecal 
delivery of a TRPV1 antagonist reduced morphine-induced itch in mice. Together, these studies 
suggest that neuraxial morphine can evoke sensitization of central pathways, leading to an 
enhancement of responsiveness within these circuits to peripheral stimulation. 
1.3.2.2 Opioid pharmacology as a key to understanding spinal circuitry 
It is curious that opioids suppress pain, but evoke itch. Conversely, intense pain can also 
suppress itch (Liu and Ji 2013; Graham, Goodell, and Wolff 1951). Previously, it was believed 
that itch occurs due to a reduction in pain signaling (Ikoma et al. 2006). However, detailed 
pharmacological investigations have largely ruled out this theory (Ko and Naughton 2000; Liu et 
al. 2011). Several studies have shown that mu-opioid agonists, such as morphine, elicit itch, but 
delta- and kappa-opioid receptor agonists, which also produce analgesia (Woolf 2009), do not 
cause scratching behavior (Ko 2015; Ko et al. 2003; Ko and Naughton 2000). Instead, selective 
kappa-opioid receptor agonists have been shown to suppress itch in preclinical models (Kamei 
and Nagase 2001; Ko and Husbands 2009; Kardon et al. 2014) and have been approved to treat 
chronic pruritus in Japan (Cowan, Kehner, and Inan 2015). Notably, mu and kappa-opioid 
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receptors often exert opposing effects in several regions of the central nervous system; whereas 
mu-opioid receptor agonists produce analgesia, euphoria, and itch, kappa-opioid receptor 
agonists are anti-pruritic and dysphoric (Pfeiffer et al. 1986; Pan 1998). Clearly, a simple model 
whereby a suppression of pain is sufficient to evoke itch does not explain these observations. The 
differential roles of these opioid receptors and their agonism in the context of itch underscores 
that opioid-induced pruritus is a complex and active process. 
1.3.2.3 Neuronal disinhibition underlies neuraxial opioid-induced itch 
The mechanisms of opioid-induced itch at the level of the dorsal horn have only recently 
begun to be examined. One study in mice suggested that neuraxial morphine causes itch through 
activation of gastrin-releasing peptide receptor (GRPR) neurons in the dorsal horn (Liu et al. 
2011), an excitatory population that is involved in mediating itch (Sun and Chen 2007; Pagani et 
al. 2019) (Figure 3).  This study suggested that neuraxial morphine could induce 
heterodimerization of the mu-opioid receptor (MOR) with GRPR, activating the PLCβ3 and 
IP3R3 pathway, resulting in itch (Liu et al. 2011). However, recent sequencing (Sathyamurthy et 
al. 2018; Häring et al. 2018) and neurochemical studies (Wang et al. 2020) cast doubt on this 
possibility and, mechanistically, binding of morphine to the mu opioid receptor causes 
hyperpolarization, rather than activation, of neurons (Al-Hasani and Bruchas 2011; Torrecilla et 
al. 2008). Thus, the notion that opioids cause itch through heterodimerization of MOR and 




Figure 3. Mechanisms of action of proposed therapies for neuraxial opioid-induced pruritus. 
Antagonists (naloxone) of the mu-opioid receptor (MOR) are proposed to act on MOR-expressing inhibitory 
neurons to relieve pruritus. Propofol may potentiate the inhibitory action of these inhibitory neurons to suppress itch. 
Mixed antagonist-agonists (nalbuphine and butorphanol) inhibit itch through antagonism of MOR and agonism of 
the kappa-opioid receptor (KOR). Dopamine and serotonin receptor antagonists (droperidol and ondansetron, 
respectively) are thought to exert their action on spinal neurons, although this has not been tested directly.  
 
 
Alternatively, molecularly defined inhibitory neurons have been implicated in the 
modulation of itch. For example, inhibitory neurons containing dynorphin (Pdyn) and 
neuropeptide Y (Npy) have been shown to be important for the inhibition of chemical (Kardon et 
al. 2014; Ross et al. 2010; Huang et al. 2018) and mechanical itch (Acton et al. 2019; Bourane et 
al. 2015), respectively. When either Pdyn neurons or Npy neurons are lost during development, 
mice show spontaneous scratching behavior suggesting that these populations are involved in the 
tonic inhibition of itch (Ross et al. 2010; Bourane et al. 2015; Kardon et al. 2014; Huang et al. 
2018; Acton et al. 2019). In a recent study, selective removal of the mu-opioid receptor from 
inhibitory neurons (neurons that produce GABA, gamma-amino butyric acid) abolished opioid-
induced itch in a mouse model (Wang et al. 2021). A second study focused on a subset of 
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inhibitory neurons containing dynorphin, the endogenous peptide for the kappa-opioid receptor 
(Nguyen et al. 2021). In this study, the expression of the mu-opioid receptor was found to be 
required for morphine-induced itch (Nguyen et al. 2021). Kappa-opioid signaling alleviated 
morphine-induced itch in both mice and non-human primates (Nguyen et al. 2021). Therefore, 
emerging evidence highlights that opioids could cause itch through inhibition of inhibitory 
neurons; rather than through MOR/GRPR heterodimerization, there is now compelling evidence 
that opioids cause itch through a mechanism of neuronal disinhibition (Figure 3). 
These two recent studies, from two independent groups, highlight the role of inhibitory 
neurons in the spinal cord as the crucial mediators of opioid-induced itch. To date, they provide 
the most compelling evidence for how a spinal mechanism is responsible for neuraxial opioid-
induced itch. 
1.4 Treatments for opioid-induced pruritus 
Given the dose-dependent nature of opioid-induced pruritus, clinicians have managed to 
control unwanted side effects by tightly titrating the dose needed to optimize analgesia. 
Furthermore, multimodal analgesia has also been shown to be effective at both managing pain 
and reducing the side effect of pruritus. For example, the addition of a local anesthetic, such as 
bupivacaine, with the opioid analgesic appears to reduce the severity of pruritus in the immediate 
postoperative period (Mulroy, Larkin, and Siddiqui 2001; Asokumar et al. 1998). However, the 
half-lives of these local anesthetics are short compared to opioids (Liu et al. 1996; DeSousa 
2014; Smith et al. 2008), and thus it is challenging to determine whether local anesthetics reduce 
the pruritus caused by opioids or simply reduce sensation more generally. Despite efforts to 
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reduce the dose of opioids administered and to apply a multi-modal approach to neuraxial 
analgesia, pruritus as a side effect persists. For these patients, the most common treatment 
options are described below (Table 2).  
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Table 2. Frequently prescribed treatments for opioid-induced pruritus.  
Examples and sites of action are listed. H1R, histamine receptor; 5HT3R, 5-hydroxytryptamine receptor 3A; D2R, 
dopamine receptor; GABA, gamma-aminobutyric acid; PONV, postoperative nausea and vomiting. 
Class 










Diphenhydramine (25 mg IV) Peripheral 
Parenteral 
morphine 
Sedation is a common and 
problematic side effect (Anwari 
and Iqbal 2003; Jannuzzi 2016; 
Roth et al. 1987) 
Mu antagonist 





Limited by reduction in analgesia 




Nalbuphine (1-5 mg IV), 
butorphanol (.2-2 mg IV) 
Central Neuraxial opioids 
Highly effective anti-pruritic, 
without major reductions in 
analgesia, but can cause 
drowsiness (Jannuzzi 2016; Cohen 
et al. 1992; Lee et al. 2007) 
5HT3R 
antagonist 
Ondansetron (4 mg IV) Central Neuraxial opioids 
Does not decrease the incidence of 
pruritus, but prophylactic treatment 
may reduce severity (George, 
Allen, and Habib 2009; Somrat 
Charuluxananan et al. 2003; 
Sarvela et al. 2006; Yeh et al. 
2000; Yazigi et al. 2002; Siddik-
Sayyid et al. 2007; Kyriakides, 





Nalfurafine (in primates: 0.1-1 
μg/kg IV; 0.3 μg IT; in mice: 40 
ng IT) 
Central Neuraxial opioids 
Clinically approved for pruritus of 
systemic disease in Japan (Cowan, 
Kehner, and Inan 2015). 
Effectively treats morphine-
induced itch in preclinical models 
without affecting analgesia 
(Nguyen et al. 2021) 
D2R 
antagonist 
Droperidol (1.25 mg IV) Central Neuraxial opioids 
Data limited, but has been 
observed to reduce incidence of 
pruritus (Horta and Vianna 2003; 
Horta, Ramos, and Gonçalves 




Gabapentin (1200 mg PO) Central Neuraxial opioids 
Effective for pruritus in systemic 
disease (Anand 2013), but 
effectiveness is unclear for opioid-
induced pruritus (Chiravanich, 
Oofuvong, and Kovitwanawong 




Propofol (10-30 mg IV) Central Neuraxial opioids 
Controversial; reduces incidence of 
pruritus in patients undergoing 
some elective surgeries (Törn et al. 
1994; Borgeat et al. 1992), but not 
cesarean delivery (Warwick, 
Kearns, and Scott 1997) 
 
1.4.1 Antihistamines 
The role of antihistamines in neuraxial opioid-induced pruritus is contested. 
Antihistamines reduce diaphoresis and wheal-and-flare responses to parenteral opioids (Philbin 
et al. 1982), and many providers continue to use antihistamines to manage pruritus induced by 
opioids. Nevertheless, the appropriateness of this practice in the setting of neuraxial opioid-
induced pruritus is questionable (McNicol et al. 2003). Several studies indicate that H1R 
antagonists, such as diphenhydramine and promethazine, reduce itch in obstetric patients who 
receive neuraxial opioids (Liao et al. 2011; Horta et al. 2006; Eldor et al. 1994; Millington et al. 
2018). However, antihistamines have also been shown to cause sedation (Anwari and Iqbal 2003; 
Jannuzzi 2016; Roth et al. 1987), and it has been observed that the sedating effects of 
antihistamines have caused patients to verbally deny itch, but continue to scratch or that patients 
report itchiness in between periods of sleep (Roth et al. 1987; Ballantyne, Loach, and Carr 1988; 
Horta et al. 2006). Thus, it is possible that the apparent reduction in itch with antihistamine 
treatment seen in some studies may, in fact, be secondary to drowsiness (Kamei et al. 2005).  
Comparisons between the effectiveness of mixed kappa agonist-mu antagonists and 
antihistamines for the management of neuraxial opioid-induced pruritus have revealed major 
limitations of antihistamine treatment for this form of pruritus (Eldor et al. 1994; Dunteman, 
Table 2. Frequently prescribed treatments for opioid-induced pruritus. (continued) 
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Karanikolas, and Filos 1996; Liao et al. 2011; Somrat et al. 1999; Horta et al. 2006; Juneja, 
Ackerman, and Bellinger 1991). In spite of these limitations, they continue to be prescribed for 
both peripheral and central opioid-induced pruritus (Millington et al. 2018; Kumar and Singh 
2013). Given new evidence that spinal neurons mediate neuraxial opioid-induced pruritus (Ko 
2015; Wang et al. 2021; Nguyen et al. 2021), antihistamines likely have no role in the treatment 
of neuraxial opioid-induced pruritus, but they may have a key role in the treatment of 
subcutaneous, oral, and intravenous morphine-induced pruritus. 
1.4.2 Mu-opioid receptor antagonists 
To date, the most effective treatments for opioid-induced pruritus have included 
pharmacological agents that antagonize the mu-opioid receptor, which pose disadvantages in that 
they can reverse analgesia (Cohen et al. 1992; Miller and Hagemann 2011). Clinically, mu-
opioid receptor antagonists have also been shown to be effective for the management of 
parenteral opioid-induced pruritus (Dunteman, Karanikolas, and Filos 1996). For patients on 
parenteral opioid therapy, such as patients with sickle cell disease, the co-administration of the 
opioid analgesic and its antagonist helps to mitigate pruritus, (Koch et al. 2008) particularly 
when small doses are infused (e.g. naloxone 0.25-2 μg·kg-1·h-1 intravenous push) (Kjellberg and 
Tramèr 2001; Maxwell et al. 2005). Naloxone is also effective at reducing wheal and flare 
responses caused by morphine (Levy et al. 1989). These findings highlight the utility of mu-
opioid receptor antagonists in the management of peripherally mediated and histamine-
dependent opioid induced pruritus.  
Mu-opioid receptor antagonists are also effective for the treatment of pruritus induced by 
neuraxial opioid administration (Ganesh and Maxwell 2007; Kumar and Singh 2013). Naloxone 
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and naltrexone are direct opioid receptor antagonists often used to reduce both the frequency and 
severity of pruritus evoked by neuraxial opioid analgesia (Miller and Hagemann 2011). 
Unfortunately, these antagonists, at doses that are clinically effective at reversing pruritus, may 
also reverse the analgesic effects of opioids (Gan et al. 1997) (e.g., complete reversal for opioid-
induced respiratory depression at doses of naloxone 0.1 mg/kg intravenous push) (Rzasa Lynn 
and Galinkin 2018). In non-human primates, the one-time administration of a selective mu-
opioid receptor antagonist, such as nalmefene, produced a 10-fold rightward shift in both 
morphine-induced scratching and analgesia (M. C. Ko and Naughton 2000). Furthermore, the 
mean pKB  (an estimate of antagonist affinity) of nalmefene was found to be similar for both 
scratching and thermal nociception endpoints (M. C. Ko and Naughton 2000), indicative of a 
circumscribed window for the management of itch without affecting analgesia by mu-opioid 
receptor antagonism, making these agents suboptimal for the treatment of pruritus in obstetric 
patients. Thus, optimal doses of mu antagonists, such as naloxone or naltrexone, to relieve 
clinical pruritus often come with a risk-benefit discussion with patients about their preferential 
priorities on pain control versus itch. 
Alternatively, mixed opioid receptor agonists, such as nalbuphine (1-5 mg IV) (S 
Charuluxananan et al. 2001) and butorphanol (0.2-2 mg IV) (Lawhorn et al. 1991) are also 
clinically effective therapies for neuraxial opioid-induced pruritus (Jannuzzi 2016; Cohen et al. 
1992; Lee et al. 2007). They are frequently used due to their improved ability to manage pruritus 
without reducing analgesia compared to selective mu-opioid receptor antagonists (Cohen et al. 
1992). Nalbuphine is a mixed antagonist of the mu-opioid receptor and agonist of the kappa-
opioid receptor and due to its partial antagonism of the mu-opioid receptor, reversal of analgesia 
remains a concern (Kendrick et al. 1996). Another potential limitation of nalbuphine is its 
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sedating side effect (Kjellberg and Tramèr 2001; Jannuzzi 2016), although this is only observed 
when a high dose (10 mg/70 kg) is used (Goletiani et al. 2007), which is beyond the range used 
to manage pruritus clinically (Tubog et al. 2018). In contrast, butorphanol is a partial agonist of 
both the mu- and kappa-opioid receptors. Similar to nalfurafine, butorphanol has also been 
reported as an effective treatment of opioid-induced pruritus, particularly among pediatric 
patients (Gunter et al. 2000; Bailey et al. 1994). Thus, nalfurafine and butorphanol may pose 
therapeutic advantages over selective mu antagonists due to their agonism of the kappa opioid 
receptor and the ability to directly modulate spinal itch circuits.  
Notably, both opioid antagonists and mixed agonist-antagonists are effective for other 
clinical instances of pruritus, including those associated with systemic disease or of dermatologic 
origin. Nalbuphine, for example, is effective at managing pruritus among patients with end stage 
renal disease (Hawi et al. 2015; Reszke and Szepietowski 2018) and contact dermatitis (Inan et 
al. 2019). These observations suggest that different forms of pruritus (spanning from systemic 
disease to drug-induced) converge on a common itch pathway that depend on central opioid 
signaling, likely centered upon the involvement of endogenous endorphin and dynorphin tone. 
Presently, the use of nalbuphine for the clinical management of opioid-induced pruritus is off-
label, despite its effectiveness for the prevention and severity of pruritus (Jannuzzi 2016). As is 
the case with many drugs frequently used for anesthesia that lack FDA labeling (Smith et al. 
2012), a new drug indication of nalbuphine for pruritus would only facilitate its widespread use 
within clinical practice. 
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1.4.3 Selective kappa opioid receptor agonists 
The dynorphin-kappa-opioid receptor system has been heavily implicated in itch. 
Pharmacologic and genetic manipulations of spinal dynorphin-expressing neurons in mice have 
uncovered that spinal dynorphin is required for the inhibition of itch (Kardon et al. 2014; Huang 
et al. 2018). In rodent and non-human primate models, selective kappa-opioid receptor agonists, 
such as nalfurafine, have been shown to be important for the inhibition of several forms of 
chemical, immunologic, and drug-induced (including opioid-induced) itch (Umeuchi et al. 2003; 
Togashi et al. 2002; Ko and Husbands 2009). Clinically, nalfurafine (2.5 or 5.0 μg PO) (Kozono, 
Yoshitani, and Nakano 2018) has been shown to be effective for the treatment of uremic and 
cholestatic pruritus in Japan (Cowan, Kehner, and Inan 2015). 
Emerging evidence in preclinical models, involving both mice and non-human primates, 
indicate that the intrathecal and systemic administration kappa-opioid receptor agonists can 
reduce morphine-induced itch without reducing morphine-induced analgesia (Ko and Husbands 
2009; Akiyama et al. 2015; Nguyen et al. 2021). In preclinical models, nalfurafine has been 
found to restore dynorphin signaling disrupted by neuraxial mu-opioid receptor agonists, such as 
morphine (Nguyen et al. 2021). These preclinical findings indicate that selective kappa-opioid 
receptor agonists should be further considered for opioid-induced pruritus in the future.  
Presently, however, nalfurafine does not have approval by the European Medicines 
Agency or Federal Drug Administration for clinical use in Europe and the United States, 
respectively (Mores et al. 2019). One concern has been its sedating effects, which has been 
observed following long-term use in dogs (European Medicines Agency. Assessment Report: 
Winfuran. European Medicines Agency. Committee for Medicinal Products for Human Use; 
2013), but this has not been a consistent finding in other animal models and in patients (Brust et 
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al. 2016; Kozono, Yoshitani, and Nakano 2018; Ko and Husbands 2009) In European trials, 
nalfurafine (5 μg PO) did not significantly reduce the severity of uremic pruritus compared to 
placebo over 8 weeks. (European Medicines Agency. Assessment Report: Winfuran. European 
Medicines Agency. Committee for Medicinal Products for Human Use; 2013) However, one key 
difference between the studies conducted in Europe and Japan (Kumagai et al. 2010) was the 
duration of the trial (weeks compared to days, respectively) and notably, in the European trials 
both the nalfurafine-treated and placebo groups exhibited significant reductions in self-reported 
VAS intensities of pruritus over the course of the study (European Medicines 
Agency. Assessment Report: Winfuran. European Medicines Agency. Committee for Medicinal 
Products for Human Use; 2013). Given the incidence of opioid-induced pruritus in the 
postoperative setting, the effectiveness of nalfurafine may be more evident in acute settings, 
although further testing is necessary in preclinical and clinical trials. 
1.4.4 Serotonin receptor antagonists 
5-hydroxytryptamine receptor (5HT3R) antagonists are frequently used to treat 
postoperative nausea and vomiting (PONV). Both of these side effects are observed in 
postoperative patients who receive neuraxial morphine (Grangier et al. 2020; Norris et al. 1994). 
Several studies have revealed that prophylaxis with a 5HT3R antagonist (such as ondansetron, 
ranging from 4-8 mg IV) does not significantly reduce the incidence of pruritus (George, Allen, 
and Habib 2009; Somrat Charuluxananan et al. 2003; Sarvela et al. 2006; Yeh et al. 2000; Yazigi 
et al. 2002; Siddik-Sayyid et al. 2007; Kyriakides, Hussain, and Hobbs 1999). A systematic 
review by Bonnet et al. of 15 randomized controlled trials suggests that 5HT3R antagonists may 
reduce the intensity of opioid-induced pruritus, but also concluded that the trials included in the 
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systematic review, such as small studies that favor the publication of positive findings, may have 
suffered from publication bias (Bonnet et al. 2008). Thus, there is still a lack of consensus on the 
clinical effectiveness of 5HT3R antagonists in opioid-induced pruritus (Bonnet et al. 2008; 
George, Allen, and Habib 2009).  
The mechanism by which 5HT3R antagonists, such as ondansetron, alleviate itch is not 
clear. 5HT3R immunoreactivity has been observed in the spinal dorsal horn (Morales, 
Battenberg, and Bloom 1998) and the endogenous source of serotonin is thought to originate 
from descending fibers arising within the brainstem (Marinelli et al. 2002). Depletion of 
supraspinal serotonin has been shown to alleviate pruritogen-induced itch in rodents (Zhao et al. 
2014), which may partially explain how antagonism of 5HT3R reduces opioid-induced itch. 
However, spinal neurons expressing 5HT3R and MOR have been found comprise non-
overlapping populations (Häring et al. 2018), making it unlikely that agents such as ondansetron 
could directly reduce the activity of neurons responsible for opioid-induced itch. In rhesus 
monkeys, ondansetron has also been found to be ineffective at reducing morphine-induced itch, 
even at high doses that caused extrapyramidal effects (Ko 2015). Given these conflicting reports 
between human and animal models, and the lack of a cellular basis for how serotonin and opioid 
signaling could converge, 5HT3R antagonists are currently not considered front-line therapies 
for opioid-induced pruritus, and likely have a limited role in prophylaxis against opioid-induced 
pruritus.   
1.4.5 Propofol 
The effectiveness of sub-hypnotic doses of propofol (10-30mg IV) for the treatment of 
opioid-induced pruritus remains controversial. In one double-blind trial, propofol (10mg IV) was 
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observed to reduce morphine-induced pruritus compared to placebo (85% compared to 16%, 
respectively) (Borgeat et al. 1992). The patients in this study had received either epidural or 
spinal morphine for a variety of surgical procedures including gynecologic, gastrointestinal, 
thoracic, and orthopedic surgery (Borgeat et al. 1992). Another study also reported that propofol 
(10mg IV) protected against pruritus following intrathecal morphine for arthroplasty surgery 
(Törn et al. 1994). However, Warwick et al. did not confirm these findings in a double-blind 
study of obstetric patients; propofol (10-20mg IV) had no effect on the onset or severity of 
pruritus following intrathecal morphine (Warwick, Kearns, and Scott 1997) Age and sex 
differences among these studies may account for the variable effectiveness of the similar doses 
of propofol used to mitigate neuraxial morphine-induced pruritus. These studies further 
underscore that pruritus disproportionately occurs in younger and female obstetric patients 
(Tubog et al. 2018; Wells, Paech, and Evans 2004; Yurashevich and Habib 2019; S 
Charuluxananan et al. 2000) who may be less responsive to the antipruritic effects of propofol. 
Another possibility for the observed differences across studies is that the dose of propofol used 
may not have been adequate to achieve clinical effect. Thus, although propofol has been 
observed to reduces incidence of pruritus in patients receiving morphine for a variety of elective 
surgeries (Törn et al. 1994; Borgeat et al. 1992), its benefit in the treatment of opioid-induced 
pruritus within the obstetric population remains questionable (Warwick, Kearns, and Scott 1997).  
Recent work in rodents have revealed that neurons producing GABA are required for neuraxial 
opioid-induced itch (Wang et al. 2021; Nguyen et al. 2021) and the administration of propofol, 
through potentiation of GABA receptors, may enhance the ability of these neurons to dampen 
excitatory spinal circuits (Sun and Chen 2007) involved in itch transmission. Additional dose-
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response studies are necessary to identify the appropriate dose of propofol for management of 
pruritus without sedation. 
1.4.6 Gabapentin 
Gabapentin has been shown to be effective for several forms of pruritus in systemic 
disease, including uremic pruritus, pruritus in multiple sclerosis, and pruritus of unknown origin 
(Anand 2013; Yesudian and Wilson 2005; Gunal et al. 2004). Its use in the treatment of 
neuraxial opioid-induced pruritus is less clear. Preoperative gabapentin (1200 mg PO) has been 
found to significantly delay the onset and reduce the incidence and severity of intrathecal 
morphine-induced pruritus in patients undergoing orthopedic surgery (Sheen et al. 2008) and 
prolong the onset of pruritus in patients receiving spinal morphine for unilateral hernia repair 
(Akhan et al. 2016). However, a lower dose (600 mg) was not found to significantly decrease the 
incidence of pruritus compared to placebo and was associated with urinary retention 
(Chiravanich, Oofuvong, and Kovitwanawong 2012). Further pharmacological studies in 
preclinical and clinical models are necessary to characterize the mechanism of action of 
gabapentin within the nervous system and to determine its dosing in the management of opioid-
induced pruritus.  
1.4.7 Dopamine D2 receptor antagonists 
Droperidol (1.25 mg IV), a short-acting, potent dopamine receptor (D2R) antagonist, has 
been shown in several studies to be effective at reducing the incidence and severity of neuraxial 
opioid-induced pruritus and has previously been used for postoperative nausea and vomiting 
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(Horta and Vianna 2003; Horta, Ramos, and Gonçalves 2000; Horta et al. 2006). However, D2R 
antagonists have been reported to be effective only when small doses of opioids are 
administered. Sedation has been shown to increase with escalating doses of droperidol (2.5 to 5 
mg IV), which may confound its antipruritic effects (Horta, Ramos, and Gonçalves 2000). Given 
the broad influences of supraspinal dopamine signaling on the functions of spinal and dorsal root 
ganglion neurons, the anti-pruritic effects observed may be non-specific (Wood 2008). Emerging 
evidence indicates that low doses of droperidol may be safely used; however, clinical use of 
droperidol in a perioperative setting is limited by an FDA black box warning issued (2001) due 
to its risk for sudden cardiac death (Jackson, Sheehan, and Reddan 2007). The warning will 
likely preclude any clinical adoption of droperidol to treat opioid-induced pruritus. 
1.4.8 Emerging treatments 
All existing treatment options for opioid-induced pruritus have undesirable side effect 
profiles. Furthermore, many of these treatments are used empirically and off-label. Due to the 
limitations of currently available treatments, some patients or providers may elect to forgo 
analgesia or opt for sub-optimal analgesia that excludes neuraxial opioids, but these practices can 
lead to unnecessary pain and suffering (Arendt and Segal 2008). Recent success in preclinical 
models suggests that nalfurafine, a selective kappa-opioid receptor agonist, may be used to 
manage opioid-induced pruritus without limiting opioid-induced analgesia (Nguyen et al. 2021). 
but further basic, translational and clinical research is required before recommendations for 
clinical use in opioid-induced pruritus can be made. Optimization of opioid analgesia as well as 
development of improved therapies for opioid-induced pruritus have the potential to significantly 
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improve the clinical standards of care for patients who receive opioids for the management of 
perioperative pain and experience pruritus as an unwanted side effect. 
1.5 Summary 
Pruritus following neuraxial opioids remains a highly common and dissatisfying side 
effect. Advancements in the understanding of mast cell biology and neuronal itch circuitry have 
provided clues as to how opioids can induce analgesia as well as evoke pruritus. Existing 
evidence suggests that parenteral opioids cause pruritus through histamine release, whereas 
neuraxial opioid-induced pruritus occurs through a mechanism of neuronal disinhibition in the 
spinal cord dorsal horn. The differential modulation of peripheral and neuraxial opioid-induced 
pruritus by mast cells and neurons, respectively, further highlight the complexity of the side 
effects of opioid use. Emerging evidence suggests that pruritus arises due to the dysregulation of 
opioid-sensitive pathways involving mu- and kappa-opioid receptor signaling, which parallels 
other forms of chronic, systemic, and drug-induced pruritus. Ultimately, a richer understanding 
of the genetic, molecular, and cellular underpinnings of opioid-induced pruritus may provide a 
basis upon which to develop improved therapies that can manage pain but do not cause itch. 
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2.0 Translation of models of morphine-induced itch: from mice to obstetric patients 
2.1 Introduction 
Neuraxial morphine and other mu opioid receptor (Oprm1) agonists are routinely 
administered in hospitals around the world (Waxler et al. 2005a). For instance, many pregnant 
women undergoing cesarean delivery in North America and Europe receive epidural or spinal 
morphine (Butwick, Wong, and Guo 2018; Alran et al. 2002; Kumar and Singh 2013). 
Moreover, epidural or spinal morphine is given as an analgesic for a large proportion of surgical 
procedures, including hip and knee arthroplasty (Kaye et al. 2019). Unfortunately, one of the 
major unwanted side effects of the spinal or epidural delivery routes is morphine-induced itch, 
which is observed in more than half of patients (Waxler et al. 2005b; Jannuzzi 2016; Ganesh and 
Maxwell 2007; Szarvas, Harmon, and Murphy 2003; Ballantyne, Loach, and Carr 1988). 
Although it is clear that neuraxial morphine causes itch in humans (Waxler et al. 2005b; 
Jannuzzi 2016; Ganesh and Maxwell 2007; Szarvas, Harmon, and Murphy 2003; Ballantyne, 
Loach, and Carr 1988), the characterization of clinical endpoints for morphine-induced itch 
remains limited. We sought to further characterize itch dysesthesias elicited by morphine in 





A prospective observational approach was chosen. Written consent was obtained from all 
research participants and this study was approved by the University of Pittsburgh Institutional 
Review Board. A convenience sampling of women aged 18 years or older with scheduled 
cesarean sections was conducted. Exclusion criteria included chronic pain, current opioid 
maintenance therapy, or emergency cesarean delivery. Upon enrollment, morphine-induced itch, 
hyperknesis, and alloknesis were established, each using a numerical rating scale (NRS) (e.g., 
“How itchy do you currently feel?”). Zero indicated “no intensity (or unpleasantness) at all” and 
10 indicated “the most intense (or unpleasant) itch I can imagine.” Hyperknesis was assessed 
using a 2.0 gram von Frey monofilament applied to a distal extremity. Alloknesis was assessed 
using a brush (SenseLab, Somedic AB, Sweden) applied to a distal extremity. Assessments 
occurred during hospitalization prior to and 24 hours after cesarean delivery. Responses were de-
identified, coded, and stored on a secure, web-based application on Research Electronic Data 
Capture (REDCap). 
Mice 
The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 background. Even numbers of male and female mice were used for all 
experiments. No sex differences were found and, thus, animals were pooled. Mice were given 
food and water ad libitum and housed under standard laboratory conditions. The use of animals 




Intradermal and intrathecal injections 
For intradermal injection of chloroquine, hair was clipped from the neck or calf of each 
mouse at least 24 hours before the experiment. Chloroquine (100 μg in 10 μL) was administered 
into the nape of the neck or calf, which could be subsequently visualized by the formation of a 
small bubble under the skin. For intrathecal injections, hair was clipped from the back of each 
mouse at least 24 hours before the experiment. All intrathecal injections were delivered in a total 
volume of 5 μL using a 30-gauge needle attached to a luer-tip 25 μL Hamilton syringe. The 
needle was inserted into the tissue at a 45° angle through the fifth intervertebral space (L5 – L6). 
Solution was injected at a rate of 1 μL/s. The needle was held in position for 10 seconds and 
removed slowly to avoid any outflow of the solution. Only mice that exhibited a reflexive flick 
of the tail following puncture of the dura were included in behavioral analysis. These procedures 
were performed in awake, restrained mice. 
Observation of scratching behavior  
Scratching behavior was observed using a previously reported method (Kardon et al. 
2014). Mice were individually placed in the observation cage (12 x 9 x 14 cm) to acclimate for 
30 minutes. The mice were assigned to dosing conditions in a randomized manner. For dose-
dependent subcutaneous morphine-induced itch, animals received either 5 μL morphine (0.3, 3, 
or 300 pmol) or saline to the nape of the neck. Scratching behavior was videotaped for 60 
minutes after administration. The total numbers of scratch bouts by the hind paws at various 
body sites during the first 60 minutes after intrathecal morphine were counted.  
Alloknesis 
One hour after the intrathecal injection of morphine, mice were assessed for alloknesis. 
As previously described (Akiyama et al. 2012), alloknesis was assessed by delivering 3 separate 
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innocuous mechanical stimuli using a von Frey filament (bending force: 0.7 mN; Stoelting, 
USA) every 5 minutes. Each application of the von Frey filament was reported as 1 trial, yielding 
a total of 18 trials over 30 minutes. 
Hyperknesis 
One hour after the intrathecal injection of morphine, mice were assessed for hyperknesis. 
Chloroquine (100 μg in 10 μL) was injected intradermally into the nape of the neck or calf and 
scratching behavior was recorded for 30 minutes. The total number of scratch bouts by the hand 
paws directed to the nape of the neck was counted.  
2.3 Results 
2.3.1 Spinal morphine is associated with morphine induced itch, hyperknesis, and 
alloknesis in obstetric patients. 
We found that morphine not only caused itch in women receiving spinal morphine for 
cesarean delivery, as previously reported (Szarvas, Harmon, and Murphy 2003; Ballantyne, 
Loach, and Carr 1988), but also gave rise to clinical hyperknesis, as defined by exacerbation of 
itch in response to punctate stimulation (Andersen et al. 2018), and clinical alloknesis, as defined 
by touch-evoked itch in response to brushing (Andersen et al. 2018) (Figure 4, Figure 5). These 
newly identified endpoints for morphine-induced itch in humans were highly correlated with 
overall self-reported itch ratings obtained using a numerical rating scale (Figure 5), suggesting 
that morphine-induced itch is accompanied by central sensitization (Andersen et al. 2018). 
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Figure 4. Novel endpoints for sensitization caused by morphine-induced itch in human subjects and in mice. 
(A) I.T. morphine-induced itch, hyperknesis, and alloknesis in obstetric patients. I.T., intrathecal. n = 39 human 
subjects. (B) I.T. morphine-induced itch, hyperknesis, and alloknesis in mice. n = 7-9 mice per group. P value was 
determined by (A) Wilcoxon matched-pairs signed rank test and (B) one-way ANOVA, with Bonferroni’s correction 
and two-tailed unpaired t-test. (A) data points represent individual human subjects pre and post spinal morphine (B) 








































































































































Figure 5. Morphine-induced itch, hyperknesis, and alloknesis in obstetric patients. 
(A) Proportion of women reporting itch, hyperknesis, and alloknesis before and after spinal morphine. (B and C) 
Correlation between subjects’ spontaneous score and (B) hyperknesis score, (C) and alloknesis score. n = 39 
subjects. (B and C) P value was determined by a linear regression (left) and Mann-Whitney test (right). Data are 
mean + S.E.M with dots representing individual patients. 
2.3.2 Intrathecal morphine is associated with morphine induced itch, hyperknesis, and 
alloknesis in mice. 
Next, we reverse-translated these findings in a mouse model (with even numbers of males 
and females) using an analgesic dose of morphine given intrathecally (300 pmol; I.T). In addition 
to morphine-induced scratching behavior, consistent with previous reports (Sakakihara, 
Imamachi, and Saito 2016), mice showed morphine-induced hyperknesis, as demonstrated by an 



















































































































touch-evoked itch in response to a von Frey filament  (Figure 4, Figure 6). Thus, morphine-
induced itch in mice appears to recapitulate our observations in humans, thereby enabling 
detailed mechanistic investigations of this phenomenon. 
 
 
Figure 6. Morphine-induced itch, hyperknesis, and alloknesis in mice. 
(A) Time course of itch following I.T. administration of morphine (100 pmol and 300 pmol) and saline. n = 7-9 
mice per group. (B to D) Effect of morphine-induced (B) itch, (C) hyperknesis, and (D) alloknesis separated by sex. 
n = 3-4 mice per group. (E) Effect of I.T. morphine on heat sensitivity. n = 7-9 mice per group, two-way ANOVA 
with Bonferroni’s correction. (F and G) Effect of morphine on heat sensitivity among (F) female (G) and male 
mice. (A and E to G) Data are mean  S.E.M. (B to D) Data are mean + S.E.M. with individual dots representing 
individual mice. 
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Hyperknesis and alloknesis have been used to characterize the sensitization of itch, such 
as in setting of atopic dermatitis and eczema (Andersen et al. 2018). Although itch-specific 
quantitative sensory testing (QST) is used to assess experiences of pruritus (Sikand et al. 2011, 
2009), it is less frequently used compared to QST in pain. Particularly, in the context of 
morphine-induced itch, alloknesis and hyperknesis have only been assessed in anesthetized rats 
(Moser and Giesler 2013). Here, we uncovered heightened responses to brushing and von Frey 
stimulation in obstetric patients following spinal morphine, indicative of morphine-induced 
alloknesis and hyperknesis, respectively. In mice, we found analogous results; morphine-treated 
mice exhibited alloknesis with von Frey stimulation of the nape of the neck and hyperknesis 
following the intradermal injection of chloroquine. These results expand on the existing 
paradigms for assessment of itch dysesthesias in both humans and mice. 
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3.0 Role of mast cells in morphine-induced itch 
3.1 Introduction 
First-generation antihistamines, such as diphenhydramine (the active ingredient in 
Benadryl), are commonly used in many hospitals globally to alleviate morphine-induced itch 
(Kumar and Singh 2013; Siddik-Sayyid et al. 2010; Millington et al. 2018). The use of 
antihistamines likely stems from the observation that morphine causes histamine release from 
mast cells within the skin, and that histamine produces itch (Lansu et al. 2017; Grosman 1981; 
Hermens et al. 1985). Moreover, clinical data appear to support this idea because numerous 
studies confirm that antihistamines reduce itch in laboring women who receive morphine (Liao 
et al. 2011; Horta et al. 2006; Eldor et al. 1994). While antihistamines are widely used to treat 
morphine-induced itch (Millington et al. 2018), whether this type of itch is indeed a result of 
peripheral histamine release has never been established and remains controversial (Liu et al. 
2011; Ko et al. 2004). 
It is widely assumed that histamine release from degranulated mast cells in the skin 
underlies neuraxial morphine-induced itch (Szarvas, Harmon, and Murphy 2003). When given 
subcutaneously, morphine, indeed, causes degranulation of peripheral mast cells, which results in 
itch (Lansu et al. 2017; Grosman 1981; Hermens et al. 1985). However, the evidence for this 
mechanism is less clear for neuraxial morphine-induced itch; mast cells are not found in the 
spinal cord and emerging evidence has called the role of mast cells in neuraxial morphine-





The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 background. Even numbers of male and female mice were used for all 
experiments. No sex differences were found and, thus, animals were pooled. Mice were given 
food and water ad libitum and housed under standard laboratory conditions. RosaDTA (Jax 
#009669) mice are available at Jackson Laboratories. Mcpt5Cre mice were a gift from Axel Roers 
(Dresden University of Technology). The use of animals was approved by the Institutional 
Animal Care and Use Committee of the University of Pittsburgh. 
Pharmacologic agents used in mice 
Morphine sulfate (4 mg/ml; Henry Schein Animal Health) and chloroquine diphosphate 
salt (Sigma) were dissolved in physiological saline. Salvinorin B (SalB; Tocris) was dissolved in 
DMSO and administered subcutaneously (10 mg/kg). Clozapine-N-oxide (CNO; Tocris) was 
dissolved in PBS and administered intraperitoneally (5mg/kg). Nalfurafine (Sigma) was 
dissolved in saline and administered intrathecally. Loratadine (Sigma) and diphenhydramine 
(Sigma) were prepared in 10% DMSO and given 10 mg/kg I.P. For experiments involving 
antihistamines, animals were pretreated with vehicle, loratadine, or diphenhydramine 30 minutes 
prior to recording scratching behavior. 
Intrathecal injections 
All intrathecal injections were delivered in a total volume of 5 μL using a 30-gauge 
needle attached to a luer-tip 25 μL Hamilton syringe. The needle was inserted into the tissue at a 
45° angle through the fifth intervertebral space (L5 – L6). Solution was injected at a rate of 1 
μL/s. The needle was held in position for 10 seconds and removed slowly to avoid any outflow 
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of the solution. Only mice that exhibited a reflexive flick of the tail following puncture of the 
dura were included in behavioral analysis. These procedures were performed in awake, 
restrained mice. 
Observation of scratching behavior 
Scratching behavior was observed using a previously reported method (Kardon et al. 
2014). Mice were individually placed in the observation cage (12 x 9 x 14 cm) to acclimate for 
30 minutes. The mice were assigned to dosing conditions in a randomized manner. For dose-
dependent subcutaneous morphine-induced itch, animals received either 5 μL morphine (0.3, 3, 
or 300 pmol) or saline to the nape of the neck. Scratching behavior was videotaped for 60 
minutes after administration. For all other experiments, unless otherwise indicated, 300 pmol of 
morphine was administered (S.C. and I.T.). The total numbers of scratch bouts by the hind paws 
at various body sites during the first 60 minutes after subcutaneous (morphine or 48/80) 
intrathecal injection (morphine or 100 pmol GRP) were counted. For subcutaneous injections, 
only scratch bouts directed to the nape of the neck were counted. 
Heat sensitivity assay (Hargreaves testing) 
Mice were acclimated on a glass plate held at 30°C (IITC Life Science Inc.). A radiant 
heat source (activity intensity of 15%) was applied to the hindpaw and latency to paw 
withdrawal was recorded (Hargreaves et al. 1988). Two trials were conducted on each paw, with 
at least 5 minutes between testing the opposite paw and at least 10 minutes between testing the 
same paw. To avoid tissue damage, a cut off latency of 20 seconds was set. Values from both 
paws were averaged to determine withdrawal latency. 
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Open field activity 
Spontaneous activity in the open field was conducted over 30 minutes in an automated 
Versamax Legacy open field apparatus for mice (Omnitech Electronics Incorporated, Columbus, 
OH). Distance traveled (s), ambulatory average velocity (cm/s), and ambulatory time (s) were 
measured by infrared photobeams located around the perimeter of the arenas interfaced to a 
computer running Fusion v.6 for Versamax software (Omnitech Electronics Incorporated) which 
monitored the location and activity of the mouse during testing. Activity plots were generated 
using the Fusion Locomotor Activity Plotter analyses module (Omnitech Electronics 
Incorporated). To determine whether antihistamines would modify locomotion, mice were placed 
into the open field 30 post vehicle, loratadine, or diphenhydramine treatment. For all tests, mice 
were transferred to the testing room one hour prior to testing. 
Quantification of mast cells 
For staining of cutaneous mast cells, hair was removed from the nape of the neck two 
days prior to S.C. injection. S.C. injections for histological analyses were performed in lightly 
anesthetized (isoflurane) animals to prevent the confounds of scratching on degranulation. Skin 
and dural samples were collected fresh-frozen, sectioned at 8 μm, and post-fixed in 4% PFA for 
60 minutes. Toluidine blue was used to stain mast cells. Images were collected using a 
TissueGnostics brightfield microscope. Compound 48/80 (100 μg, Sigma) was used as a positive 
control for mast cell degranulation. Mast cells that contained a nucleus surrounded by granules 




All statistical analyses were performed using GraphPad Prism 7. Values are presented as 
mean  SEM. P values were determined by tests indicated in applicable figure legends. Sample 
sizes were based on pilot data and are similar to those typically used in the field. 
3.3 Results 
3.3.1 Role of histamine in peripheral and central morphine-induced itch. 
Given the contested role of mast cells in morphine-induced itch, we sought to determine 
their contribution to itch caused by either intrathecal (I.T.) or subcutaneous (S.C.) morphine 
(Figure 7A). Consistent with previous results (Melo et al. 2018), we found that S.C. morphine 
caused site-directed scratching in mice in a dose-dependent manner (Figure 8A). In parallel 
experiments in which mice were given morphine but prevented from scratching, we observed 
that S.C. morphine (300 pmol) caused the degranulation of cutaneous mast cells that was similar 
in magnitude to that observed with the mast cell degranulator, compound 48/80 (Figure 7B and 
Figure 8, B and C). In contrast, the same dose of I.T. morphine, although sufficient for robust 
analgesia (Figure 6E to G), did not cause peripheral mast cell degranulation (Figure 7B and 
Figure 8, B and C). Thus, neuraxial morphine for the purpose of analgesia is unlikely to cause 
the degranulation of mast cells in the periphery. 
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Figure 7. Intrathecal morphine-induced itch is mast-cell independent. 
(A) Schematic describing the pharmacological strategy to determine how morphine causes itch. I.T., intrathecal and 
S.C., subcutaneous. (B) Quantification of degranulated mast cells. n = 4 mice per group. (C to E) Effect of 
antihistamines on (C) S.C. morphine-induced itch (D) I.T. morphine-induced itch (E) and locomotor activity.  n = 
10 mice per group. (F) Mast cell deletion and quantification in Mcpt5Cre; RosaDTA mice. n = 3 mice per group. Scale 
bar = 10 μm. (G and H) Effect of mast cell depletion on (G) S.C. morphine-induced itch (H) and I.T. morphine-
induced itch. n = 9-10 mice per group. P value was determined by (B to E) one-way ANOVA, with Bonferroni’s 
correction, (F) two-tailed, unpaired t-test, (G and H) and two-way ANOVA with Bonferroni’s correction. (B to H) 
data are mean + S.E.M with dots representing individual mice. 
 
Diphenhydramine is clinically efficacious for neuraxial morphine-induced itch (Kumar 
and Singh 2013; Siddik-Sayyid et al. 2010) and is frequently prescribed for its treatment (Kumar 
and Singh 2013). However, the site at which histamine receptor antagonists exert their effects to 
reduce itch remains unclear. To address this gap, we compared the effects of two antihistamine 
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compounds in mice: diphenhydramine, a first-generation histamine receptor (H1) antagonist that 
crosses the blood-brain barrier, and loratadine, a second-generation H1 antagonist that remains 
peripherally restricted (Figure 7A). As expected, both diphenhydramine and loratadine reduced 
itch caused by the degranulation of mast cells with compound 48/80 (Figure 8E). Similarly, 
scratching in response to S.C. morphine was reduced by both types of antihistamines (Figure 
7C), consistent with the idea that S.C. morphine causes itch that is mediated by peripheral 
histamine receptors (Melo et al. 2018). For I.T. morphine-induced itch, diphenhydramine was an 
effective treatment, just as is observed in humans (Kumar and Singh 2013) (Figure 7D); in 
contrast, the peripherally restricted H1 antagonist, loratadine, had no effect (Figure 7D). 
Analogous findings were observed using I.T. gastrin releasing peptide (GRP) to cause central 
itch: only diphenhydramine reduced scratching bouts (Figure 8F).  
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Figure 8. Differential role of mast cells on subcutaneous vs. intrathecal morphine-induced itch. 
(A) Itch caused by escalating doses of S.C. morphine. n = 8 mice per group. (B) Representative images of cutaneous 
mast cells. Scale bar = 10 μm. (C) Quantification of B. n = 4 mice per group. (D to H) Comparison of the effects of 
antihistamines on (D) S.C. and I.T. morphine-induced itch, (E) S.C. 48/80 induced itch, (F) I.T. GRP induced itch, 
(G) ambulatory velocity, (H) and ambulatory time. (D to H) n = 10 mice per group. (I) Validation of dural mast cell 
deletion in Mcpt5Cre; RosaDTA mice. n = 2-3 mice per group. P value was determined by (A and E to H) one-way 
ANOVA, with Bonferroni’s correction, (D) two-way ANOVA, with Bonferroni’s correction (I) and two-tailed, 
unpaired t-test. (A and D to I) Data are mean + S.E.M with dots representing individual mice. 
 
These findings suggest that H1 antagonists must inhibit centrally-mediated itch through 










































































































































































































noteworthy that a concentration of diphenhydramine that reduced scratching behavior in mice 
was also accompanied by a reduction in their locomotor activity (Figure 7D and E and Figure 8D 
to H). This locomotor effect is in keeping with the idea that drowsiness is a side effect of 
diphenhydramine in humans (Roth et al. 1987; Ballantyne, Loach, and Carr 1988; Horta et al. 
2006). Thus, although diphenhydramine reduces neuraxial-morphine induced scratching 
behavior, it is possible that this apparent reduction in itch may be secondary to somnolence 
(Kamei et al. 2005). 
3.3.2 Mast cells are dispensable for intrathecal morphine-induced itch. 
To directly test whether mast cells are required for morphine-induced itch, we used a 
mouse model of mast cell depletion. Selective ablation of mast cells was achieved using 
Mcpt5Cre mice (Scholten et al. 2008) together with Cre-dependent expression of diphtheria toxin 
(RosaDTA) (Schubert et al. 2018) (Figure 7F and Figure 8I). As expected, mice lacking mast cells 
no longer exhibited itch upon S.C. delivery of morphine (Figure 7G). However, neuraxial 
morphine-induced itch was still intact in these mice (Figure 7H). Overall, these findings indicate 
that mast cells are dispensable for neuraxial morphine-induced itch, and that, insofar as first-
generation antihistamines reduce itch, this effect is central. 
3.4 Discussion 
Diphenhydramine is still frequently prescribed as a first-line treatment for morphine-
induced itch (Szarvas, Harmon, and Murphy 2003; Jannuzzi 2016). However, clinicians have 
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observed that the severe anticholinergic effects of antihistamines have caused patients to verbally 
deny itch while continuing to scratch, and that patients are itchy in between periods of sleep 
(Roth et al. 1987; Ballantyne, Loach, and Carr 1988; Horta et al. 2006). Furthermore, the 
sedating side effects of antihistamines have raised concerns about the safety of antihistamine 
treatment for neuraxial morphine-induced itch in view of their potential to exacerbate respiratory 
depression caused by opioids (Anwari and Iqbal 2003; Jannuzzi 2016; Roth et al. 1987). 
Our results challenge this practice of using diphenhydramine for neuraxial morphine-
induced itch because we show that mast cells are not involved in neuraxial morphine-induced 
itch. In addition, the finding that diphenhydramine only reduces scratching at a dose that also 
suppresses locomotor activity further underscores the concept that the use of antihistamines for 
neuraxial morphine-induced itch may be inappropriate. 
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4.0 Dynorphin neurons mediate morphine-induced itch 
4.1 Introduction 
Molecularly-defined inhibitory neurons have been implicated in the modulation of itch. 
Prior studies have contributed significant advances in our understanding of spinal circuitry; 
particularly, inhibitory neurons containing dynorphin (Pdyn) and neuropeptide Y (Npy) are 
critically important for the inhibition of chemical (Kardon et al. 2014; Ross et al. 2010; Huang et 
al. 2018) and mechanical itch (Acton et al. 2019; Bourane et al. 2015), respectively. 
Developmental deletion of either Pdyn neurons or Npy neurons results in profound spontaneous 
scratching behavior suggesting that these populations tonically inhibit itch (Ross et al. 2010; 
Bourane et al. 2015; Kardon et al. 2014; Huang et al. 2018; Acton et al. 2019).  
To begin to address how these neurons could be involved in opioid-induced itch, we 
considered the canonical view that opioids typically signal through Gαi-coupled G-protein 
coupled receptors to inhibit neuronal activity (Al-Hasani and Bruchas 2011; Torrecilla et al. 






The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 background. Even numbers of male and female mice were used for all 
experiments. No sex differences were found and, thus, animals were pooled. Mice were given 
food and water ad libitum and housed under standard laboratory conditions. PdynCre, NpyCre, 
Oprm1fl/fl, and Ai34(RCL-Syp/tdT)-D (Rosatdt) back-crossed into the C57Bl/6 background were 
bred and raised at the University of Pittsburgh. PdynCre (Jax #027958), NpyCre (Jax #027851), 
Oprm1fl/fl (Jax #030074), and Rosatdt (Jax #012570) mice are available at Jackson Laboratories. 
Pharmacologic agents used in mice 
Morphine sulfate (4 mg/ml; Henry Schein Animal Health) and chloroquine diphosphate 
salt (Sigma) were dissolved in physiological saline. Salvinorin B (SalB; Tocris) was dissolved in 
DMSO and administered subcutaneously (10 mg/kg). Clozapine-N-oxide (CNO; Tocris) was 
dissolved in PBS and administered intraperitoneally (5mg/kg). 
Intradermal and intrathecal injections 
For intradermal injection of chloroquine, hair was clipped from the neck or calf of each 
mouse at least 24 hours before the experiment. Chloroquine (100 μg in 10 μL) was administered 
into the nape of the neck or calf, which could be subsequently visualized by the formation of a 
small bubble under the skin. For intrathecal injections, hair was clipped from the back of each 
mouse at least 24 hours before the experiment. All intrathecal injections were delivered in a total 
volume of 5 μL using a 30-gauge needle attached to a luer-tip 25 μL Hamilton syringe. The 
needle was inserted into the tissue at a 45° angle through the fifth intervertebral space (L5 – L6). 
Solution was injected at a rate of 1 μL/s. The needle was held in position for 10 seconds and 
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removed slowly to avoid any outflow of the solution. Only mice that exhibited a reflexive flick 
of the tail following puncture of the dura were included in behavioral analysis. These procedures 
were performed in awake, restrained mice. 
Intraspinal injections 
Mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine. An incision 
was made at the spinal cord level corresponding to L4-6 dermatome. The intrathecal space was 
exposed, and two injections of approximately 300 nl of virus (AAV8-DF-KORD-mCitrine, 
Addgene #65417; AAV2.hSyn.DIO.mCherry Addgene #50459; AAV2.hSyn.DIO.hM4D(Gi)-
mCherry, Addgene #44362) were infused 300 mm below the surface of the spinal cord at 5 nL/s 
via glass pipette through the intrathecal space corresponding to L4-6 of the spinal cord. The glass 
pipette was left in place for an additional 5 minutes before withdrawal. The incision was closed 
with 5-0 vicryl suture. Ketofen was delivered I.P. 10 mg/kg and mice were allowed to recover 
over a heat pad. The injections were validated post-mortem by fluorescent in-situ hybridization 
of Pdyn and eYFP or mCherry to detect KORD-mCitrine or hM4Di-mCherry, respectively. 
All behavioral tests described below were performed in a blinded manner. 
Observation of scratching behavior 
Scratching behavior was observed using a previously reported method (Kardon et al. 
2014). Mice were individually placed in the observation cage (12 x 9 x 14 cm) to acclimate for 
30 minutes. The mice were assigned to dosing conditions in a randomized manner. Scratching 
behavior was videotaped for 60 minutes after administration. 300 pmol of morphine was 
administered (I.T.). For experiments directed at the calf, the amount of time spent biting the leg 
was quantified over 60 minutes. Both control and KORD or control and hM4Di treated animals 
were pretreated with SalB or CNO, respectively, 30 minutes prior to the start of the experiment. 
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 Heat sensitivity assay (Hargreaves testing) 
Mice were acclimated on a glass plate held at 30°C (IITC Life Science Inc.). A radiant 
heat source (activity intensity of 15%) was applied to the hindpaw and latency to paw 
withdrawal was recorded (Hargreaves et al. 1988). Two trials were conducted on each paw, with 
at least 5 minutes between testing the opposite paw and at least 10 minutes between testing the 
same paw. To avoid tissue damage, a cut off latency of 20 seconds was set. Values from both 
paws were averaged to determine withdrawal latency. 
Alloknesis 
One hour after the intrathecal injection of morphine, mice were assessed for alloknesis. 
As previously described (Akiyama et al. 2012), alloknesis was assessed by delivering 3 separate 
innocuous mechanical stimuli using a von Frey filament (bending force: 0.7 mN; Stoelting, 
USA) every 5 minutes. Each application of the von Frey filament was reported as 1 trial, yielding 
a total of 18 trials over 30 minutes. 
Hyperknesis 
One hour after the intrathecal injection of morphine, mice were assessed for hyperknesis. 
Chloroquine (100 μg in 10 μL) was injected intradermally into the nape of the neck or calf and 
scratching behavior was recorded for 30 minutes. The total number of scratch bouts by the hand 
paws directed to the nape of the neck was counted. For hyperknesis following chemogenetic 
inhibition, chloroquine (100 μg in 10 μL) was injected intradermally into the calf and biting 
behavior was recorded for 30 minutes. 
RNAscope fluorescent in-situ hybridization 
Multiplex fluorescent in-situ hybridization (FISH) was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 μm-thick fresh-
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frozen sections containing the mouse or human spinal cord were fixed in 4% paraformaldehyde, 
dehydrated, treated with protease for 15 minutes, and hybridized with gene- and species-specific 
probes. Probes were used to detect eYFP-C1 (#312131), mCherry-C2 (#431201), Mm-Oprm1-
C1 (#315841), Mm-Npy-C2 (#313321-C2), Mm-Pdyn-C2 (#318771-C2), Mm-GRPR-C2 
(#317871-C2), Mm-Pvalb-C2 (#421931-C2), Mm-Nos1-C2 (#437651-C2), Mm-Slc32a1-C3 
(#319191), Hs-OPRM1-C1 (#410681), Hs-PDYN-C2 (#507161-C2). DAPI (#320858) was used 
to visualize nuclei. 3-plex positive (#320881) and negative (#320871) control probes were tested. 
Immunohistochemistry 
Mice were anesthetized with an intraperitoneal injection of urethane, transcardially 
perfused, and post-fixed at least four hours in 4% paraformaldehyde. 25 μm thick spinal cord or 
dorsal root ganglion sections were collected on a cryostat and slide-mounted for 
immunohistochemistry. Sections were blocked at room temperature for two hours in a 5% 
donkey serum, 0.2% triton, in phosphate buffered saline. Primary antisera was incubated for 14 
hours overnight at 4°C with rabbit anti-RFP (1:1K; Cat #600-401-379, Rockland, USA). 
Sections were subsequently washed and incubated in secondary antibodies (Life Technologies, 
1:500) at room temperature for two hours. Sections were then incubated in Hoechst 
(ThermoFisher, 1:10K) for 1 minute and washed, mounted, and a cover slip was applied. 
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in-situ hybridization experiments, confocal images of tissue samples (3-4 
dorsal horns per mouse over 3-4 mice or 5-6 images per dorsal horn from two human spinal 
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cords) were imaged and only cells whose nuclei were clearly visible by DAPI staining and 
exhibited fluorescent signal were counted. 
Electrophysiological recordings 
The semi-intact somatosensory preparation was made as previously described (Hachisuka 
et al. 2016; Hachisuka, Koerber, and Ross 2020). Briefly, young adult mice (5–9 weeks old) 
were deeply anesthetized and perfused transcardially through the left ventricle with oxygenated 
(95% O2 and 5% CO2) sucrose-based artificial cerebrospinal fluid (ACSF) (in mM; 234 sucrose, 
2.5 KCl, 0.5 CaCl2, 10 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, 11 Glucose) at room temperature. 
Immediately following perfusion, the skin was incised along the dorsal midline and the spinal 
cord was quickly exposed via dorsal laminectomy. The right hindlimb and spinal cord (~C2 – 
S6) were excised, transferred into Sylgard-lined dissection/recording dish, and submerged in the 
same sucrose-based ACSF, which circulated at 50 ml/min to facilitate superfusion of the cord. 
The skin innervated by the saphenous nerve and the femoral cutaneous nerve was dissected free 
of surrounding tissue. L2 and L3 DRG were left on the spine. Pial membrane was carefully 
removed and the spinal cord was pinned onto the Sylgard chamber with the right dorsal horn 
facing upward. Following dissection, the chamber was transferred to the rig. Then the 
preparation was perfused with normal ACSF solution (in mM; 117 NaCl, 3.6 KCl, 2.5 CaCl2, 
1.2 MgCl2, 1.2 NaH2PO4, 25 NaHCO3, 11 glucose) saturated with 95% O2 and 5% CO2 at 32 
°C. Tissue was rinsed with ACSF for at least 30 min to wash out sucrose. Thereafter, recordings 
were performed for up to 6 hours post-dissection. 
Patch clamp recording from dorsal horn neurons 
Neurons were visualized using a fixed stage upright microscope (BX51WI Olympus 
microscope, Tokyo, Japan) equipped with a 40x water immersion objective lens, a CCD camera 
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(ORCA-ER Hamamatsu Photonics, Hamamatsu City, Japan) and monitor screen. A narrow beam 
infrared LED (L850D-06 Marubeni, Tokyo, Japan, emission peak, 850 nm) was positioned 
outside the solution meniscus, as previously described (Szucs, Pinto, and Safronov 2009; 
Safronov, Pinto, and Derkach 2007; Hachisuka et al. 2016). PdynCre neurons in lamina I were 
easily identified by td-Tomato expression. Whole-cell patch-clamp recordings were made with a 
pipette constructed from thin-walled single-filamented borosilicate glass using a microelectrode 
puller (PC-10; Narishige International, East Meadow NY). Pipette resistances ranged from 6 to 
12 MΩ. Electrodes were filled with an intracellular solution containing the following (in mM): 
135 K-gluconate, 5 KCl, 0.5 CaCl2, 5 EGTA, 5 HEPES, 5 MgATP, pH 7.2. Alexa fluor 488 
(Invitrogen; 25 µM) was added to confirm recording from the target cell. Signals were acquired 
with an amplifier (Axopatch 200B, Molecular Devices, Sunnyvale CA). The data were low-pass 
filtered at 2 kHz and digitized at 10 kHz with an A/D converter (Digidata 1322A, Molecular 
Devices) and stored using a data acquisition program (Clampex version 10, Molecular Devices). 
The liquid junction potential was not corrected. 
Statistical analysis 
All statistical analyses were performed using GraphPad Prism 7. Values are presented as 
mean  SEM. P values were determined by tests indicated in applicable figure legends. Sample 
sizes were based on pilot data and are similar to those typically used in the field. 
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4.3 Results 
4.3.1 Pdyn neurons are required for neuraxial morphine-induced itch 
Given that morphine-induced itch is most commonly seen in humans when morphine is 
given neuraxially (Ballantyne, Loach, and Carr 1988), we next examined the possible role of 
spinal neurons. A previous study suggested that neuraxial morphine causes itch through 
activation of gastrin-releasing peptide receptor (Grpr) neurons in the dorsal horn (Liu et al. 
2011), an excitatory population that is involved in mediating itch (Sun and Chen 2007; Pagani et 
al. 2019). However, when we performed dual fluorescent in-situ hybridization (FISH) for Oprm1 
and Grpr in the dorsal horn, we found very limited overlap (Figure 9A). 
 
 
Figure 9. Spinal expression of Oprm1 in Grpr, Pdyn, and Npy neurons. 
(A to C) Representative image of fluorescent in-situ hybridization in the spinal dorsal horn comparing expression of 
Oprm1 to (A) Grpr, (B) Pdyn, (C) and Npy. The overlap is quantified below. Scale bar = 50 μm. n = 3 mice. Data 
are mean + S.E.M with dots representing individual mice. 
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Because opioids typically signal through Gαi-coupled G-protein coupled receptors to 
inhibit neuronal activity (Al-Hasani and Bruchas 2011; Torrecilla et al. 2008), we favored the 
hypothesis that morphine causes itch through disinhibition. Therefore, we examined the 
expression of Oprm1 across four distinct populations that account for the majority of inhibitory 
neurons in the dorsal horn (Boyle et al. 2017): Pdyn, Npy, Nos1, and Pvalb. Through multiplex 
FISH, we found that roughly half of the neurons in the dorsal horn that express Oprm1 are 
inhibitory neurons, as revealed by co-expression of Slc32a1, the gene encoding Vgat. Among 
these neurons, we found that Oprm1 is expressed across all four populations, with the highest 
expression in Pdyn neurons (40.52.7% of Pdyn neurons express Oprm1, representing 33.01.0% 
of Oprm1-expressing inhibitory neurons in the dorsal horn) followed by Npy neurons (23.53.6% 
and 18.22.6%, respectively) (Figure 10A and Figure 9B and C). 
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Figure 10. Oprm1 expression in Pdyn neurons is required for morphine-induced itch. 
(A) Oprm1 expression in neurons in the mouse spinal dorsal horn. n = 3 mice. (B) Fluorescent in-situ hybridization 
of human spinal dorsal horn depicting the co-expression of OPRM1 and PDYN. n = 3 individual dorsal horns. Arrow 
indicates the cell shown in the inset. Scale bar = 50 μm. (C) Electrophysiological recordings of PdynCre; Rosatdt 
neurons in the presence of DAMGO. n = 10 neurons. (D) Deletion of Oprm1 in Pdyn neurons in the spinal dorsal 
horn of PdynCre; Oprm1fl/fl animals compared to Oprm1fl/fl controls. Arrow indicates the cell shown in the inset. 
Scale bar = 50 μm, inset = 25 μm. n = 4 mice per group. (E to G) Deletion of Oprm1 in Pdyn neurons on morphine-
induced (E) itch (F) alloknesis, (G) and hyperknesis. (H) and heat sensitivity. n = 11-13 mice per group. (I) Oprm1 
deletion in Npy neurons on morphine-induced itch. n = 12 mice per group. P value was determined by (D) two-
tailed, unpaired t-test., (E to I), two-way ANOVA, with Bonferroni’s correction. (A to I) Data are mean + S.E.M. 
with individual dots representing (A and D to I) individual mice, (B) individual human dorsal horns, (C) and 
individual neurons. 
 
The Pdyn and Npy inhibitory neurons were particularly intriguing to us because we and 
others had previously discovered that these two populations inhibit itch (Acton et al. 2019; 
Bourane et al. 2015; Ross et al. 2010; Kardon et al. 2014). Indeed, when either Pdyn neurons or 
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Npy neurons are lost during development, mice show spontaneous scratching behavior 
suggesting that these populations are involved in the tonic inhibition of itch (Ross et al. 2010; 
Bourane et al. 2015). We therefore investigated these populations in more detail, beginning with 
Pdyn neurons. Just as in rodents, we found that human PDYN neurons express OPRM1, as 
revealed by dual FISH of the spinal dorsal horn from post-mortem tissue (Figure 10A and B). 
Furthermore, recordings from tdTomato-labeled Pdyn neurons (in PdynCre; Rosatdt mice) 
revealed that ~50% showed outward current in response to the Oprm1 agonist D-Ala2, N-
MePhe4, Gly-ol-enkephalin (DAMGO) (Figure 10C), consistent with the idea that Pdyn cells 
express functional Oprm1 and that activation of this receptor inhibits the cells. 
Based on these findings, we next asked whether expression of Oprm1 in Pdyn neurons 
was required for morphine-induced itch. Using a conditional deletion strategy, we selectively 
removed Oprm1 from Pdyn neurons (Figure 10D). Strikingly, this genetic manipulation 
completely eliminated I.T. morphine-induced itch, alloknesis, and hyperknesis (Figure 10E to 
G). Importantly, morphine-induced increases in paw withdrawal latency was unaffected in these 
animals (Figure 10H), indicating that Oprm1 expression on Pdyn neurons is required for 
morphine-induced itch but not morphine-induced analgesia. Because our data suggested that Npy 
neurons also express Oprm1 (Figure 10A and Figure 9C) and that these cells are known to inhibit 
itch, we also examined the contribution of this population. In contrast to Pdyn neurons, 
conditional deletion of Oprm1 from Npy neurons had no effect on neuraxial morphine-induced 
itch (Figure 10I and Figure 11A to D). These findings identify Pdyn neurons as the cellular 
mediator of morphine-induced itch. 
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Figure 11. Expression of Oprm1 in Npy neurons is not required for morphine-induced itch. 
(A) Fluorescent in-situ hybridization to validate deletion of Oprm1 in Npy neurons in the spinal dorsal horn in 
NpyCre; Oprm1fl/fl animals compared to Oprm1fl/fl controls. Scale bar = 50 μm. n = 4 mice per group. (B to D) 
Deletion of Oprm1 in Npy neurons on morphine-induced (B) hyperknesis, (C) alloknesis, (D) and heat sensitivity. n 
= 12 mice. P value was determined by (A) two-tailed, unpaired t-test, (B to D) and two-way ANOVA, with 
Bonferroni’s correction. Data are mean + S.E.M with dots representing individual mice. 
4.3.2 Inhibition of Pdyn neurons causes itch 
Our loss-of-function experiments implied that morphine causes itch through disinhibition 
of Pdyn cells. To test this idea directly, we sought to mimic opioid signaling in these cells 
through chemogenetic manipulation using either KORD or hM4Di, two Gi-coupled designer 
receptors exclusively activated by designer drugs (DREADDs). In these experiments, we 
injected Cre-dependent adeno-associated viruses (AAVs) into the lumbar spinal cord of PdynCre 
mice (Figure 12A and Figure 13A to D). Notably, in both approaches, chemogenetic inhibition 
of Pdyn neurons elicited spontaneous itch in the form of increased time spent biting the leg (the 
dermatome segment that corresponded to the site of viral delivery) (Figure 12B and C). We also 
observed hyperknesis and alloknesis, but no changes to heat sensitivity, upon chemogenetic 
inhibition of Pdyn neurons (Figure 12D to F). Together, these findings suggest that morphine 
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Figure 12. Inhibition of Pdyn neurons is sufficient to evoke itch. 
(A) Experimental design. (B and C) Time course for itch following chemogenetic inhibition of Pdyn neurons with 
(B) KORD (C) or hM4Di. (D to F) Chemogenetic inhibition of Pdyn neurons with KORD (green, left) and hM4Di 
(red, right) on (D) hyperknesis, (E), alloknesis, (F), and heat sensitivity. n = 7-11 mice per group. P value was 
determined by (B to E) two-tailed, unpaired t-test (F), and two-way ANOVA, with Bonferroni’s correction. (B, C) 



















































































































Figure 13. Validation of viral infection of Pdyn neurons. 
(A) Cre-dependent viruses used to selectively express KORD and hM4Di DREADDs into the spinal cord of PdynCre 
mice. (B and C) Representative image of fluorescent in-situ hybridization (left) and quantification (right) of the 
dorsal horn in Pdyn-Cre mice injected with (B) hM4Di (C) and KORD. n = 3 mice per group. (D) Representative 
image of a spinal cord and dorsal root ganglion section in PdynCre; Rosatdt mouse. Scale bar = 50 μm. (B and C) Data 
are mean + S.E.M with dots representing individual mice. 
4.4 Discussion 
Our study has uncovered a previously undescribed role for neuronal disinhibition in 
morphine-induced itch. It was previously suggested that an excitatory population of Grpr+ spinal 
neurons mediates morphine-induced itch through a specific isoform of the mu-opioid receptor, 
MOR1D (Liu et al. 2011). However, we observed very little overlap in the dorsal horn between 
Grpr and Oprm1 using a probe that targets a region common to all Oprm1 isoforms, including 
MOR1D (Figure 9A). Instead, we show that deletion of the mu opioid receptor from dynorphin 
neurons eliminated neuraxial morphine-induced itch. Furthermore, we found that ectopic 



















































































These findings further validate the concept that inhibitory spinal neurons inhibit itch 
(Ross et al. 2010; Kardon et al. 2014; Wang, Jiang, Yao, Chen, Rahman, Gu, Zhao, et al. 2020) 
and demonstrate that the dynorphin population of spinal neurons is modulated by mu agonists, 
such as morphine, to elicit itch. Dynorphin neurons provide a substrate upon which future 
therapies could be targeted for the management of itch conditions. 
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5.0 Nalfurafine treats morphine-induced itch in preclinical models 
5.1 Introduction 
Mixed opioid agonist-antagonists, such as nalbuphine and butorphanol, are frequently 
used for neuraxial opioid-induced pruritus (Jannuzzi 2016; Cohen et al. 1992; Lee et al. 2007). 
Compared to pure mu opioid antagonists, mixed agonist-antagonists are often preferred to 
manage pruritus because they do not reduce morphine’s analgesic effects (Cohen et al. 1992). 
However, one potential limitation of this class of antipruritics is sedation (Kjellberg and Tramèr 
2001; Jannuzzi 2016). 
Selective kappa opioid receptor agonists, such as nalfurafine, have also been proposed as 
therapeutic candidates for the treatment of opioid-induced pruritus (Ko 2015). Nalfurafine is 
frequently used for the treatment of uremic and cholestatic pruritus in Japan (Cowan, Kehner, 
and Inan 2015), although it is not presently FDA approved for use in the United States. Emerging 
evidence in preclinical models, involving both mice and non-human primates, support that kappa 
agonists can reduce morphine-induced itch without affecting morphine-induced analgesia (Ko 
and Husbands 2009; Akiyama et al. 2015). Thus, we tested whether nalfurafine, a selective 





The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 background. Even numbers of male and female mice were used for all 
experiments. No sex differences were found and, thus, animals were pooled. Mice were given 
food and water ad libitum and housed under standard laboratory conditions. 
Non-human primates 
All animal care and experiments in non-human primate study were conducted according 
to the Guide for the Care and Use of Laboratory Animals by the US National Institutes of Health 
(Bethesda, MD, USA), reported according to the ARRIVE guidelines (Kilkenny et al. 2010), and 
approved by the Institutional Animal Care and Use Committee of Wake Forest University 
(Winston-Salem, NC, USA). Five adult male and female rhesus monkeys (Macaca mulatta), 8–
16 years of age, 5.1–12.2 kg, with implanted intrathecal catheters (Ding et al. 2015) were used in 
this study. The monkeys were housed at an indoor facility accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care International (Frederick, MD, USA). 
The monkeys were individually housed in cages with 6-12 square feet of floor space with 
ceilings 2.7-5.4 feet high in a temperature-controlled room (21–25 °C, 40–60% relative 
humidity) with a 12-h light/dark cycle (Light On: 6:30-18:30). The monkeys were provided with 
water and their diet consisted of approximately 20–30 biscuits (Purina Monkey Chow; Ralston 
Purina Co., St. Louis, MO, USA) and fresh fruit ad libitum. Primate enrichment devices and 
small amounts of treats were provided daily. 
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Drug administration in non-human primates 
Morphine sulfate (National Institute on Drug Abuse, Bethesda, MD, USA) and 
nalfurafine HCl (provided by Dr. Stephen Husbands, University of Bath, Bath, UK) were 
dissolved in sterile water. For intrathecal administration(Ding et al. 2015), 1 mL of the test 
compound was administered through the subcutaneous access port, followed by 0.35 mL of 
saline to flush the dead volume of the port and catheter. 
Pharmacologic agents used in mice 
Morphine sulfate (4 mg/ml; Henry Schein Animal Health) and chloroquine diphosphate 
salt (Sigma) were dissolved in physiological saline. Nalfurafine (Sigma) was dissolved in saline 
and administered intrathecally. Loratadine (Sigma) and diphenhydramine (Sigma) were prepared 
in 10% DMSO and given 10 mg/kg I.P. For experiments involving antihistamines, animals were 
pretreated with vehicle, loratadine, or diphenhydramine 30 minutes prior to recording scratching 
behavior. 
Intradermal and intrathecal injections 
For intradermal injection of chloroquine, hair was clipped from the neck or calf of each 
mouse at least 24 hours before the experiment. Chloroquine (100 μg in 10 μL) was administered 
into the nape of the neck or calf, which could be subsequently visualized by the formation of a 
small bubble under the skin. For intrathecal injections, hair was clipped from the back of each 
mouse at least 24 hours before the experiment. All intrathecal injections were delivered in a total 
volume of 5 μL using a 30-gauge needle attached to a luer-tip 25 μL Hamilton syringe. The 
needle was inserted into the tissue at a 45° angle through the fifth intervertebral space (L5 – L6). 
Solution was injected at a rate of 1 μL/s. The needle was held in position for 10 seconds and 
removed slowly to avoid any outflow of the solution. Only mice that exhibited a reflexive flick 
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of the tail following puncture of the dura were included in behavioral analysis. These procedures 
were performed in awake, restrained mice. 
Observation of scratching behavior 
Scratching behavior was observed using a previously reported method (Kardon et al. 
2014). Mice were individually placed in the observation cage (12 x 9 x 14 cm) to acclimate for 
30 minutes. The mice were assigned to dosing conditions in a randomized manner. Scratching 
behavior was videotaped for 60 minutes after administration. 300 pmol of morphine was 
administered (I.T.). For experiments directed at the calf, the amount of time spent biting the leg 
was quantified over 60 minutes.  
To assess the effect of nalfurafine on intrathecal morphine-induced itch in non-human 
primates, scratching activity (Ko et al. 2004) was recorded when monkeys were in their home 
cages. Each 15-minute recording session was conducted at 0.5, 1, 2, 2.5 and 3 hours following 
intrathecal morphine administration. Nalfurafine (0.1 or 0.3 μg) or vehicle was intrathecally 
administered at 1.5 hours after intrathecal morphine (10 or 30 μg) administration. A scratch was 
defined as one brief (<1 second) action of scraping on the skin surface of other body parts using 
the forepaw or hind paw (Ko et al. 2004). The total number of scratches were counted and 
summed for each 15-minute period. 
Acute thermal nociception 
To assess the effect of nalfurafine on intrathecal morphine-induced antinociception in 
non-human primates, nalfurafine (0.3 μg) or vehicle was intrathecally administered at 1.5 hours 
after intrathecal morphine (10 μg). The warm water tail-withdrawal assay (Ko et al. 1999) was 
conducted before and 0.5, 1, 2, 2.5 and 3 hours after intrathecal morphine administration. The 
lower parts of their shaved tails (~15 cm) were immersed in water maintained at 42, 46, or 50 °C. 
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The monkeys were assigned to dosing conditions in a randomized manner. Water at 42 or 46 °C 
was used as a non-noxious stimuli (no tail-withdrawal movement was expected), and water at 50 
°C was used as an acute noxious stimulus (2-3 second tail-withdrawal latency). Experimenters 
measured tail-withdrawal latencies at each temperature by using a computerized timer. If a 
monkey did not withdraw its tail within 20 seconds (cut-off), the stimulus was removed and a 
maximum time of 20 seconds was recorded. 
Heat sensitivity assay (Hargreaves testing) 
Mice were acclimated on a glass plate held at 30°C (IITC Life Science Inc.). A radiant 
heat source (activity intensity of 15%) was applied to the hindpaw and latency to paw 
withdrawal was recorded (Hargreaves et al. 1988). Two trials were conducted on each paw, with 
at least 5 minutes between testing the opposite paw and at least 10 minutes between testing the 
same paw. To avoid tissue damage, a cut off latency of 20 seconds was set. Values from both 
paws were averaged to determine withdrawal latency. 
Alloknesis 
One hour after the intrathecal injection of morphine, mice were assessed for alloknesis. 
As previously described (Akiyama et al. 2012), alloknesis was assessed by delivering 3 separate 
innocuous mechanical stimuli using a von Frey filament (bending force: 0.7 mN; Stoelting, 
USA) every 5 minutes. Each application of the von Frey filament was reported as 1 trial, yielding 
a total of 18 trials over 30 minutes. 
Hyperknesis 
One hour after the intrathecal injection of morphine, mice were assessed for hyperknesis. 
Chloroquine (100 μg in 10 μL) was injected intradermally into the nape of the neck or calf and 
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scratching behavior was recorded for 30 minutes. The total number of scratch bouts by the hand 
paws directed to the nape of the neck was counted. 
RNAscope fluorescent in-situ hybridization 
Multiplex fluorescent in-situ hybridization (FISH) was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 μm-thick fresh-
frozen sections containing the mouse or human spinal cord were fixed in 4% paraformaldehyde, 
dehydrated, treated with protease for 15 minutes, and hybridized with gene- and species-specific 
probes. Probes were used to detect Mm-Oprk1-C1 (#316111), Mm-Slc17a6-C3 (#319171). 
DAPI (#320858) was used to visualize nuclei. 3-plex positive (#320881) and negative (#320871) 
control probes were tested. 
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in-situ hybridization experiments, confocal images of tissue samples (3-4 
dorsal horns per mouse over 3-4 mice or 5-6 images per dorsal horn from two human spinal 
cords) were imaged and only cells whose nuclei were clearly visible by DAPI staining and 
exhibited fluorescent signal were counted. 
Quantification of Fos 
Mice were lightly anesthetized with isoflurane before receiving I.T. morphine or saline. 
Twenty minutes later, their spinal cords were harvested for FISH. The total number of cells co-
expressing Fos, Oprk1, and Slc17a6 were counted and compared to the total number of cells co-
expressing Oprk1 and Slc17a6. 
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Statistical analysis 
All statistical analyses were performed using GraphPad Prism 7. Values are presented as 
mean  SEM. P values were determined by tests indicated in applicable figure legends. Sample 
sizes were based on pilot data and are similar to those typically used in the field. 
5.3 Results 
5.3.1 Restoration of dynorphin signaling alleviates morphine-induced itch 
Next, studies involving the immediate-early gene Fos were performed to examine the 
mechanism through which the inhibition of Pdyn+ neurons by morphine causes itch (Figure 
14A). Following I.T. morphine, we found an upregulation of Fos expression in neurons that 
express the kappa opioid receptor (Oprk1), consistent with the idea that inhibition of Pdyn+ 
neurons results in disinhibition (activation) of Oprk1+ neurons (Figure 14B and C, and Figure 
15A). Because Pdyn+ neurons release several inhibitory mediators, including dynorphin and 
GABA (Sardella et al. 2011; Tiong et al. 2011), we wondered which ones might be involved 
(Figure 14A). Therefore, we performed occlusion studies using the long-acting Oprk1 antagonist 
nor-binaltorphimine dihydrochloride (norBNI) to inhibit Oprk1 (Figure 17A and B). Substantial 
scratching was observed in mice pretreated with I.T. norBNI (Figure 17A), consistent with the 
idea that ongoing dynorphin tone in the spinal cord inhibits itch, as previously described (Kardon 
et al. 2014). However, pretreatment with norBNI did not prevent morphine from causing further 
itch (Figure 17A). This lack of occlusion suggests that morphine-induced itch is not due solely to 
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the inhibition of dynorphin release, and might therefore involve the disinhibition of Oprk1 
neurons through a reduction in the release of both inhibitory transmitters: dynorphin and GABA. 
 
 
Figure 14. Restoration of dynorphin signaling alleviates morphine-induced itch. 
(A) Model for morphine-induced itch. (B) Representative image for the expression of Fos in excitatory (Slc17a6 
containing) Oprk1 neurons. Arrow indicates the cell shown in the inset. Scale bar = 50 μm, inset = 25 μm. (C) 
Quantification of B. n = 3 mice. (D to G), in mice, the effect of nalfurafine (40 ng) on morphine-induced (D) itch, 
(E) hyperknesis, (F) alloknesis, (G) and heat sensitivity. n = 8 mice per group. P value was determined by  (D to F) 
two-tailed, unpaired t-test and (G) two-way ANOVA, with Bonferroni’s correction. (C to G) Data are mean + 
S.E.M. with dots representing individual mice. (D) Time course data are mean +/- S.E.M. 
 
Our model suggested that inhibition of Oprk1+ neurons should alleviate morphine-
induced itch. To test this idea, we examined the effect of nalfurafine, a selective Oprk1 agonist 
(Schattauer et al. 2017). In mice, we found that co-administration of nalfurafine and morphine 
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(I.T.) reduced morphine-induced itch, hyperknesis, and alloknesis compared to controls (Figure 
14D to F and Figure 15B to D). Importantly, the dose of nalfurafine that abrogated morphine-
induced itch did not reduce the analgesic efficacy of morphine to thermal sensitivity (Figure 14G 
and Figure 15E). These findings suggest that inhibition of Oprk1 neurons suppresses morphine-




Figure 15. Dose-response analysis of nalfurafine treatment for morphine-induced itch. 
(A) Representative image for the expression of Fos in Oprk1 neurons containing Slc17a6. These panels are 
shown merged in the main figure. Scale bar = 50 μm. (B to E) in mice, the effect of nalfurafine (1.25 ng) on 
morphine-induced (B) itch, (C) hyperknesis, (D) alloknesis (E) and heat sensitivity. n = 8 mice per group. 
(F and G) in primates, the effect of nalfurafine (10 ug) following I.T. morphine (30 ug) on itch (F) as a 
time course, (G) and cumulatively over 60 minutes. n = 4 primates per group. P value was determined by 
(B to D) two-tailed, unpaired t-test, (E and F) two-way ANOVA, with Bonferroni’s correction, (G) and 
one-way ANOVA with Bonferroni’s correction.  (B and F) Time course data are mean  S.E.M. (B to E and 
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Figure 16. Antagonism of the kappa-opioid receptor evokes itch. 
(A) Antagonism of the kappa-opioid receptor with nor-Binaltorphimine dihydrochloride (norBNI, (1 μg) on 
spontaneous and morphine-induced itch. (B) Oprk1 antagonism on morphine-induced analgesia to heat sensitivity. n 
= 6-8 mice per group. P value was determined by two-way ANOVA with Bonferroni’s correction. Data are mean + 
S.E.M with dots representing individual mice. 
 
To examine the translational relevance of these findings, we repeated these experiments 
in non-human primates. Again, I.T. nalfurafine reduced the number of morphine-induced 
scratches without affecting analgesia to tail withdrawal (Figure 17A and B, and Figure 15F and 
G). Thus, in both mouse as well as non-human primate models, we observed that treatment with 







































Figure 17. I.T. nalfurafine alleviates morphine-induced itch in non-human primates. 
(A) The effect of nalfurafine (0.3 μg) on I.T. morphine-induced itch (10 μg). P values were determined by two-way 
ANOVA, with Bonferroni’s correction (left) and two-tailed, unpaired t-test (right). (B) Effect of nalfurafine (0.3 μg) 
on tail-withdrawal. n = 5 primates per group. Data are mean + S.E.M. with dots representing individual primates. 
Time course data are mean  S.E.M. 
5.4 Discussion: relation to human health 
In mice and in non-human primates models, we found that the intrathecal administration 
of nalfurafine significantly reduces morphine-induced itch. These results help explain the 
mechanism of action for nalbuphine (a mixed kappa agonist and mu antagonist) (Szarvas, 
Harmon, and Murphy 2003; Jannuzzi 2016) as a treatment for morphine-induced itch. However, 
a major limitation of nalbuphine is that it reduces the analgesia provided by morphine (Anwari 
and Iqbal 2003; Jannuzzi 2016). Unlike nalbuphine, we found that nalfurafine does not affect the 
therapeutic analgesic effects of morphine, assessed by thermal behaviors (Figure 14G and Figure 
17B).  
However, one limitation of our study is that we did not perform extensive dose-response 

































































Although nalfurafine is a selective agonist for the kappa-opioid receptor, it is possible it may also 
have off-target effects on other receptors, such as the mu-opioid receptor. Furthermore, potential 
extra-pyramidal effects were not assessed in our models. The dose that was chosen (40 ng IT) 
was based on a previous study from our group (Kardon et al. 2014) that demonstrated that 
nalfurafine inhibits various forms of pruritogen-evoked itch in mice. Before nalfurafine can be 
considered in clinical studies, it will be necessary to evaluate its appropriate dosing regimen and 
specificity for opioid-induced itch and not opioid-induced analgesia. 
Our results provide a mechanistic explanation for how nalbuphine may be useful for 
morphine-induced itch, our experiments in mice and non-human primates model a circuit upon 
which a selective Oprk1 agonist, such as nalfurafine, can effectively be used for the treatment of 
clinical neuraxial morphine-induced itch in humans.  
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6.0 Conclusion 
In this study, we first addressed the long-standing controversy regarding the mechanism 
through which antihistamines block neuraxial morphine-induced itch by demonstrating that mast 
cells are not involved. Instead, our studies suggest that the apparent reduction in itch mediated by 
centrally-acting antihistamines may be secondary to their somnolescent effects. Next, we 
discovered that Oprm1 expression in Pdyn+ neurons is required for neuraxial morphine-induced 
itch and that chemogenetic inhibition of Pdyn+ neurons is sufficient to cause itch. Lastly, we 
activated Oprk1 signaling using nalfurafine, an Oprk1 agonist, to block morphine-induced itch in 
mice and non-human primates. Together, these findings reveal a distinct disinhibitory neural 
circuit for morphine-induced itch, which might have important implications for the clinical 
management of this condition. 
Diphenhydramine is still frequently prescribed as a first-line treatment for morphine-
induced itch (Szarvas, Harmon, and Murphy 2003; Jannuzzi 2016). However, clinicians have 
observed that the sedating effects of antihistamines have caused patients to verbally deny itch 
while continuing to scratch, and that patients are itchy in between periods of sleep (Roth et al. 
1987; Ballantyne, Loach, and Carr 1988; Horta et al. 2006). Histaminergic neurons in the 
tuberomammillary nucleus of the posterior hypothalamus are thought to promote wakefulness 
through their activation of H1R, and antihistamines are thought to cause sedation through the 
antagonism of these receptors, which are widely distributed in the brainstem (Lin et al. 1996) and 
cortex (Tashiro et al. 2009; Reiner and Kamondi 1994; Thakkar 2011). Importantly, this 
unwanted side effect of sedation is particularly undesirable in the context of morphine-induced 
itch because it raises safety concerns due to the potential of antihistamines to exacerbate 
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respiratory depression caused by opioids (Anwari and Iqbal 2003; Jannuzzi 2016; Roth et al. 
1987).  
Our findings support that diphenhydramine reduces morphine-induced itch in mice, but is 
accompanied by a reduction in locomotor activity, consistent with the clinical observation that 
diphenhydramine also reduces opioid-induced pruritus and is sedating in patients. We rule out 
the contribution of mast cells using a mast cell depletion model. However, the possibility that 
opioids act on descending histamine-producing neurons to elicit itch remains an open question. It 
is interesting to speculate that the ability to restrict the action of an H1R antagonist to the spinal 
cord (to avoid its action on supraspinal targets involved in wakefulness) may also attenuate 
morphine-induced itch. Future experiments that could separate the possible itch-producing and 
sleep-producing effects of histamine in the nervous system may help to address the role and 
appropriateness of using antihistamines for neuraxial opioid-induced itch. 
Presently our results suggest that mast cells are not involved in opioid-induced itch. In 
addition, the finding that diphenhydramine only reduces scratching at a dose that also suppresses 
locomotor activity further underscores the concept that the use of antihistamines for neuraxial 
morphine-induced itch may be inappropriate. 
In human, non-human primate, and mouse models, we have validated that neuraxial 
morphine causes itch (Waxler et al. 2005b; Jannuzzi 2016; Ganesh and Maxwell 2007; Szarvas, 
Harmon, and Murphy 2003; Ballantyne, Loach, and Carr 1988; Sakakihara, Imamachi, and Saito 
2016; Liu et al. 2011; Ko and Husbands 2009; Lee et al. 2007; Ko 2015). Intriguingly, although 
neuraxial morphine elicited itch in all three species, the duration of itch in humans and non-
human primates was longer than that observed in mice. This difference in duration of morphine 
action likely reflects species differences in a variety of factors that influence drug distribution 
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and half-life, including the relative expression levels of metabolic enzymes, receptor signaling, 
and trafficking (Yamamoto et al. 2018). Other possible explanations include the ways in which 
animals (such as rodents and primates) model itch compared to patients. It is possible that mice 
are sensitized to opioid-induced itch on a more extended timeframe, but this does not result in 
significant scratching behaviors compared to grooming at later timepoints. In humans, a single 
rating is typically reported at specific timepoints and this may not completely capture patients’ 
experiences with itch over time. A more interesting comparison may be made using wearable 
devices that could quantify scratching over time in human subjects. Another possible explanation 
is that there may be additional, divergent mechanisms that underlie opioid-induced itch in 
different species. Nevertheless, the finding that nalfurafine reduces morphine-induced itch in 
both mice and non-human primates suggests a common underlying circuit mechanism, which 
may also apply to humans. 
6.1 Limitations 
6.1.1 The mu-opioid receptor is only expressed in a subset of spinal dynorphin neurons 
One prior study identified Pdyn excitatory neurons, largely enriched in the medial third of 
the dorsal horn, and these neurons are presumed to innervate the glabrous skin and modulate 
mechanical sensitivity (Huang et al. 2018). In our experiments, we only counted the expression 
of the mu-opioid receptor within Pdyn neurons as a subset of the GABAergic population. 
Chemogenetic activation was previously found to facilitate mechanical allodynia (Huang et al. 
2018), but did not affect thermal thresholds, consistent with our lack of Hargreaves findings. The 
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finding that chemogenetic activation of Pdyn neurons facilitates mechanical hypersensitivity 
(Huang et al. 2018) is consistent with the upregulation of dynorphin in models of chronic pain 
(Luo et al. 2008). Although we did not test animals for mechanical thresholds, in this paradigm, 
if excitatory Pdyn neurons involved in mechanical sensitivity contain the mu-opioid receptor, 
then it is plausible that morphine could also inhibit this excitatory population to produce anti-
allodynic effects, consistent with its role as an analgesic. However, excitatory Pdyn neurons are 
unlikely to be involved in the inhibition of itch. Nevertheless, it is interesting to speculate that 
patients who experience chronic pain may also have elevated levels of dynorphin as well as 
reduced susceptibility to opioid-induced pruritus. This would be in line with the high incidence 
of opioid-induced pruritus in healthy patients. Examination of spinal dynorphin levels in the CSF 
among chronic pain and healthy patients prior to the administration of neuraxial opioid 
anesthesia and correlation to patients’ experiences with pain and itch following neuraxial opioid 
anesthesia may test this idea further. 
Our finding that roughly 40% of Pdyn neurons contain Oprm1 highlights the possibility 
that there may exist sub-populations of Pdyn neurons. It is possible that different subsets of these 
Pdyn cells modulate chemical and mechanical itch as well as mechanical hypersensitivity 
(Huang et al. 2018). By using the Pdyn-Cre allele, our approach does not allow us to assess the 
contributions of distinct subpopulations within the dynorphin population; thus, our approach 
lacks genetic specificity. Advances in intersectional genetic strategies can allow further 
dissection of individual subpopulation and their contributions to itch and pain. 
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6.1.2 The role of Oprm1 isoforms 
Although several studies have implicated differential contributions of Oprm1 isoforms in 
opioid-induced pruritus and analgesia (Pasternak 2004; Andoh et al. 2008; Sia et al. 2008), one 
limitation of our study is that the specific Oprm1 isoform in Pdyn+ neurons that could be 
responsible for morphine-induced itch was not addressed because our genetic strategy does not 
distinguish among splice variants. Specific knock-down studies are necessary to differentiate the 
contributions of specific splice variants to morphine-induced analgesia and pruritus (discussed 
further in the future directions). 
6.1.3 Peptides and transmitters involved in opioid-induced pruritus 
Another limitation is that although we found that mu-opioid signaling inhibits dynorphin 
neurons and although we do not yet know the degree to which this modulation involves 
dynorphin or GABA release from these cells, our occlusion studies raise the possibility that both 
may be involved. Interestingly, we found that treatment with a kappa antagonist, norBNI, in the 
presence of morphine resulted in an enhancement of morphine-induced itch. This implicates the 
role of GABA in the modulation of opioid-induced itch in mice. In any case, the finding that 
nalfurafine reverses morphine-induced itch suggests that neurons containing the kappa opioid 
receptor are the relevant target for inhibition by Pdyn neurons. 
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6.1.4 Other sources of dynorphin in the spinal cord 
Our conditional deletion approach provided genetic specificity and permitted the 
selective removal of the mu-opioid receptor from dynorphin neurons. However, this approach 
lacks spatial specificity. Although we speculate that it is the expression of the mu-opioid receptor 
on inhibitory spinal neurons that make dynorphin that is required for morphine-induced itch, it is 
unknown what, if any, role other dynorphin neurons expressing the mu-opioid receptor may have 
on itch. We believe that the intrathecal administration of morphine supports the idea that spinal 
dynorphin neurons are important, it is possible that the drug may spread rostrally to other 
possible, mu-sensitive dynorphin neurons. These other targets are not likely to include the dorsal 
root ganglia (due to a lack of dynorphin expression in primary sensory neurons), but may include 
descending dynorphin neurons recently identified in the lateral pons that also inhibit itch 
(Agostinelli 2020). Genetic approaches that allow for the targeting of mu-expressing dynorphin 
neurons at different sites of the nervous system will provide more clarity on this question. 
6.2 Future directions 
6.2.1 Modulation of itch and pain by Oprm1 polymorphisms and splice isoforms 
Sequencing of the OPRM1 gene has revealed that certain polymorphisms may be 
associated with protection against the side effect of pruritus (Tsai et al. 2010; Pettini et al. 2018). 
For example, genetic association studies have focused on the A118G polymorphism of OPRM1 
(Tsai et al. 2010; Pettini et al. 2018). The recessive G allele in this polymorphism is associated 
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with lower incidences of pruritus among obstetric patients receiving epidural (4.8%) and spinal 
(0-50%) morphine (Tsai et al. 2010; Pettini et al. 2018). This variant is further associated with 
reduced sensitivity to the analgesic effects of opioids (Sia et al. 2008), suggesting that the 
A118G polymorphism may give rise to a mu-opioid receptor that is less responsive to opioid 
medications. In mice, distinct splice variants of the mu-opioid receptor, MOR1D and MOR1, 
have been shown to differentially modulate morphine-induced itch and morphine-induced 
analgesia, respectively (Liu et al. 2011).  
Nearly 20 splice variants have been identified in humans, which may explain the varied 
effects of opioid medications on patient outcomes (Pasternak 2010). However, the contributions 
of these splice variants have not yet been fully characterized in humans. Additional multi-center 
genetic association studies are necessary to further assess the clinical contributions of genetic 
variations to acute postoperative pain management and its side effects. Furthermore, knockdown 
studies of these isoforms in preclinical models, such as in rodents, or in vitro, within specific 
neuronal populations could further elucidate the differential contributions of these isoforms in 
pruritus and analgesia. These findings could pave the way for genetic therapies that target 
specific receptors to improve the clinical management of both itch and pain. 
6.2.2 Role of KOR neurons in itch 
A similar, contemporary study found that expression of Oprm1 in GABAergic neurons is 
required for opioid-induced itch in mice (Wang, Jiang, Yao, Chen, Rahman, Gu, Huh, et al. 
2020). It was also found that intrathecal administration of an Npy antagonist also treated opioid-
induced itch. In our experiments, we found that deletion of Oprm1 from Npy neurons did not 
affect morphine induced-itch (P=0.1832, two-way ANOVA with Bonferroni’s correction). We 
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also observed that morphine-induced alloknesis in mice lacking Oprm1 in Npy neurons was not 
different from saline-controls (P>0.9999, two-way ANOVA with Bonferroni’s correction). 
Based on these findings, we propose that it is unlikely that Oprm1 in Npy neurons is contributory 
to morphine-induced alloknesis. This, in some ways, is a departure from previous work 
implicating Npy neurons in the inhibition of mechanical itch (Bourane et al. 2015; Acton et al. 
2019). We propose that unlike Npy neurons, which are not presently thought to be involved in 
gating chemical itch, Pdyn neurons could be involved in gating both forms of itch.  
In particular, from our data, we speculate that both chemical and mechanical itch 
following morphine exposure, as observed in humans and in mice, could arise from downstream 
pathways that can be modulated with a kappa-opioid receptor agonist. Our pharmacological 
management of spontaneous itch, alloknesis, and hyperknesis with nalfurafine suggests that 
mechanical and chemical itch could converge on neurons containing the kappa opioid receptor.  
These results highlight the importance of defining the roles of spinal neurons containing 
the kappa opioid receptor (KOR) in both chemical and mechanical forms of itch. 
Pharmacological studies have highlighted the potential roles of KOR neurons in the modulation 
of pain and itch (Ko and Husbands 2009; Akiyama et al. 2015; Phan et al. 2012). They have also 
been proposed to overlap with an excitatory population of itch neurons containing GRPR 
(Munanairi et al. 2018). Thus, given the established role of dynorphin neurons in the inhibition 
of itch and the efficacy of kappa agonists in the management of itch, it follows that KOR spinal 
neurons could also function as mediators of itch. It remains unknown whether KOR-expressing 
spinal neurons comprise a class of interneurons, projection neurons, or both. The development of 
the KOR-Cre knock-in allele from our laboratory provides an opportunity to begin the 
investigations (Cai et al. 2016; Snyder et al. 2018). Determination of the locus of dynorphin 
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neurons within an itch circuit, particularly with respect to downstream neurons that express 
KOR, could provide a definitive explanation for how chemical itch is spinally-processed, 
transmitted to the brain, and capable of entering conscious perception.  
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7.0 Introduction to the role of the rostral ventromedial medulla in descending pain 
modulation 
The rostral ventromedial medulla RVM constitutes one of the major bulbospinal regions 
that conveys information from the brainstem to the spinal cord (Liang, Watson, and Paxinos 
2016; Basbaum and Fields 1984). Through a process known as descending modulation, the RVM 
has been shown to participate in many critical processes including nociception, arousal, 
thermoregulation, and feeding (Fields, Malick, and Burstein 1995; De Felice et al. 2011; Mason, 
Gao, and Genzen 2007; Foo and Mason 2003; Foo, Crabtree, and Mason 2010; Mason 2012).  
The RVM has functionally been defined as the midline medullary structure in which 
electrical stimulation or opioid microinjection is sufficient to evoke behavioral antinociception 
(Heinricher et al. 2009). It is thought to comprise two major structures: the raphe nuclei, 
including raphe magnus (RMg) and the nucleus gigantocellularis, alpha (NGCɑ). Within these 
structures are diverse populations of neurons, heterogeneous in size and morphology. 
Furthermore, their molecular identities and functional roles remain to be fully characterized. 
Understanding the roles of specific RVM neurons is further complicated by the structure’s 
importance in broad functions: from feeding, to thermosensation, nociception, and arousal. This 
section highlights the role of the RVM in these varied functions, examines the putative cell types 
involved based on pharmacological studies, and summarizes the recent findings of genetically 




7.1 Descending modulation of pain 
In the 1970s, it was discovered that stimulation of the PAG was sufficient to inhibit 
behavioral responses to noxious stimulation in rats (Reynolds 1969; Mayer and Liebeskind 1974; 
Mayer et al. 1971). This discovery was further translated and reproduced in humans, whereby 
neurosurgical electrical stimulation of the PAG produced clinically significant relief for pain 
(Hosobuchi, Adams, and Linchitz 1977; Baskin et al. 1986). Critically, stimulation of the PAG 
also inhibited nociceptive dorsal horn neurons, suggesting that analgesia was mediated through 
sensory, rather than motor, responses (Liebeskind et al. 1973; Budai, Harasawa, and Fields 1998; 
Peng, Lin, and Willis 1996b, 1996a). 
The discovery of an endogenous system for analgesia, together with the expansion of 
methodology to investigate this system (including pharmacology, anatomical tract tracing, and 
combined electrophysiology with electrical stimulation) rapidly led to detailed knowledge of the 
role of the PAG in descending modulation (Millan 2002). Ultimately, it was found that the PAG 
does not project directly to the spinal cord (Basbaum and Fields 1979), but, instead, modulates 
nociception through projection projections to the RVM, which can be considered the output of 
the pain-modulation system (Prieto, Cannon, and Liebeskind 1983; Basbaum and Fields 1979; 
Gebhart 1982). Thus, the RVM produces endogenous modulation of pain at the spinal level. 
The majority of research into the RVM has focused on its role in the descending 
modulation of pain. Although it may be enticing to ascribe the role of the RVM to an exclusively 
pain-modulatory hub, RVM functions are highly diverse and complex (Ma and Huang 2016). A 
few of its other roles are discussed in the following sections. 
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7.2 Circuitry of RVM neurons in descending modulation 
7.2.1 Inputs to the RVM 
The most well-studied region projecting to the RVM is the PAG. Lesioning and 
inactivation of the RVM (with local anesthetics) block the antinociceptive action of PAG 
(Behbehani and Fields 1979; Prieto, Cannon, and Liebeskind 1983; Gebhart 1982). Therefore, 
the RVM is a necessary component within the descending modulatory circuit activated by 
stimulation of the PAG. The PAG receives direct inputs from the hypothalamus and from the 
limbic system, including the frontal neocortex and several subregions of the amygdala that could 
pertain to nociception (Tracey and Mantyh 2007). For instance, microinjection of opioids in the 
basolateral amygdala (BLA) is sufficient to produce antinociception and modulates RVM ON 
and OFF cells in a manner similar to that seen following systemic or RVM opioid administration 
(McGaraughty and Heinricher 2002). Whether the effect of the BLA on RVM is direct or is 
mediated through the PAG as an intermediary region remains unclear (Barbaro, Heinricher, and 
Fields 1986; Ansah et al. 2009; Helmstetter et al. 1998). Together with these corticolimbic 
structures, such as the amygdala, the PAG has been implicated in the affective and cognitive 
aspects of pain (Millan 1999) 
Currently, it is thought that the PAG also contains at least two classes of neurons that 
divergently modulate nociception, not unlike the ON/OFF model in the RVM. In addition to their 
differences in sensitivity to pharmacological agents (Moreau and Fields 1986; Carstens, Stelzer, 
and Zimmermann 1988; Behbehani et al. 1990), PAG neurons can also be distinguished by their 
transmitter. Vgat, or inhibitory neurons are thought to be pain facilitating, whereas Vglut2, or 
excitatory neurons are thought to be anti-nociceptive (Samineni et al. 2019, 2017; Aimone and 
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Gebhart 1986; Jiang and Behbehani 2001). Interestingly, unlike RVM neurons, PAG neurons 
appear to have modality-specificity and are differentially engaged to modulate pain and itch 
(Samineni et al. 2019). While there have considerable advances to the understanding of PAG 
circuitry, such as the discoveries that implicate a disinhibitory model by which inhibitory 
neurons in the PAG exert tonic inhibition over RVM-projecting, excitatory neurons (Vaughan et 
al. 1997; Budai and Fields 1998; Heinricher et al. 2009), how these circuits are engaged for 
distinct somatosensory modalities warrants further investigation. 
Another midbrain structure that has also been extensively documented in relaying 
nociceptive information to the RVM is the PBN. The PBN is thought to be a central “alarm” 
nucleus, one that synchronizes information that could represent threats to the body (Han et al. 
2015; Campos et al. 2018; Carter, Han, and Palmiter 2015). The PBN has also been shown to 
engage descending pain modulatory systems (Lapirot et al. 2009; Roeder et al. 2016). 
Optogenetic activation of PBN terminals in the RVM has a net effect of inhibiting OFF cells and 
activating ON cells, giving rise to pro-nociceptive phenotypes (Chen et al. 2017). However, it is 
also important to note that in addition to nociceptive information, the PBN also conveys 
information to the RVM pertaining to autonomic homeostasis, such as thermoregulation 
(Nakamura et al. 2004; Tupone, Madden, and Morrison 2014; Cano et al. 2003; Shaun F 
Morrison 2016). Some experiments have been able to dissociate the pain-modulating and 
autonomic functions of RVM neurons by using pharmacology to selectively block specific 
classes of neurons (Martenson, Cetas, and Heinricher 2009). However, it remains unknown how 
nociception and thermoregulation may be encoded at the cellular, molecular, and circuit level. 
Research into the hypothalamus has emphasized its role in coordinating autonomic and 
sensory information, particularly in response to stress (Martenson, Cetas, and Heinricher 2009) 
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and sleep (Foo and Mason 2003). Further, stimulation of the lateral hypothalamus has also been 
shown to produce antinociception via the PAG and RVM (Aimone, Bauer, and Gebhart 1988; 
Dafny et al. 1996; Behbehani, Park, and Clement 1988; Cechetto and Saper 1988; Manning and 
Franklin 1998), which leads to the descending inhibition of pain. Considering that patients with 
chronic pain have poor sleep Disturbed Sleep in Patients Complaining of Chronic Pain : The 
Journal of Nervous and Mental Disease; Drewes et al. 1998; Mahowald et al. 1989; 
Gudbjörnsson et al. 1993; Drewes et al. 1994), this pathway may represent a promising candidate 
to help these patients.  
Lastly, stimulation of the nucleus tractus solitarius (NTS) can elicit antinociception 
(Morgan et al. 1989; Aicher and Randich 1990; Lewis, Baldrighi, and Akil 1987) as well as the 
facilitation of pain through vagal stimulation (Zhuo and Gebhart 1992; Ren, Randich, and 
Gebhart 1991; Wiertelak et al. 1997). This bi-directional modulation of pain is thought to occur 
through NTS projections to the RVM (Aicher and Randich 1990; Zhuo and Gebhart 1992, 1997). 
In addition to these dualistic roles in the descending modulation of pain, the NTS also conveys 
visceral and autonomic information to the RVM (Pérez and Ruiz 1995). Further research is 
needed to elucidate these roles. 
Although there are many other brain regions that participate in the descending 
modulation of pain and may exhibit connectivity with the RVM, this section emphasizes the 
structures that have received recent attention and highlight the role of the RVM in the integration 




Figure 18. Nodes for descending modulation and identified cell types. 
Within the canonical PAG RVM spinal pathway, distinct neuronal populations have been directly manipulated using 
genetic tools. These molecular populations are shown and their roles in the modulation of itch and pain are denoted. 
In the spinal cord dorsal horn, RVM and other supraspinal inputs that have been identified using labeled genetic 
drivers are detailed. PAG, periaqueductal gray; RVM, rostral ventromedial medulla; LC, locus coeruleus; MdD, 
medullary reticular nucleus; PVN, paraventricular nucleus of hypothalamus; LJA5, lateral pons, juxta A5; Vgat, 
vesicular GABA transporter; Vglut2, vesicular glutamate transporter 2; Tac1, tachykinin 1; Gad2, glutamate 
decarboxylase 2; Tph2, tryptophan hydroxylase 2; GRPR, gastrin releasing peptide receptor; Penk, proenkephalin; 
NE, norepinephrine; NK1R, neurokinin 1 receptor; Dyn, dynorphin; KOR, kappa opioid receptor. 
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7.2.2 RVM efferent projections 
7.2.2.1 Ascending projections 
Supraspinal targets of RVM projections have been observed in the brainstem (PAG, NTS, 
PBN) as well as the midbrain (parafascicular nucleus, lateral hypothalamus, and locus coeruleus) 
(François et al. 2017; Sim and Joseph 1992; Hammond, Tyce, and Yaksh 1985). It is proposed 
that RVM projections to the PBN and lateral hypothalamus may be involved in analgesia and 
hyperalgesia in the setting of acute and chronic stress, respectively (François et al. 2017). 
However, these efferent pathways arising from the RVM have not been tested directly with 
respect to pain.  
7.2.2.2 Projections to the spinal cord 
Input from the RVM to the dorsal horn of the spinal cord has been well-characterized 
(Fields, Malick, and Burstein 1995; Watkins et al. 1980). The RVM has been shown to project to 
superficial as well as deep laminae in the spinal cord (Fields, Malick, and Burstein 1995; Martins 
and Tavares 2017; Millan 2002) via the dorsolateral and ventrolateral funiculi (F Wei, Ren, and 
Dubner 1998; Jones and Gebhart 1987; Mokha, McMillan, and Iggo 1986; McMahon and Wall 
1988).  
One recent study used optogenetics to examine RVM inputs to neurons in the spinal cord 
(François et al. 2017). This study found that GABAergic projections from the RVM provided 
pro-nociceptive input to enkephalinergic (Penk) neurons in the dorsal horn and that these Penk 
neurons presynaptically inhibit mechanosensory neurons, thereby reducing mechanical pain 
(François et al. 2017). The contributions of other RVM neurons, such as the excitatory ones, to 
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dorsal horn circuits remain unknown. Nevertheless, advances in molecular approaches (François 
et al. 2017) present exciting opportunities to uncover the complexity of top-down modulation. 
There exists a precedent for the direct innervation of primary sensory neurons by the 
RVM. Inoculation of the DRG with a retrograde virus has resulted in labeling in the RVM, 
suggesting that RVM neurons could project to primary afferents (Zhang et al. 2015). Axo-axonic 
synapses between inhibitory RVM to DRG neurons are proposed to modulate heat, but not 
mechanical pain (Zhang et al. 2015). However, these same inhibitory (Gad2) RVM neurons also 
project extensively to the dorsal horn, and experiments have not been conducted to differentiate 
between the contributions of RVM neurons that project directly to spinal neurons or to DRG 
inputs into spinal neurons. Furthermore, electron microscopy of RVM-spinally projecting 
neurons have previously revealed that RVM contacts to the dorsal horn are largely axo-somatic 
in nature (Aicher et al. 2012). Given the paucity of further literature that supports a direct 
projection from the RVM to primary afferents, it is likely that the labeling detected in the RVM 
with DRG infection may be nonspecific and that observed behavioral phenotypes are a result of 
the RVM influence over dorsal horn neurons. 
7.2.3 Differential modulation of dermatomal segments by the RVM 
The question as to whether somatotopic organization exists within the RVM with respect 
to descending modulation remains an open one. Previous studies have reported variations in 
descending modulation between spinally-innervated lumbar segments, and uncovered differential 
modulation to heat to the tail and foot (Fang and Proudfit 1996). Furthermore, another study in 
an inflammatory model found that RVM inactivation completely blocked allodynia to the face, 
but not plantar hind paw (Edelmayer et al. 2009). Recordings of RVM neurons has revealed that 
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different proportions of ON, OFF, and NEUTRAL cells respond to noxious stimuli directed to 
different parts of the body, such as pinching of the hind paw, facial skin, intra-TMJ injection of 
ATP, and capsaicin to the ocular surface (Khasabov et al. 2015). RVM projections to the dorsal 
horn have also been shown to be more likely to contain GAD67 than those to the trigeminal 
dorsal horn (Aicher et al. 2012). Given the precedent for divergent modulation of different body 
parts by the RVM, further studies are necessary to consistently examine the roles of RVM 
neurons at modulating pain at different dermatomal segments. 
7.2.4 RVM interneurons 
In addition to ascending and descending projections, RVM neurons have also been shown 
to participate in local microcircuits (Millan 2002). For example, infusions of KOR agonists into 
the RVM have uncovered that in addition to the ON and OFF classification scheme (discussed 
further in the next section), RVM neurons can also be classified as primary and secondary cells 
(Pan, Tershner, and Fields 1997). In this model, primary cells function similarly to OFF cells, are 
inhibited by KOR agonists, and receive inhibition from secondary (ON) cells. The ability of 
primary cells to inhibit spinal pain transmission occurs when they are disinhibited by mu-opioid 
receptor inhibition of secondary cells (Pan, Tershner, and Fields 1997). This model highlights an 
opposing relationship between mu- and kappa-opioid receptors in the RVM. In other areas of the 
CNS, a disruption between mu and kappa signaling has been implicated in pathophysiological 
processes such as addiction, emotion, and itch (Pfeiffer et al. 1986; Hooke, He, and Lee 1995; 
Bolanos et al. 1996; Ko 2015). Thus, it is possible that an imbalance in opioidergic signaling 
within the RVM could also underlie pain.  
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7.3 Characterizations of RVM neurons 
Single unit recordings within the RVM in lightly anesthetized rats have provided 
significant insight into three types of neurons in the RVM: ON, OFF, NEUTRAL neurons based 
on their firing activity and responses to noxious stimulation (Fields, Malick, and Burstein 1995; 
Heinricher et al. 2009; Mason, Gao, and Genzen 2007). ON cells are active during noxious 
stimulation, inhibited by morphine and proposed to facilitate nociception, whereas OFF cells are 
inactive or exhibit silent ongoing activity during noxious stimulation, are excited by morphine, 
and are thought to inhibit nociception (Cleary, Neubert, and Heinricher 2008; Heinricher et al. 
2009; Mason 2012; Zhuo and Gebhart 1997). NEUTRAL cells are unaffected by noxious 
cutaneous stimuli or by exogenous opioids, and their role in nociception is unclear, although they 
are generally thought to be largely serotonergic (Potrebic, Fields, and Mason 1994) and are 
believed to participate in autonomic and homeostatic functions (Mason, Gao, and Genzen 2007; 
Hellman et al. 2009; Foo and Mason 2003; Foo, Crabtree, and Mason 2010; Foo and Mason 
2005).  
Another proposed model by which to classify RVM neurons has been achieved by 
assigning them as “primary” or “secondary” cells based on their responsiveness to opioid 
agonists and roles in the descending modulation of nociception. Under this schema, primary cells 
are anti-nociceptive and secondary cells are pro-nociceptive. Primary cells are tonically inhibited 
by secondary cells, but this inhibition is relieved in the presence of mu agonists (Pan, Tershner, 
and Fields 1997). Primary cells are proposed to be directly inhibited by kappa agonists, but 
disinhibited by mu agonists (Pan, Tershner, and Fields 1997; Pan, Williams, and Osborne 1990; 
Pan, Hirakawa, and Fields 2000). However, it is important to note that the sensitivity of RVM 
neurons to kappa agonists remains contested. Other studies have found that kappa agonists 
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inhibit excitatory input onto secondary cells as well as produce outward currents in primary cells 
(Ackley et al. 2001; Meng et al. 2005). Still, the net behavioral effect was antinociception -- 
freely-behaving rats exhibited elevated withdrawal latencies to Hargreaves’ and hot plate tests 
(Ackley et al. 2001). Although differences in the experimental design, such as performing 
recordings in anesthetized animals but conducting behavioral assays in freely-behaving ones may 
underlie these discrepancies, it is more likely that kappa and mu receptors are co-expressed in 
some neurons (Gutstein et al. 1998), making it challenging to classify RVM neurons as simply 
primary or secondary cells by this classification scheme.  
In addition to opioid agonists, other pharmacological agents have also been infused into 
the RVM. The results from these pharmacological studies, in combination with neurochemical 
approaches have also identified putative cell types within the RVM. Based on these studies, a 
few of these cell types are discussed here: 
Tachykinin receptor-1 (NK1R) neurons 
Neurons in the RVM containing NK1R are thought to respond to substance P release 
from Tac1 neurons in the PAG (Lagraize et al. 2010) and have pro-nociceptive effects. 
Microinjection of NK1R antagonists in the RVM can inhibit and attenuate hypersensitivity to 
heat and mechanical stimuli following inflammatory injury (Lagraize et al. 2010; Hamity, White, 
and Hammond 2010; Pacharinsak et al. 2008). Furthermore, pharmacological ablation of NK1R 
RVM neurons reduces hyperalgesia in both acute and chronic pain models (Khasabov and 
Simone 2013). More recently, PAG Tac1 neurons have also been shown to facilitate itch (Gao et 
al. 2019). Neurochemically, NK1R neurons comprise roughly 8% of neurons in the RVM and a 
proportion of them have been found to overlap with 5HT and Gad67 (Chen et al. 2013). 
Furthermore, only the Gad67+, NK1R+ neurons are thought to be spinally projecting (Chen et al. 
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2013). This suggests there are at least two neurochemically distinct NK1R subtypes, but whether 
they are both pro-nociceptive is unclear. 
Neurotensin-R (NTR1) neurons 
Neurotensin produces persistent antinociceptive effects in the tail-flick assay following 
infusion into the RVM (Fang, Moreau, and Fields 1987). NTR1 is expressed by spinally 
projecting 5HT neurons (Wang et al. 2014) in the RVM and contributes to the descending 
inhibitory modulation of neurotensin-induced antinociception (Buhler et al. 2005). Interestingly, 
infusion of high doses of neurotensin into the RVM can evoke anti-nociception, but small doses 
produce pro-nociception (Urban and Smith 1993, 1994). These opposing actions may be due to 
the differential expression of the neurotensin receptor in the RVM. Indeed, NTR-2 has also been 
implicated in mediating the anti-nociceptive effects of neurotensin (Buhler et al. 2005), and 80% 
of NTR-2 expressing neurons also express NTR-1 (Buhler et al. 2005), further highlighting the 
diversity of subtypes in the RVM.  
Serotonergic (5HT) neurons 
The contribution of serotonergic neurons is highly disputed. It was previously thought 
that serotonergic neurons comprise NEUTRAL cells (Potrebic, Fields, and Mason 1994), engage 
in autonomic responses (Mason, Gao, and Genzen 2007; Hellman et al. 2009; Foo and Mason 
2003; Foo, Crabtree, and Mason 2010; Foo and Mason 2005), or participate in the inhibition of 
pain when the NTR1 subpopulation is targeted (Buhler et al. 2005), but recent studies suggest 
they may also be pronociceptive (Cai et al. 2014; Kim et al. 2014; Wei et al. 2010). In addition to 
this emerging view of 5HT neurons as pain-facilitatory, depletion of serotonin in the RVM has 
been shown to also be anti-pruritic (Wei et al. 2010). Neurochemical characterizations of 
serotonergic neurons have revealed their overlap with many other markers including NK1R 
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(Chen et al. 2013), MOR (Cai et al. 2014), Gad67 (Cai et al. 2014; Wei et al. 2010), and NTR1 
(Buhler et al. 2005). Given the highly diverse roles of serotonergic neurons and their 
heterogeneity, it is clear that serotonin does not label a specific and molecularly distinct RVM 
population. 
Inhibitory (GABAergic) neurons 
Expression of the mu opioid receptor (Oprm1), which is thought to be a marker for ON or 
secondary cells (H. Fields 2004), is found in inhibitory GABAergic neurons (François et al. 
2017). In one study, selective activation of Vgat neurons was found to be allodynic (François et 
al. 2017). However, in another, Gad2 neurons, which comprise a subpopulation of GABAergic 
neurons, were found to be important for suppressing heat and mechanical pain (Zhang et al. 
2015). Further complicating the classification of these neurons is the expression of Gad1 
(Gad67) in kappa opioid receptor-expressing (OFF) and NEUTRAL cells (Winkler et al. 2006). 
Thus, similar to serotonergic neurons, GABA is found in many RVM neuronal subtypes, making 
it challenging to ascribe a specific role to RVM neurons based solely on their expression of this 
marker.  
Excitatory (glutamatergic) neurons 
Although most spinally-projecting RVM neurons are GABAergic (Aicher et al. 2012; 
François et al. 2017; Y. Zhang et al. 2015; Millhorn et al. 1987), and it remains unclear what 
role, if any, the sparsely labeled glutamatergic neurons may have in descending modulation 
(François et al. 2017). Whether glutamatergic RVM neurons participate in cortical, local, or in 




The neuropeptide cholecystokinin (CCK), arising from CCK-expressing neurons in the 
dorsomedial hypothalamus is thought to act in the RVM to enhance nociception (Wagner et al. 
2013). It is proposed that this is one pathway by which chronic stress can lead to hyperalgesia 
(Wagner et al. 2013). Indeed, several pharmacological studies have shown that CCK infusion 
into the RVM can activate the descending pain facilitatory system (Xie et al. 2005; Heinricher 
and Neubert 2004; Zhang et al. 2009; Heinricher, McGaraughty, and Tortorici 2001). CCK 
produces its pro-nociceptive actions at CCK2, Gαs-coupled receptors in the RVM (Ghilardi et al. 
1992; Zhang et al. 2009; Xie et al. 2005). Conversely, CCK antagonists can augment the 
antinociceptive effects of opioid administration (Faris et al. 1983; Dourish et al. 1990). Lastly, 
CCK2 receptors are expressed on neurons with mu opioid receptors, further implicating that they 
may be on pro-nociceptive cells (Zhang et al. 2009).  
Nitric oxide synthase (nNOS) neurons 
The role of neurons that produce nitric oxide in the RVM is presently thought to be 
important for antinociception, based on studies that have inhibited the NO synthase enzyme 
(Ohgami et al. 2009). Nos1 neurons have been shown to overlap with Gad67 (Buhler et al. 2018) 
and possibly 5HT (Lu et al. 2010), though this is debated (Buhler et al. 2018). Interestingly, 
however, nNOS neurons are not spinally-projecting and are thought to instead mediate their 
antinociceptive effects through local RVM circuits or to cortical and subcortical areas (Buhler et 
al. 2018; Lu et al. 2010). 
Given the extensive overlap among various markers, the neurochemical identities for pro- 
and anti- nociceptive RVM cells remain unclear. Advances in sequencing, neurochemical, 
tracing, and behavioral methods may one day elucidate and define specific RVM cell types. 
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7.4 Manipulations of cell types using mouse genetics 
Recent advances in molecular techniques have enabled researchers to use genetically-
modified mouse lines to target unique subsets of RVM neurons expressing specific receptors and 
molecular markers. These studies allow for genetic manipulations of distinct subpopulations of 
neurons for targeted anatomical, molecular, and functional dissection. 
Still, one limitation of these manipulations is that while researchers may have tight 
control over neurons based on their expression of a particular marker, conclusions made from the 
targeting of individual alleles ignores the heterogeneity within the RVM. For example, 
expression of the mu opioid receptor (Oprm1), which is thought to be a marker for ON cells (H. 
Fields 2004), is found in inhibitory neurons. In one study, Vgat neurons were found to facilitate 
mechanical hypersensitivity (François et al. 2017). However, in another study, Gad2 neurons, 
which comprise a subpopulation of Vgat neurons, were found to be important for suppressing 
thermal and mechanical nociception (Zhang et al. 2015).  
Furthermore, it has been widely presumed that serotonergic neurons are NEUTRAL cells, 
but when neurons containing Tph, the enzyme necessary for serotonin synthesis, were 
optogenetically manipulated, they were found to drive mechanical and thermal hypersensitivity 
(Cai et al. 2014). It is interesting to note that serotonergic neurons have previously been shown to 
co-express Oprm1 (Marinelli et al. 2002; Wang and Wessendorf 1999), an indication that there 
may be some overlap between putative ON and NEUTRAL cells. One may be able to speculate 
that the global activation of Tph neurons exerts a dominant effect over the NEUTRAL 
phenotype, which gives rise to a pro-nociceptive one (Cai et al. 2014). Another possibility is that 
the genetic tool, the Tph-Cre allele, may not capture 5HT-expressing neurons in the adult mouse 
with high fidelity which may explain discordant findings from single unit recordings of 
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classically-defined NEUTRAL cells. Reconciling these studies that have directly manipulated 
RVM neurons using individual alleles, it is likely that a reasonable population of Oprm1+, 
Vgat+ neurons are pro-nociceptive (François et al. 2017), and that not all inhibitory neurons in 
the RVM are pro-nociceptive (Zhang et al. 2015). The role of serotonergic, GABA-expressing 
neurons that do not contain the mu-opioid receptor still remains unclear. 
In addition to the molecular complexity in the RVM illuminated by these discoveries, it is 
interesting that Cre-dependent manipulations of these neuronal populations gave rise to 
specificity with respect to modality (such as the finding that Vgat and Gad2 neurons are 
important for mechanical and heat pain, respectively) (François et al. 2017; Zhang et al. 2015). 
These results contrast with single unit recordings of RVM neurons, which have shown their 
responsiveness to different sensory stimuli - from itch to innocuous and noxious mechanical and 
thermal stimuli (Follansbee et al. 2018; Young and Dawson 1987; Fields and Anderson 1978). 
The variety of stimuli that can elicit a response in an individual RVM neuron suggests that these 
cells may not be tuned to the processing of distinct modalities of sensory input. Additional work 
is needed, and recordings in freely-behaving mice with genetic manipulations could someday 
clarify this discrepancy.  
Thus, while it is possible to use genetic tools to discern unique properties among neurons 
within a subset, it is important to consider that they may not represent truly unique populations 
per se. Advances in molecular techniques, such as the ability to use intersectional recombinant 
strategies, through viral delivery or genetic breeding (François et al. 2017; Plummer et al. 2015), 
will permit access to neurons expressing multiple markers and will provide further, important 
insight into RVM function.  
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7.5 The role of the RVM beyond descending modulation of pain 
7.5.1 Thermoregulation 
The rRPA, which constitutes more rostral segments of the RMg, has been consistently 
targeted following retrograde tracing of brown adipose tissue using pseudorabies virus and 
analysis of tissue samples at short time points following inoculation (Cano et al. 2003; Yoshida 
et al. 2003, 2002). Through this approach, experimenters have highlighted a connection between 
the rRPA and sympathetic preganglionic neurons in the intermediolateral cell column (IML). In 
addition to the labeling observed in the rRPA following infection of the IML and BAT, viral 
retrograde labeling of cardiac as well as skeletal muscle result in dense labeling of the rRPA (Ter 
Horst et al. 1996; Kerman et al. 2003). Changes in heart rate, heart contractility, and muscle 
contractions (such as shivering) that promote thermogenesis may also be mediated by the rRPA, 
implicating its diverse and important roles on several aspects of the sympathetic response to 
generate heat. 
Other lines of evidence highlighting the crucial role of the rRPA on thermogenesis 
include fos induction studies and microinjections of pharmacologic agents into this region. In the 
studies involving viral retrograde labeling of BAT, fos, an immediate early gene used to infer 
neuronal activity, localized with BAT-innervating rRPA neurons following cold exposure (Cano 
et al. 2003).  
Physiologically, microinjections of bicuculline into the rRPA, which leads to blockade of 
GABA-A receptors, caused significant increases in BAT thermogenesis (Morrison, Sved, and 
Passerin 1999; Cao and Morrison 2003). This would suggest that the rRPA could promote 
thermogenesis under conditions of disinhibition. Conversely, microinjections of glycine into the 
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rRPA profoundly reversed BAT thermogenesis, heart rate, metabolism, resulting in dramatic 
reductions in heat production (Nakamura et al. 2004; Cao and Morrison 2003; Zaretsky, 
Zaretskaia, and DiMicco 2003; Zaretsky et al. 2006). Given its role as the primary bulbospinal 
pathway from the brain to sympathetic preganglionic neurons, the rRPA is, thus, critically 
important for the regulation of thermogenesis. Still the lack of specificity of infusing bicuculline 
or glycine, which may affect fibers of passage, as well as act on undetermined local circuits 
within the rRPA highlights the further investigation necessary to determine the role of inhibition 
in rRPA-mediated thermogenesis. 
7.5.2 Behavioral arousal, wakefulness, and sexual climax 
Neurons within the reticular formation, which shares overlapping boundaries with the 
RVM, participate in the reticular activating system (RAS), an ascending arousal system that is 
involved with regulating wakefulness, arousal, and sleep (Arguinchona and Tadi 2020; de Lecea, 
Carter, and Adamantidis 2012; Scammell, Arrigoni, and Lipton 2017). The reticular formation 
comprises many regions and nuclei and the specific role of the structures that are confined to the 
boundaries of the RVM have begun to be explored (Moruzzi and Magoun 1949; Satpute et al. 
2019; S. Gao et al. 2019). One recent study found that optogenetic stimulation or 
pharmacological disinhibition of neurons in the NGCa was sufficient to elicit autonomic, 
cortical, and behavioral arousal in mice and rats under deep anesthesia (Gao et al. 2019). 
Similarly, in another study, chemogenetic activation of the medullary neurons evoked 
wakefulness and reduced REM sleep (Chen et al. 2017). Conversely, optogenetic activation of 
Vgat-expressing (GABAergic) neurons produced opposite findings to the global, chemogenetic 
activation of all neurons; selective stimulation of inhibitory neurons induced REM sleep episodes 
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and prolonged their durations (Weber et al. 2015). It was also found that optogenetic inhibition 
of the inhibitory neurons produced behaviors consistent with wakefulness (Weber et al. 2015). 
These reports suggest that there are at least two types of neurons that bi-directionally modulate 
wakefulness, not unlike the ON/OFF/NEUTRAL model for the descending modulation of pain.  
Indeed, a considerable amount of work has been conducted to examine how the RVM 
could contribute to the state-dependence of somatosensation, including nociception (Mason 
2001; Mason, Gao, and Genzen 2007; Mason et al. 2001; Leung and Mason 1999; Foo and 
Mason 2003; Hellman and Mason 2012). Recordings from OFF cells revealed that they are 
tonically active during SWS and intermittently active during waking, but ON cells show bursts 
of activity during waking and exhibit low activity during SWS (Foo, Crabtree, and Mason 2010; 
Hellman and Mason 2012). Interestingly, however, although arousal to aversive stimuli are 
dampened during sleep (Foo, Crabtree, and Mason 2010), reflexive responses to noxious stimuli 
are similar in magnitude during both waking and sleep (Mason et al. 2001). Recordings from 
serotonergic neurons in cats within the RMg revealed a correlation between their discharge rates 
and wakefulness - highest rates were observed during active waking, whereas the neurons were 
nearly silent during REM sleep (Fornal, Auerbach, and Jacobs 1985). Based on the differential 
firing pattern of 5HT neurons at different stages of wakefulness, it has been proposed that 
ON/OFF cells augment and inhibit alertness to painful stimuli, respectively, and that NEUTRAL 
cells may modulate reflexive responses to these painful stimuli (Foo and Mason 2003). 
Furthermore, there is evidence for the role of the RVM in coordination of complex 
arousal states such as feeding and sexual climax. The activity of ON/OFF neurons in the context 
of feeding appears to parallel their activity during wakefulness; during feeding, ON cells are 
quiet and OFF cells are excited. Although feeding reduced animals’ responses to painful stimuli, 
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priming animals with an innocuous air puff suppressed feeding behavior and facilitated 
nocifensive responses to noxious stimuli (Foo and Mason 2005). Similar findings were 
reproduced when the RVM was inactivated with muscimol, suggesting that RVM neurons 
suppress responses to painful stimuli during feeding (Foo and Mason 2005). 
In the context of sexual climax, pseudorabies viral injections into the penis label 
serotonergic neurons in the RVM (Marson and McKenna 1996; Marson, Platt, and McKenna 
1993). Furthermore, it has been shown that intrathecal administration of a serotonin neurotoxin 
can lead to a disinhibition of the urethrogenital reflex. Conversely, intrathecal serotonin raises 
the threshold needed to evoke an urethrogenital reflex (Marson and McKenna 1992). Thus, there 
is evidence for the role of serotonergic neurons in the RVM to contribute to the modulation of 
sexual climax, but this connection needs to be tested directly. 
7.5.3 RVM and motor control 
There is evidence that neurons in the RVM participate in somatic motor control, but 
given the broad functions of the RVM, it seems unlikely that a specific role for these neurons in 
motor control will emerge. In a tract-tracing study, researchers found that inoculation of shoulder 
and arm muscles with pseudorabies virus led to the detection of labeling in the ventral raphe 
nuclei, the NGCɑ, and reticular formation (Rubelowski et al. 2013). When brain tissues are 
collected at earlier time points, labeling in the RVM is not detected, and signal is detectable only 
in the superior colliculus (Rubelowski et al. 2013). Stimulation of the superior colliculus has 
been shown to be sufficient for voluntary motor control (Stuphorn, Bauswein, and Hoffmann 
2000; Werner, Dannenberg, and Hoffmann 1997; Werner 1993). These findings suggest that 
RVM neurons may innervate neurons in the superior colliculus to modulate motor activity within 
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arm and shoulder muscles. Given that RVM neurons are situated to coordinate autonomic motor 
activity, it is conceivable they may also modulate axial motor functions to properly maintain and 
harmonize sensory, motor, and homeostatic control critical for survival. Currently, these findings 
are, at best, correlative. With the labeling approach used, it is difficult to determine whether 
these projections are motor-specific because all neurons that innervate the superior colliculus are 
labeled. Still, functional studies to directly test the contribution of RVM neurons are necessary. 
A group of excitatory neurons within the gigantocellular nucleus, defined by their 
expression of Chx10 (named V2a neurons) have been shown to be involved in the inhibition of 
ongoing locomotion (Bouvier et al. 2015). Optogenetic activation of these glutamatergic neurons 
was sufficient to arrest ongoing motor activity. Interestingly, mini-endoscopic imaging of V2a 
neurons in freely-behaving mice uncovered that although many of these neurons are active 
during locomotion arrest, several are activated by other movements, such as grooming 
(Schwenkgrub et al. 2020). This suggests that much like the ON/OFF cell model for nociception, 
there also exists distinct subsets of V2a neurons that could be differentially engaged for diverse 
motor behaviors. Given that RVM neurons are situated to coordinate autonomic motor activity, it 
is conceivable they may also modulate axial motor functions to properly maintain and harmonize 
sensory, motor, and homeostatic control critical for survival.  
These diverse sensory, autonomic, and homeostatic roles of the RVM underscore its 
myriad contributions to integrating and coordinating ascending and descending pathways crucial 
for survival. The functions described are by no means exhaustive, but provide an overview on 
the scope of research that has been conducted to elucidate RVM functions (Figure 19. 
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Figure 19. Descending circuits for diverse functions. 
The regions discussed in this review have primarily been thought to be important for nociception. However, these 





This section examines the role of the RVM as a conduit between the brain and spinal cord 
and focuses on its powerful control over the descending modulation of pain. Given the myriad 
roles of the RVM and the heterogeneity of cell types within it, it has been a challenge to 
precisely define the molecules, cells, and circuits that participate in specific aspects of 
descending modulation. Although the evidence for the bidirectional role of the RVM in 
descending modulation has been reproduced across numerous studies, the identities of the pro- 
and anti-nociceptive cells remain elusive. The use of optogenetics and chemogenetics, combined 
with advances in molecular techniques such as sequencing and intersectional strategies, will 
continue to develop a more comprehensive and precise study of the integrative role and the 
specificity of the intricate circuits of the RVM.  
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8.0 Identification of RVM populations involved in descending modulation 
8.1 Introduction 
The brain exerts powerful control over nociceptive processing at the level of the spinal 
cord. This occurs through a process known as the descending modulation of pain (Liang, 
Watson, and Paxinos 2016; Basbaum and Fields 1984). Critically, the rostral ventromedial 
medulla (RVM), represents the final common node within the brain that directly modulates the 
activity of spinal neurons involved in pain transmission (Heinricher et al. 2009). Placebo and 
stress can alter the perception of pain through the descending endogenous opioidergic and 
adrenergic pain modulatory system, centered upon the RVM (Eippert et al. 2009; Shamsizadeh et 
al. 2014; Wiedenmayer and Barr 2000; Bellgowan and Helmstetter 1998; Pertovaara 2006). 
Elucidating how neurons within the RVM can modulate pain presents unique opportunities to 
harness the brain’s natural pain-inhibitory system to potentially treat chronic pain disorders, 
which can avoid the unwanted and deadly side effects of existing pharmacological approaches. 
Through extensive pharmacological studies involving microinjection of various agents 
into the RVM, which comprises the nucleus raphe magnus and gigantocellularis, pars alpha 
(Heinricher et al. 2009), several interesting neuronal cell types have been implicated in the 
descending modulation of pain. Single unit recordings within the RVM in lightly anesthetized 
rats have provided significant insight into three types of neurons in the RVM: ON, OFF, 
NEUTRAL neurons based on their firing activity and responses to noxious stimulation (Fields, 
Malick, and Burstein 1995; Heinricher et al. 2009; Mason, Gao, and Genzen 2007). ON cells are 
active during noxious stimulation, inhibited by morphine and proposed to facilitate nociception, 
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whereas OFF cells are inactive or exhibit silent ongoing activity during noxious stimulation, are 
excited by morphine, and are thought to inhibit nociception (Cleary, Neubert, and Heinricher 
2008; Heinricher et al. 2009; Mason 2012; Zhuo and Gebhart 1997). However, until recently, 
there lacked molecular tools with which to directly manipulate these unique cell types and assess 
their contributions to pain behaviors in vivo.  
Previous work has highlighted the existence of OFF neurons in the RVM that robustly 
inhibit pain (Cleary, Neubert, and Heinricher 2008; Heinricher et al. 2009; Mason 2012; Zhuo 
and Gebhart 1997) yet distinct cell types have not been identified due to technical challenges that 
precluded experimentation in awake, freely behaving animals. To discover OFF cells, we 
acquired Cre lines to test the serotonin (Fev), Gad65 (Gad2), nNOS, tachykinin 1 (Tac1) and 
kappa opioid receptor (KOR) populations. Immunohistochemical, pharmacologic, 
electrophysiological, and behavioral studies have implicated that these neurons could participate 
in the descending modulation of pain (Cai et al. 2014; Kim et al. 2014; Wei et al. 2010; Zhang et 
al. 2015; François et al. 2017; Buhler et al. 2018; Lu et al. 2010; Maduka et al. 2016; Pan, 
Tershner, and Fields 1997; Pan, Williams, and Osborne 1990; Pan, Hirakawa, and Fields 2000).  
8.2 Methods 
Mice 
The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 background. Fev-Cre (Jax #012712), Gad2-Cre (Jax #010802), Nos1-Cre 
(Jax #014541), Tac1-Cre (Jax #021877), and KOR-Cre mice were used. Even numbers of male 
and female mice were used for all experiments. Mice were given free access to food and water 
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and housed under standard laboratory conditions. The use of animals was approved by the 
Institutional Animal Care and Use Committee of the University of Pittsburgh.  
Pharmacologic agents 
Clozapine-N-oxide (Tocris) was dissolved in PBS and administered intraperitoneally (5mg/kg). 
Chloroquine diphosphate salt (Sigma) was dissolved in physiological saline (100μg in 10μL) and 
administered intradermally. 
Intradermal injections 
For intradermal injection of chloroquine, hair was removed at least 24 hours before the 
experiment. Chloroquine (100μg in 10μL) was administered into the nape of the neck or calf, 
which could be subsequently visualized by the formation of a small bubble under the skin. These 
procedures were performed in awake mice.  
Stereotaxic injections 
Animals were anesthetized with 2% isoflurane and placed in a stereotaxic head frame. A 
drill bit (MA Ford, #87) was used to create a burr hole and custom-made metal needle (33 gauge) 
loaded with virus was subsequently inserted through the hole to the injection site. Virus was 
infused at a rate of 100nL/min using a Hamilton syringe with a microsyringe pump (World 
Precision Instruments). Mice received 250-500 nL of virus (AAV2.hSyn.DIO.mCherry Addgene 
#50459; AAV2.hSyn.DIO.hM3D(Gq)-mCherry, Addgene #44361). The injection needle was left 
in place for an additional 15 min and then slowly withdrawn over another 15 min. Injections 
were performed at the following coordinates for each brain region: RVM: AP -5.80 mm, ML 
0.00 mm, DV -6.00. The incision was closed using Vetbond and animals were given ketofen (IP 




All assays were performed in the Pittsburgh Phenotyping Core and scored by an 
experimenter blind to treatment.  
Observation of scratching behavior  
All tests were performed in a blinded manner. Scratching behavior was observed using a 
previously reported method (Kardon et al. 2014). On the testing day, the mice were individually 
placed in the observation cage (12x9x14 cm) to permit acclimation for 30 minutes. Scratching 
behavior was videotaped for 30 minutes after administration of chloroquine. The temporal and 
total numbers of scratch bouts by the hind paws at various body sites during the first 30 minutes 
after intrathecal injection were counted.  
Hargreaves testing 
Animals were acclimated on a glass plate held at 30°C (Model 390 Series 8, IITC Life 
Science Inc.). A radiant heat source was applied to the hindpaw and latency to paw withdrawal 
was recorded (Hargreaves et al. 1988). 2 trials were conducted on each paw, with at least 5 min 
between testing the opposite paw and at least 10 min between testing the same paw. To avoid 
tissue damage, a cut off latency of 20 sec was set. Values from both paws were averaged to 
determine withdrawal latency.  
Von Frey testing 
Mechanical sensitivity was measured using the Chaplan up-down method of the von Frey 
test (Chaplan et al. 1994). Calibrated von Frey filaments (North Coast Medical Inc.) were 
applied to the plantar surface of the hindpaw. Lifting, shaking, and licking were scored as 
positive responses to von Frey stimulation. Average responses were obtained from each 
hindpaw, with 3 min between trials on opposite paws, and 5 min between trials on the same paw.  
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Cold plantar assay 
Paw withdrawal to cold sensitivity was measured as previously described (Brenner et al. 
2015; Brenner, Golden, and Gereau 2012). Briefly, animals were acclimated to a 1/4” glass plate 
and crushed dry ice was packed into a modified 3 mL syringe and used as a probe. The dry ice 
probe was applied to the glass beneath the plantar hindpaw and the latency to withdrawal was 
recorded. Two trials were conducted on each hindpaw, with 3 min between trials on opposite 
paws, and 5 min between trials on the same paw. A cut off latency of 20 s was used to prevent 
tissue damage. Withdrawal latencies for each paw were determined by averaging values across 2 
trials per paw. 
Tail immersion test  
Mice were habituated to mice restraints 15 minutes for 3 days before testing. Tails were 
immersed 3 cm into a water bath at 48°C, and the latency to tail flick was measured three times 
with a 1 minute interval between trials.  
Rotarod  
Coordination and balance were determined using an accelerating rotarod. A session 
involving 120 s on a non-accelerating rotarod was prior to experimentation. Five consecutive 
trials were performed while the rotarod accelerated from 4 to 40 rpm in 30 s increments. The 
latency to fall off (s) was recorded for each trial. 
Open field activity 
Spontaneous activity in the open field was conducted over 30 minutes in an automated 
Versamax Legacy open field apparatus for mice (Omnitech Electronics Incorporated, Columbus, 
OH). Distance traveled (s), ambulatory average velocity (cm/s), and ambulatory time (s) were 
measured by infrared photobeams located around the perimeter of the arenas interfaced to a 
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computer running Fusion v.6 for Versamax software (Omnitech Electronics Incorporated) which 
monitored the location and activity of the mouse during testing. Activity plots were generated 
using the Fusion Locomotor Activity Plotter analyses module (Omnitech Electronics 
Incorporated). Mice were placed into the open field 30 post CNO injection. For all tests, mice 
were transferred to the testing room one hour prior to testing.  
Acoustic startle 
Prepulse inhibition of acoustic startle was measured by placing mice into a soundproof 
chamber (Kinder Scientific Startle Monitor). After 5 min of white noise acclimation, mice were 
exposed to randomized trials of 500 ms exposures to 65 or 115 decibel sound pressure level (dB 
SPL) with a 500 ms intertrial interval. Trials were repeated between seven and eight times for 
each mouse in a randomized order. Startle was measured as the maximum force in Newtons (N) 
and the average response across the trial repetitions for each mouse was used for data analysis. 
RNAscope in situ hybridization  
Multiplex fluorescent in situ hybridization was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 um-thick fresh-
frozen sections containing the RVM were fixed in 4% paraformaldehyde, dehydrated, treated 
with protease for 15 minutes, and hybridized with gene-specific probes to mouse. Probes were 
used to detect Mm-Oprm1-C1 (#315841), Mm-Oprk1-C1 (#316111), Mm-Nos1-C2 (#437651-
C2), Mm-Tac1-C1 (#517971), Mm-Tph2-C2 (#318691-C2), Mm-Slc32a1-C3 (#319191), and 
Mm-Slc17a6-C3 (#319171). DAPI (#320858) was used to visualize nuclei. 3-plex positive 
(#320881) and negative (#320871) control probes were tested. Three to four z-stacked sections 




Mice were anesthetized with an intraperitoneal injection of urethane, transcardially 
perfused, and post-fixed at least four hours in 4% paraformaldehyde. 40um and 25um thick 
RVM and spinal cord sections were collected on a cryostat and slide-mounted for 
immunohistochemistry. Sections were blocked at room temperature for two hours in a 5% 
donkey serum, 0.2% triton, in phosphate buffered saline. Primary antisera was incubated for 14 
hours overnight at 4°C: rabbit anti-RFP (1:1K). Sections were subsequently washed three times 
for 20 minutes in wash buffer (0.2% triton, in PBS) and incubated in secondary antibodies (Life 
Technologies, 1:500) at room temperature for two hours. Sections were then incubated in 
Hoechst (ThermoFisher, 1:10K) for 1 minute and washed 3 times for 15 minutes in wash buffer, 
mounted and cover slipped.  
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in situ hybridization experiments, confocal images of tissue samples (3-4 
sections per mouse over 3-4 mice) were imaged and only cells whose nuclei were clearly visible 
by DAPI staining and exhibited fluorescent signal were counted.  
Statistical analysis 
All statistical analyses were performed using GraphPad Prism 8. Values are presented as 
mean +/- SEM. Statistical significance was assessed using tests indicated in applicable figure 
legends. Significance was indicated by p < 0.05. Sample sizes were based on pilot data and are 
similar to those typically used in the field. 
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8.3 Results 
As a starting point, we examined the expression of these putative neuronal cell types 
using multiplex fluorescent in situ hybridization (Figure 20A) and found that most neurons in the 
RVM are GABAergic (based on their expression of Slc32a1) and expressed a combination of 
Tph2, Nos1, Tac1, and Oprk1. Using commercially-available Cre-alleles and Cre-dependent 
viral vectors, we sought to selectively label and manipulate distinct RVM neuronal cell types 
using fluorescent tracers and chemogenetically activate them with AAV2-hSyn-DIO-hM3Dq-
mCherry (Figure 20B, Figure 21A, B).  
When we chemogenetically activated these neurons and assessed animals using a variety 
of somatosensory tests for cold, thermal, pruritic, mechanical stimuli and tail flick, we found, 
strikingly, that the chemogenetic activation of KOR-RVM neurons in the KOR-Cre allele 
robustly inhibited responses to cold and thermal sensitivities, chloroquine-evoked itch, but not 
responses to von Frey testing and tail flick assay (Figure 20C-G). 
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Figure 20. Identification and manipulation of diverse RVM neuronal cell types. 
(A) Characterization of neuronal populations in the RVM using fluorescent in-situ hybridization. Intersecting venn 
diagrams indicate the relative abundance of neurons expressing particular markers and their relative overlap.  
(B) Experimental approach to deliver Cre-dependent hM3Dq-mCherry to visualize labeled RVM neurons and their 
spinal projections across Fev, Gad2, nNos, Tac1, and KOR-Cre alleles. 4v: fourth ventricle, RMg: raphe magnus, 
pyr: pyramidal tract. Scale bar = 100 μm. 
(C) Chemogenetic activation of Fev, Gad2, nNos, Tac1, and KOR-Cre neurons on the latency to respond to the cold 
plantar assay. Data are mean + SEM with dots representing individual mice. Fev (n=14), Gad2 (n=3), nNos (n=15), 
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Tac1 (n=15), KOR (n=18) mice. Asterisks indicate the results of paired t-tests, corrected for multiple comparisons 
(ns p>0.05, **** p<0.0001). 
(D) Chemogenetic activation of Fev, Gad2, nNos, Tac1, and KOR-Cre neurons on the latency to respond to the 
hargreaves assay. Data are mean + SEM with dots representing individual mice. Fev (n=14), Gad2 (n=11), nNos 
(n=15), Tac1 (n=15), KOR (n=18) mice. Asterisks indicate the results of paired t-tests, corrected for multiple 
comparisons (ns p>0.05, * p<0.05, ** p<0.01, **** p<0.0001). 
(E) Chemogenetic activation of Fev, Gad2, nNos, Tac1, and KOR-Cre neurons in chloroquine-evoked itch. Data are 
mean + SEM with dots representing individual mice. Fev (n=8), Gad2 (n=10), nNos (n=7), Tac1 (n=15), KOR 
(n=18) mice. Asterisks indicate the results of paired t-tests, corrected for multiple comparisons (ns p>0.05, **** 
p<0.0001). 
(F) Chemogenetic activation of Fev, Gad2, nNos, Tac1, and KOR-Cre neurons in mechanical thresholds in the von 
Frey assay. Data are mean + SEM with dots representing individual mice. Fev (n=14), Gad2 (n=3), nNos (n=15), 
Tac1 (n=15), KOR (n=18) mice. Asterisks indicate the results of paired t-tests, corrected for multiple comparisons 
(ns p>0.05). 
(G) Chemogenetic activation of Fev, Gad2, nNos, Tac1, and KOR-Cre neurons in the tail-flick assay. Data are mean 
+ SEM with dots representing individual mice. Fev (n=14), Gad2 (n=10), nNos (n=15), Tac1 (n=15), KOR (n=18) 
mice. Asterisks indicate the results of paired t-tests, corrected for multiple comparisons (ns p>0.05). 
(H) FISH characterization of Oprk1-expressing neurons in the RVM relative to other markers of interest. Data are 
mean +/- SEM with dots representing individual mice (n=3-4 mice per group). 
(I) Experimental approach to deliver Cre-dependent hM3Dq-mCherry to KOR-Cre mice to visualize labeled RVM 
neurons and their supraspinal projections. MDm: mediodorsal nucleus of the thalamus, medial part, LHA: lateral 
hypothalamic area, PCN: paracentral nucleus, PO: posterior complex of the thalamus, APN: anterior pretectal 
nucleus, SC: superior colliculus, vlPAG: ventrolateral periaqueductal gray, MRN: midbrain reticular nucleus, PRNr: 
pontine reticular nucleus, PBN: parabrachial nucleus, PPNc: pontine reticular nucleus, caudal part. Scale bar = 50 
μm. 
(J) Activation of KOR-RVM neurons suppresses locomotor activity measured in an open field test. Data are mean + 
SEM with dots representing individual mice (n=3 controls, n=6 hM3Dq mice). Asterisks indicate the results of 
unpaired t-test (** p<0.01). 
(K) Activation of KOR-RVM neurons reduces the latency to fall on a rotarod test. Data are mean +/- SEM (n=8 
controls, n=14 hM3Dq mice). Asterisks indicate the results of two-way ANOVA with Bonferroni’s correction (** 
p<0.01, *** p<0.001, **** p<0.0001). 
(L) Activation of KOR-RVM neurons suppresses responses to the acoustic startle test. Data are mean + SEM with 
dots representing individual mice (n=8 controls, n=7 hM3Dq mice). Asterisks indicate the results of two-way 
repeated measures ANOVA with Bonferroni’s correction (ns p>0.05, ** p<0.01). 
 
Strikingly, we also observed that KOR-RVM neurons comprised a significant number of 
neurons in the brainstem that were molecularly diverse (Figure 20H, Figure 22A) and provided 
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inputs to many structures through the brainstem (Figure 20I). In agreement with prior reports 
(Gutstein et al. 1998; Winkler et al. 2006), many Oprk1 neurons co-expressed Slc32a1 and 
Oprm1 (Figure 20H). Beyond the observed reductions in pain and itch responses with 
chemogenetic activation (Figure 20C-E), we also found that chemogenetic activation of these 
neurons suppressed animals’ locomotor behaviors on an open field and rotarod (Figure 20J, K). 
Moreover, in the acoustic startle assay, activation of KOR-RVM neurons also reduced animals’ 
responses to a 115 decibels noise burst (Figure 20L). These remarkable motor and arousal 
responses could have confounded our significant behavioral findings (Figure 20C-G); thus, we 
attempted to isolate the somatosensory deficits from the motor and arousal ones by restricting the 
amount of virus delivered to the RVM using a very dilute titer (Figure 222B). This approach 
allowed us to sparsely label KOR-RVM neurons (Figure 22B). Using very dilute titers, we found 
that animals in which spinally-projecting KOR-RVM neurons were infected exhibited robust 
inhibition of itch with chemogenetic activation (Figure 22C, D). In contrast, animals in which the 
spinally-projecting KOR-RVM neurons were not captured did not exhibit a reduction in 
chloroquine-evoked itch and behaved similarly to controls (Figure 21C, D). We chose the 
chloroquine-induced itch assay due to its robust and consistent effects on itch behaviors, allow us 
to efficiently screen animals for a sensory response with chemogenetic activation. Although we 
did not assess whether motor behaviors or startle were affected in our serial dilution studies, we 
determined that at dilute titers, chemogenetic activation of RVM-KOR neurons depressed itch, 
but not locomotor behaviors, suggesting that our approach was selective for sensory, but not 
motor responses.   
Lastly, we used a modified iDISCO clearing approach to compare labeling of KOR-RVM 
projections throughout the brain and spinal cords of animals receiving viral titers with and 
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without dilution (Figure 22E). Thus, we determined that only a small number of KOR-RVM 
neurons, and only those projecting to the spinal cord, could be sufficient to drive the descending 
modulation of itch.  
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Figure 21. Tracing of RVM cell types to supraspinal structures. 
(A) FISH characterization of Tph2, Tac1, and Nos1 RVM neurons and their overlap with inhibitory (Slc32a1) and 
excitatory (Slc17a6) markers.  
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(B) Experimental approach to deliver Cre-dependent hM3Dq-mCherry to visualize labeled RVM neurons and their 
supraspinal projections across Fev, Gad2, nNos, Tac1, and KOR-Cre alleles. Representative supraspinal targets of 
Fev-Cre, Gad2-Cre, nNOS-CreER, and Tac1-Cre labeled RVM neurons are shown. PBN: parabrachial nucleus, Drt: 
doral reticular nucleus, MPO: medial preoptic area, vlPAG: ventrolateral periaqueductal gray, PRNr: pontine 
reticular nucleus, NTS: nucleus solitary tract, RVM: rostralventromedial medulla, and SC: superior colliculus. Scale 




Figure 22. Restricted targeting of KOR-RVM spinally-projecting neurons reveals their contribution to 
somatosensation. 
(A) Representative images of FISH characterization of KOR-RVM neurons for the quantifications shown in Figure 
20H. Scale bar = 50 μm. 
(B) Serial dilutions of the hM3Dq-mCherry virus (originaly titer 8.6x10^10) captures smaller populations of KOR-
RVM neurons. Scale bar = 50 μm. 
(C) A separation in the distribution of animals receiving 32x diluted hM3Dq reveals animals that behave 
comparably to controls (red) and animals with abolished itch responses to chloroquine (light blue). 
(D) Representative RVM and spinal cord images of animals highlighted in (C). Scale bar = 50 μm. 
(E) iDISCO cleared brain and brainstem-spinal samples in animals receiving viral injections into the RVM with and 
without dilution. Scale bar = 1 mm 
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8.4 Discussion 
In perilous and stressful situations, the ability to suppress pain can be critical for survival. 
The rostral ventromedial medulla (RVM) contains neurons that can robustly inhibit pain 
processing in the spinal cord through a top-down modulatory pathway. Although much is known 
about the role of the RVM in the inhibition of pain, the precise identities and mechanisms of 
pain-inhibitory neurons in the RVM have never been identified. In this chapter, we tested a 
battery of known genetic markers of RVM neurons and found that among the five populations 
tested, by far the most promising candidate were neurons expressing KOR. We found that across 
all assays, chemogenetic activation of this population robustly inhibited nociception to cold and 
thermal plantar testing and itch. However, activation of RVM-KOR neurons did not elevated 
mechanical thresholds above baseline, likely due to a ceiling effect and did not reduce sensitivity 
to the tail-flick assay. The divergent findings with respect to thermal nociception between the 
plantar (Hargreaves) and tail-flick test suggest that different circuits are involved in the 
modulating these different responses. Tail-flick is thought to reflect a spinal, reflexive response, 
whereas a more coordinated behavioral sequence underlies the withdrawal to plantar testing. Our 
results indicate that RVM-KOR neurons do not participate in the inhibition of the tail-withdrawal 
reflex. 
Interestingly, however, we also observed that these neurons may also modulate motor and 
arousal behaviors, which we ascribe to the non-spinally-projecting KOR brainstem neurons. By 
diluting the DREADD virus, we determined a strong correlation between animals displaying 
anti-pruritic behaviors and the presence of spinally-projecting fibers, providing us a basis upon 
which to directly test the contributions of spinally-projecting KOR-RVM neurons to the 
descending modulation of pain and itch. 
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9.0 KOR RVM neurons are anti-nociceptive 
9.1 Introduction 
Previous studies have implicated the role of neurons expressing the kappa opioid receptor 
(KOR) as OFF cells (Pan, Tershner, and Fields 1997; Pan, Williams, and Osborne 1990; Pan, 
Hirakawa, and Fields 2000), but this has been controversial (Ackley et al. 2001; Meng et al. 
2005). Previously, experiments investigating KOR-RVM neurons were conducted in 
unconscious animals and relied on reflexive behaviors, making it challenging to definitively 
prescribe the functions of these neurons in awake, freely-behaving systems. Thus, the exact 
identity of cells that could inhibit pain were never molecularly identified and directly 
manipulated.  
Given the finding that KOR-RVM neurons inhibit itch, even with the diluted viral titer 
used, we wanted to test whether KOR-RVM neurons may more broadly inhibit pain and itch. 
Among neurons in the RVM that are thought to express the kappa opioid receptor, evidence from 
pharmacological studies remains controversial. OFF cells are proposed to be directly inhibited by 
kappa agonists, but disinhibited by mu agonists (Pan, Tershner, and Fields 1997; Pan, Williams, 
and Osborne 1990; Pan, Hirakawa, and Fields 2000). However, other studies suggest that kappa 
agonists inhibit excitatory input onto secondary cells to produce anti-nociception (Ackley et al. 
2001; Meng et al. 2005). Using the KOR-Cre allele developed by our lab, we were able to 





The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 background. KOR-Cre mice were used. Even numbers of male and female 
mice were used for all experiments. Mice were given free access to food and water and housed 
under standard laboratory conditions. The use of animals was approved by the Institutional 
Animal Care and Use Committee of the University of Pittsburgh.  
Pharmacologic agents 
Clozapine-N-oxide (Tocris) was dissolved in PBS and administered intraperitoneally 
(5mg/kg), IT (50ug/kg), or locally via cannula injection (1mmol in 300nl). Morphine sulfate 
(Henry Schein; 1ug in 0.25ul) was diluted in sterile saline and microinjected into the RVM. 
Capsaicin (0.1%) in 10% EtOH in PBS was injected 10ul into the plantar hindpaw. Chloroquine 
diphosphate salt (Sigma) was dissolved in physiological saline (100μg in 10μL) and 
administered intradermally. 
Intradermal and intrathecal injections 
For intradermal injection of chloroquine, hair was removed at least 24 hours before the 
experiment. Chloroquine (100μg in 10μL) was administered into the nape of the neck or calf, 
which could be subsequently visualized by the formation of a small bubble under the skin. For 
intrathecal injections, hair was clipped from the back of each mouse at least 24 hours before the 
experiment. All intrathecal injections were delivered in a total volume of 10 μL using a 30-gauge 
needle attached to a luer-tip 25 μL Hamilton syringe. The needle was inserted into the tissue at a 
45° angle and through the fifth intervertebral space (L5 – L6). Solution was injected at a rate of 1 
μL/s. The needle was held in position for 10 s and removed slowly to avoid any outflow of the 
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solution. Only mice that exhibited a reflexive flick of the tail following puncture of the dura were 
included in our behavioral analysis. These procedures were performed in awake mice.  
Intraspinal injections 
Mice were anesthetized with 100mg/kg ketamine and 10 mg/kg xylazine. An incision 
was made at the spinal cord level corresponding to L4-6 dermatome. The intrathecal space was 
exposed, and two injections of approximately 300nl of virus was infused 300 mm below the 
surface of the spinal cord at 5nL/s via glass pipette through the intrathecal space corresponding 
to L4-6 of the spinal cord (AAVr.EF1a.DIOhChR2(H134R).eyfp-wpre-hghpa, Addgene 20298; 
AAVr-hSyn-DIO-hM3D(Gq)-mCherry, Addgene 44361; AAVr-FLEX-tdTomato, Addgene 
28306). For experiments examining RVM innervation of the cervical spinal cord, the same 
approach was used to target thoracic cord (T6-8). The glass pipette was left in place for an 
additional 5 minutes before withdrawal. The incision was closed with 5-0 vicryl suture. Ketofen 
was delivered (IP 10mg/kg) and mice were allowed to recover over a heat pad.  
Stereotaxic injections and cannula implantation 
Animals were anesthetized with 2% isoflurane and placed in a stereotaxic head frame. A 
drill bit (MA Ford, #87) was used to create a burr hole and custom-made metal needle (33 gauge) 
loaded with virus was subsequently inserted through the hole to the injection site. Virus was 
infused at a rate of 100nL/min using a Hamilton syringe with a microsyringe pump (World 
Precision Instruments). Mice received 250-500 nL of virus (AAV2.hSyn.DIO.mCherry Addgene 
#50459; AAV2.hSyn.DIO.hM3D(Gq)-mCherry, Addgene #44361). The injection needle was left 
in place for an additional 15 min and then slowly withdrawn over another 15 min. Injections and 
cannula implantations were performed at the following coordinates for each brain region: RVM: 
AP -5.80 mm, ML 0.00 mm, DV -6.00. For implantation of guide cannulas (P1 Technologies), 
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implants were slowly lowered 0.300-0.500 mm above the site of injection and secured to the 
skull with a thin layer of Vetbond (3M) and dental cement. The incision was closed using 
Vetbond and animals were given ketofen (IP 10 mg/kg) and allowed to recover over a heat pad. 
Mice were given 4 weeks to recover prior to experimentation. 
Spared nerve injury 
For spared nerve injury surgery (SNI), the sural and superficial peroneal branches of the 
sciatic nerve were ligated (size 6.0 suture thread) and transected, leaving the tibial nerve intact. 
The muscle tissue overlying the injury was gently placed back together and the skin sutured. 
Animals were tested 3 weeks post-injury. 
Behavior 
All assays were performed in the Pittsburgh Phenotyping Core and scored by an 
experimenter blind to treatment.  
Observation of scratching behavior  
All tests were performed in a blinded manner. Scratching behavior was observed using a 
previously reported method (Kardon et al. 2014). On the testing day, the mice were individually 
placed in the observation cage (12x9x14 cm) to permit acclimation for 30 minutes. Scratching 
behavior was videotaped for 30 minutes after administration of chloroquine. The temporal and 
total numbers of scratch bouts by the hind paws at various body sites during the first 30 minutes 
after intrathecal injection were counted.  
Hargreaves testing 
Animals were acclimated on a glass plate held at 30°C (Model 390 Series 8, IITC Life 
Science Inc.). A radiant heat source was applied to the hindpaw and latency to paw withdrawal 
was recorded (Hargreaves et al. 1988). 2 trials were conducted on each paw, with at least 5 min 
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between testing the opposite paw and at least 10 min between testing the same paw. To avoid 
tissue damage, a cut off latency of 20 sec was set. Values from both paws were averaged to 
determine withdrawal latency.  
Von Frey testing 
Mechanical sensitivity was measured using the Chaplan up-down method of the von Frey 
test (Chaplan et al. 1994). Calibrated von Frey filaments (North Coast Medical Inc.) were 
applied to the plantar surface of the hindpaw. Lifting, shaking, and licking were scored as 
positive responses to von Frey stimulation. Average responses were obtained from each 
hindpaw, with 3 min between trials on opposite paws, and 5 min between trials on the same paw.  
Cold plantar assay 
Paw withdrawal to cold sensitivity was measured as previously described (Brenner et al. 
2015; Brenner, Golden, and Gereau 2012). Briefly, animals were acclimated to a 1/4” glass plate 
and crushed dry ice was packed into a modified 3 mL syringe and used as a probe. The dry ice 
probe was applied to the glass beneath the plantar hindpaw and the latency to withdrawal was 
recorded. Two trials were conducted on each hindpaw, with 3 min between trials on opposite 
paws, and 5 min between trials on the same paw. A cut off latency of 20 s was used to prevent 
tissue damage. Withdrawal latencies for each paw were determined by averaging values across 2 
trials per paw. 
Tail immersion test  
Mice were habituated to mice restraints 15 minutes for 3 days before testing. Tails were 
immersed 3 cm into a water bath at 48°C, and the latency to tail flick was measured three times 
with a 1 minute interval between trials.  
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RNAscope in situ hybridization  
Multiplex fluorescent in situ hybridization was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 um-thick fresh-
frozen sections containing the RVM were fixed in 4% paraformaldehyde, dehydrated, treated 
with protease for 15 minutes, and hybridized with gene-specific probes to mouse. Probes were 
used to detect tdTomato-C2 (#317041-C2), mCherry-C2 (#431201), Mm-Oprm1-C1 (#315841), 
Mm-Oprk1-C1 (#316111), Mm-Nos1-C2 (#437651-C2), Mm-Tac1-C1 (#517971), Mm-Tph2-
C2 (#318691-C2), Mm-Fos-C3 (#498401-C3), Mm-Slc32a1-C3 (#319191), and Mm-Slc17a6-C3 
(#319171). DAPI (#320858) was used to visualize nuclei. 3-plex positive (#320881) and 
negative (#320871) control probes were tested. Three to four z-stacked sections were quantified 
for a given mouse, and 3-4 mice were used per experiment. 
Immunohistochemistry 
Mice were anesthetized with an intraperitoneal injection of urethane, transcardially 
perfused, and post-fixed at least four hours in 4% paraformaldehyde. 40um and 25um thick 
RVM and spinal cord sections were collected on a cryostat and slide-mounted for 
immunohistochemistry. Sections were blocked at room temperature for two hours in a 5% 
donkey serum, 0.2% triton, in phosphate buffered saline. Primary antisera was incubated for 14 
hours overnight at 4°C: rabbit anti-RFP (1:1K), chicken anti-GFP (1:1K), and mouse anti-NeuN 
(1:500). Sections were subsequently washed three times for 20 minutes in wash buffer (0.2% 
triton, in PBS) and incubated in secondary antibodies (Life Technologies, 1:500) at room 
temperature for two hours. Sections were then incubated in Hoechst (ThermoFisher, 1:10K) for 1 




Morphine sulfate (1ug in 0.25ul) was microinjected into the RVM. Twenty minutes 
thereafter, brain samples were collected and processed for FISH. Spinal cords were harvested 20 
minutes and 90 minutes following CNO administration for FISH and immunohistochemistry, 
respectively.  
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in situ hybridization experiments, confocal images of tissue samples (3-4 
sections per mouse over 3-4 mice) were imaged and only cells whose nuclei were clearly visible 
by DAPI staining and exhibited fluorescent signal were counted.  
Statistical analysis 
All statistical analyses were performed using GraphPad Prism 8. Values are presented as 
mean +/- SEM. Statistical significance was assessed using tests indicated in applicable figure 
legends. Significance was indicated by p < 0.05. Sample sizes were based on pilot data and are 
similar to those typically used in the field. 
9.3 Results 
In our experiments, we found that microinjection of morphine into the RVM increased in 
response latencies to Hargreaves (Figure 23A) and led to the upregulation of fos expression in 
Oprk1 neurons (Figure 23B, Figure 24A). When we recorded from spinally-projecting KOR-
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RVM neurons by injecting AAVr-FLEX-tdtomato into the spinal cord of KOR-Cre mice, we 
found that DAMGO resulted a reduction of presynaptic IPSCs (Figure 23C). Thus, our findings 
are in agreement with the idea that morphine enhances the activity of KOR-RVM neurons to 




Figure 23. Activation of KOR-RVM neurons is analgesic. 
(A) Model to test whether KOR-RVM neurons are OFF cells by examining if microinjection of opioids can 
disinhibit KOR-RVM neurons to produce analgesia. Microinjection of morphine into the RVM increased latencies 
to the hargreaves assay. Data are mean + SEM with dots representing individual mice (n=7 saline, n=8 morphine 
treated animals). Asterisks indicate the results of unpaired t-test (**** p<0.0001). 
(B) Fos expression is enriched in Oprk1 neurons following microinjection of morphine into the RVM. Data are 
mean + SEM with dots representing individual mice (n=4 saline, n=4 morphine treated animals). Scale bar = 50 μm. 
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Asterisks indicate the results of unpaired t-test (* p<0.05). 
(C) Recordings of labeled spinally-projecting KOR-RVM neurons revealed a reduction in presynaptic IPSCs in the 
presence of DAMGO (10 nM). 
(D) Validation of the diluted viral approach to target KOR-RVM neurons using FISH. Data are mean + SEM with 
dots representing individual mice (n=4). Scale bar = 50 μm. 
(E) Infection of KOR-RVM with a diluted virus does not affect locomotor activity in an open field test. Data are 
mean + SEM with dots representing individual mice (n=7 controls, n=8 hM3Dq mice). NS indicates the results of 
unpaired t-test (ns p>0.05). 
(F to J) Chemogenetic activation of KOR-RVM neurons with IP (intraperitoneal) and IT (intrathecal) CNO reduces 
naive responses to (F) cold plantar assay, (G) hargreaves assay, (H) chloroquine-evoked itch, (I) von Frey assay, and 
(J) tail-flick assay. Data are mean + SEM with dots representing individual mice (n=7 controls, n=8 hM3Dq). 
Asterisks indicate the results of two-way repeated measures ANOVA with Bonferroni’s correction (ns p>0.05, * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
(K) Chemogenetic activation of KOR-RVM inhibits thermal and mechanical responses following intraplantar 
capsaicin-induced injury. Data are mean + SEM with dots representing individual mice(n=14 controls, n=15 
hM3Dq). Asterisks indicate the results of two-way repeated measures ANOVA with Bonferroni’s correction (ns 
p>0.05, **** p<0.0001). 
(L) Chemogenetic activation of KOR-RVM inhibits mechanical hypersensitivity following spared nerve injury. Data 
are mean +/- SEM (n=14 controls, n=15 hM3Dq). Asterisks indicate the results of two-way repeated measures 
ANOVA with Bonferroni’s correction (ns p>0.05, **** p<0.0001). 
 
To more directly manipulate KOR-RVM neurons and assess their contributions to the 
inhibition of pain, we used a diluted viral titer, which we confirmed allowed us to more sparsely 
infect KOR-RVM neurons with hM3Dq (Figure 22B). Within the RVM, we found that mCherry-
expressing neurons comprised 88.6 +/-3.6% of Oprk1 neurons and that these neurons were 100% 
specific to the Oprk1 population (Figure 23D). Moreover, we confirmed that activation of these 
neurons did not affect locomotor responses in an open field test (Figure 23E), an indication that 
the use of a dilute viral titer allowed us to manipulate KOR-RVM neurons that do not affect 
motor behaviors upon activation.  
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9.3.1 KOR-RVM neurons inhibit itch and acute and chronic pain 
Next, we tested the effect of chemogenetically activating KOR-RVM neurons in cold 
plantar, hargreaves, itch, mechanical, and tail flick assays. We found that for all assays, 
chemogenetic activation of KOR-RVM neurons with intraperitoneal (IP) CNO produced anti-
nociceptive and anti-pruritic effects (Figure 23F-J). Moreover, because we had previous 
concerns that KOR-RVM neurons may also produce non-specific effects through their non-
spinal targets, we also administered intrathecal (IT) CNO, which allowed us to spatially restrict 
the activation of KOR-RVM neurons that project to the spinal cord. With this manipulation, we 
also found that chemogenetic activation of KOR-RVM neurons with IT CNO also inhibited pain 
and itch responses in a manner that was similar to the IP administration of CNO (Figure 23F-J). 
Additionally, we found that activation of these neurons also reversed thermal responses to 
Hargreaves and von Frey assays following acute injury with intraplantar capsaicin (Figure 23K). 
Thus, activation of KOR-RVM neurons seemed to be sufficient to protect against the 
development of capsaicin-induced thermal and mechanical hyperalgesia (Figure 23K, Figure 
24A, B). Finally, we tested animals in a model of persistent pain, and performed spared nerve 
injury (SNI), in which the common peroneal and sural branches are ligated and transected, 
sparing the tibial nerve. We found that following SNI, both control and hM3dq groups exhibited 
pronounced mechanical allodynia, but found that chemogenetic activation of KOR-RVM 
neurons reversed mechanical hypersensitivity (Figure 23L). Together, these data suggest that 
KOR-RVM neurons are sufficient for the inhibition of nociception, itch, and the reversal of pain 
induced by acute (capsaicin) and chronic (SNI) injury. Interestingly, activation of KOR-RVM 
neurons led to a reduction in thermal sensitivity that was more dramatic than observed with 
morphine microinjection. This suggests that the disinhibitory effects of morphine are less 
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efficient (either due to insufficient spread to presynaptic mu-sensitive fibers or due to a sub-
therapeutic dose of morphine administered) than the direct activation of neurons containing the 




Figure 24. Combined supplementary behavioral data for Figures 23, 25, and 27. 
(A-B) Effect of chemogenetic activation of KOR-RVM on (A) thermal and (B) mechanical responses following 
intraplantar capsaicin-induced injury. Data are mean + SEM with dots representing individual mice (n=14 controls, 
n=15 hM3Dq). Asterisks indicate the results of two-way repeated measures ANOVA with Bonferroni’s correction 
(* p<0.05, **** p<0.0001). 
(C-E) Effect of chemogenetic activation of spinally-projecting KOR-RVM neurons on (C) cold plantar assay, (D) 
hargreaves assay, and (E) von Frey assay. Data are mean + SEM with dots representing individual mice (n=13 
controls, n=13 hM3Dq). NS indicates the results of two-way repeated measures ANOVA with Bonferroni’s 
correction (ns p>0.05). 
(F-G) Effect of chemogenetic activation of spinally-projecting KOR-RVM on (F) thermal and (G) mechanical 
responses following intraplantar capsaicin-induced injury.  Data are mean + SEM with dots representing individual 
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mice (n=13 controls, n=13 hM3Dq). NS indicates the results of two-way repeated measures ANOVA with 
Bonferroni’s correction (ns p>0.05). 
(H-K) Effect of chemogenetic inhibition of KOR-RVM neurons on (H-I) mechanical and (J-K) thermal responses 
following intraplantar capsaicin-induced injury. Data are mean + SEM with dots representing individual mice (n=6 
control, n=7 hM4Di). NS indicates the results of two-way repeated measures ANOVA with Bonferroni’s correction 
(ns p>0.05). 
9.3.2 Spinally-projecting KOR-RVM neurons inhibit itch and pain 
Given the robust innervation of the spinal cord of KOR-RVM neurons (Figure 20B, 
Figure 21B, Figure 23D), and the role of the RVM in the descending modulation of pain, we 
sought to characterize the organization of KOR-RVM neurons that project to the spinal cord. 
Previous studies have reported variations in descending modulation between spinally-innervated 
lumbar segments, and uncovered differential modulation to heat in the tail and foot (Fang and 
Proudfit 1996). Furthermore, another study in an inflammatory model found that RVM 
inactivation completely blocked allodynia to the face, but not plantar hind paw (Edelmayer et al. 
2009). RVM projections to the dorsal horn have also been shown to be more likely to contain 
GAD67 than those to the trigeminal dorsal horn (Aicher et al. 2012). However, more recent 
recordings of RVM neurons in the presence of noxious stimuli have not replicated these findings 
and challenge the idea of somatotopic organization in the RVM (Carlson 2007). Given these 
conflicting views, we sought to examine whether KOR-RVM neurons could modulate pain at 
different dermatomal segments. We used multi-color tracers including AAVr-Ef1a-DIO-eYFP, 
AAVr-hSyn-DIO-mCherry, and CTB-647 to examine whether these neurons exhibited 
somatotopy and what fraction of all spinally-projecting RVM neurons are KOR+ (Figure 25A). 
We found a lack of somatotopic organization; KOR-RVM neurons were frequently infected by 
both eYFP and mCherry, suggesting that the same KOR-RVM neurons innervate both the 
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cervical and lumbar spinal segments, respectively and that these neurons comprised 44.9 +/- 




Figure 25. Selective activation of KOR-RVM neurons that project to the spinal cord produces analgesia. 
(A) Labeling of spinally-projecting KOR-RVM neurons using AAVr introduced to the lumbar and cervical spinal 
cords reveals that KOR-RVM neurons indiscriminately innervate all levels of the spinal cord. Scale bar = 50 μm. 
(B) FISH characterization of spinally-projecting KOR-RVM neurons reveals that they comprise a molecularly 
distinct GABAergic subset of neurons. Data are mean + SEM with dots representing individual mice (n=4). Scale 
bar = 50 μm. 
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(C) iDISCO clearing of brainstem-spinal cord specimen following intraspinal injection of AAVr-FLEX-tdtomato. 
Scale bar = 1 mm 
(D) Approach to selectively activate spinally-projecting KOR-RVM neurons using AAVr-hM3Dq, and local 
microinjection of CNO to the RVM and validation of the approach. Data are mean + SEM with dots representing 
individual mice (n=4). 
Scale bar = 50 μm. 
(E to H) Chemogenetic activation of spinally-projecting KOR-RVM neurons reduces naive responses to (E) cold 
plantar assay, (F) hargreaves assay, (G) chloroquine-evoked itch, with no effect on (H) von Frey assay. Data are 
mean + SEM with dots representing individual mice (n=13 controls, n=13 hM3Dq). Asterisks indicate the results of 
two-way repeated measures ANOVA with Bonferroni’s correction (ns p>0.05, * p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.0001). 
(I) Chemogenetic activation of spinally-projecting KOR-RVM inhibits thermal and mechanical responses following 
intraplantar capsaicin-induced injury. Data are mean + SEM with dots representing individual mice (n=13 controls, 
n=13 hM3Dq). Asterisks indicate the results of two-way repeated measures ANOVA with Bonferroni’s correction 
(**** p<0.0001). 
(J) Chemogenetic activation of spinally-projecting KOR-RVM inhibits mechanical hypersensitivity following 
spared nerve injury. Data are mean +/- SEM (n=7 controls, n=8 hM3Dq). Asterisks indicate the results of two-way 
repeated measures ANOVA with Bonferroni’s correction (ns p>0.05, *** p<0.001). 
(K) Electrophysiological recordings of spinal cord slices in KOR-RVM neurons containing channelrhodopsin. 
Representative traces are shown. 11/48 cells in lamina II received direct input from KOR-RVM neurons following 
optogenetic activation and these responses are abolished in the presence of TTX and bicuculline.  
 
Furthermore, we were able to characterize these spinally-projecting KOR-RVM neurons 
and found that they were GABAergic (based on their exclusive overlap with Slc32a1) and 
exhibited limited overlap with other markers of RVM neurons (Figure 25B). This is in striking 
contrast with KOR-RVM neurons as a heterogenous group (Figure 20H), suggesting that 
spinally-projecting KOR-RVM neurons comprise a molecularly distinct population. 
Furthermore, we performed whole-tissue clearing of intact brainstem-spinal cord specimens in 
which descending KOR-RVM neurons are labeled by AAVr-FLEX-tdtomato into the spinal cord 
to visualize this pathway (Figure 25C). 
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Using a similar approach to that used to molecularly and anatomically characterize 
spinally-projecting KOR-RVM neurons, we injected AAVr-hSyn-DIO-hM3Dq-mcherry into the 
lumbar spinal cord of KOR-Cre mice and implanted guide cannulas over the RVM, allowing us 
to infuse local CNO into the RVM. This strategy enabled us to selectively activate only the 
spinally-projecting KOR-RVM using a chemogenetics (Figure 25D). Using this approach, we 
were able to capture 88.1 +/- 3.1% of Oprk1 neurons in the RVM with 100% specificity (Figure 
25D). When we infused CNO into the cannulas of these KOR-Cre mice receiving AAVr-hSyn-
DIO-hM3Dq-mcherry, we found that chemogenetic activation of KOR-RVM inhibited responses 
to cold plantar testing, hargreaves assay, and chloroquine-evoked itch (Figure 25E-G, Figure 
24C, D), but did not affect mechanical thresholds to von Frey testing (Figure 25H, Figure 24E). 
Furthermore, activation of these neurons reversed capsaicin-induced thermal and mechanical 
hypersensitivities (Figure 25I, Figure 24F, G) as well as mechanical allodynia following chronic 
injury with spared-nerve injury (Figure 25J). We conducted slice recordings in the spinal cords 
of KOR-Cre animals receiving AAV-hSyn-DIO-ChR2-eYFP in the RVM (Figure 25K). We 
found that nearly a quarter of lamina II neurons received direct inputs from KOR-RVM neurons 
following optogenetic activation of these terminals in the spinal cord and that this input was 
inhibitory (Figure 25KFigure 26A-E). Together, we found that selective activation of spinally-
projecting KOR-RVM neurons is sufficient to drive anti-nociception and analgesia in both acute 




Figure 26. Supplementary spinal electrophysiology data. 
(A) Representative image of fibers originating from labeled KOR-RVM neurons in the spinal cord. Scale bar = 50 
μm. 
(B) Delay between the optical activation of ChR2-expressing fibers in the spinal cord and responsiveness of lamina 
II neurons at different durations of laser stimulation. (n = 11 cells from 8 animals). 
(C) Amplitude of response of lamina II neurons at different durations of laser stimulation. (n = 11 cells from 8 
animals). 
(D) Response jitter of lamina II neurons at different durations of laser stimulation. (n = 11 cells from 8 animals). 
(E) Percentage of cells responding under different durations of laser stimulation. 
9.4 Discussion 
Our findings support the idea that KOR-RVM neurons are OFF cells. Consistent with the 
idea that OFF cells are inhibited by ON cells, we found that microinjection of morphine into the 
RVM led to robust fos expression in KOR neurons and produced anti-nociception to thermal 
sensitivity. This suggests that KOR-RVM neurons are disinhibited to promote analgesia in the 
presence of mu agonists, such as morphine. 
We also found that activation of KOR-RVM neurons produced strong anti-nociceptive 
effects on cold, thermal, and mechanical thresholds. Furthermore, activation of these neurons 
inhibited the expression of acute pain (in an intraplantar capsaicin model) and mechanical 
allodynia following spared nerve injury. Together, these data suggest that KOR neurons are OFF 
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cells and activation of this population is sufficient for the inhibition of nociception, itch, and the 
reversal of pain induced by acute (capsaicin) and chronic (SNI) injury. 
Using retrograde tracers, we identified of a unique population of GABAergic KOR-RVM 
neurons that broadly and dramatically inhibit itch and pain (in both acute and chronic injury 
models). By retrogradely labeling from KOR-RVM neurons that innervate the spinal cord, we 
were able to characterize this distinct subset of KOR-RVM neurons and found that they were 
exclusively GABAergic and lacked overlap with other markers of RVM neurons. In contrast to 
the general population of KOR-RVM neurons that represent a heterogeneous group, the spinally-
projecting population is likely to be molecularly distinct.  
Using a combination of fluorescent tracers, we also determined that spinally-projecting 
KOR-RVM neurons are not somatotopically organized, highlighting their ability to 
simultaneously modulate pain and itch at different dermatomal segments. This is unsurprising 
because the lack of somatotopy could allow these neurons to integrate appropriate behavioral 
responses to noxious stimuli at different spinal levels. 
Finally, in this chapter, we build on the previous by explicitly testing the role of spinally-
projecting KOR-RVM neurons in the modulation of itch and pain. Using a targeted 
chemogenetic approach and the local delivery of CNO, we determined that activation of 
descending KOR-RVM neurons inhibits evoked itch as well as acute and chronic pain.  
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10.0 Inhibition of KOR neurons facilitates nociception and abolishes stress-induced 
analgesia 
10.1 Introduction 
Microinjection of a kappa agonist, U69,593, into the RVM has previously been shown to 
be block the analgesia driven by mu-agonists within other sites of the CNS (Pan, Tershner, and 
Fields 1997; Meng et al. 2005) and can precipitate mechanical allodynia following spinal nerve 
ligation (De Felice et al. 2011). This suggests that KOR-RVM neurons may tonically signal to 
inhibit pain. However, it is important to note that the sensitivity of RVM neurons to kappa 
agonists remains controversial. Other work suggests that kappa agonism of KOR-RVM neurons 
pre-synaptically reduces excitatory input onto secondary cells (ON cells) and leads to inhibition 
of primary cells (OFF cells) (Ackley et al. 2001; Meng et al. 2005), thereby leading to anti-
nociception. Freely-behaving rats exhibited elevated withdrawal latencies to Hargreaves and hot 
plate tests (Ackley et al. 2001) following the microinjection of U69,593 into the RVM, 
suggesting that KOR-RVM neurons may exhibit characteristics similar to ON cells. Although 
differences in the experimental design, such as performing recordings in anesthetized animals 
but conducting behavioral assays in freely-behaving ones may underlie these discrepancies, it 
has been a challenge to classify RVM neurons as simply primary or secondary cells. In prior 
chapters, we establish that chemogenetic activation of RVM-KOR  neurons gives rise to 
behaviors consistent with an OFF cell phenotype. In this section, we weigh in on how U69,593 
affects mouse behavior when microinjected into the RVM and use chemogenetic approaches to 
inhibit RVM-KOR neurons.  
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Furthermore, we sought to test the role of RVM-KOR neurons in mediating stress-
induced analgesia. Acutely, stress inhibits pain (Yilmaz et al. 2010) and stress-induced analgesia 
is thought to be mediated by the RVM because microinjection of naloxone into the RVM blocks 
stress-induced analgesia (Shamsizadeh et al. 2014). However, many of these previous studies 
were conducted in male rodents, which reduces the generalizability of past findings. This is an 
important limitation because sex differences have been shown to underlie stress-induced 
analgesia (Vendruscolo 2004). Furthermore, kappa agonists locally administered to the RVM 
have previously been shown to modulate nociception in a sexually-dimorphic manner (Tershner 
2000). Given the profound role of RVM-KOR neurons in the inhibition of itch and pain, we 
wanted to test whether stress-induced analgesia could also be mediated through these neurons 
using both male and female mice. 
10.2 Methods 
Mice 
The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 background. KOR-Cre mice were used. Even numbers of male and female 
mice were used for all experiments. Mice were given free access to food and water and housed 
under standard laboratory conditions. The use of animals was approved by the Institutional 
Animal Care and Use Committee of the University of Pittsburgh.  
Pharmacologic agents 
Clozapine-N-oxide (Tocris) was dissolved in PBS and administered intraperitoneally 
(5mg/kg). Salvinorin B (SalB; Tocris) was dissolved in DMSO and administered subcutaneously 
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(10 mg/kg). U69,593 (Sigma; 40ng in 0.25ul) was dissolved in 45% (2-Hydroxypropyl)-β-
cyclodextrin (HBC; Sigma). Capsaicin (0.1%) in 10% EtOH in PBS was injected 10ul into the 
plantar hindpaw. Chloroquine diphosphate salt (Sigma) was dissolved in physiological saline 
(100μg in 10μL) and administered intradermally. 
Intradermal injections 
For intradermal injection of chloroquine, hair was removed at least 24 hours before the 
experiment. Chloroquine (100μg in 10μL) was administered into the nape of the neck or calf, 
which could be subsequently visualized by the formation of a small bubble under the skin. These 
procedures were performed in awake mice.  
Stereotaxic injections 
Animals were anesthetized with 2% isoflurane and placed in a stereotaxic head frame. A 
drill bit (MA Ford, #87) was used to create a burr hole and custom-made metal needle (33 gauge) 
loaded with virus was subsequently inserted through the hole to the injection site. Virus was 
infused at a rate of 100nL/min using a Hamilton syringe with a microsyringe pump (World 
Precision Instruments). Mice received 250-500 nL of virus (AAV8-DF-KORD-mCitrine, 
Addgene #65417; AAV2.hSyn.DIO.hM4D(Gi)-mCherry, Addgene #44362; 
AAV2.hSyn.DIO.hM3D(Gq)-mCherry, Addgene #44361; AAV2.hSyn.DIO.mCherry Addgene 
#50459). The injection needle was left in place for an additional 15 min and then slowly 
withdrawn over another 15 min. Injections were performed at the following coordinates for each 
brain region: RVM: AP -5.80 mm, ML 0.00 mm, DV -6.00. The incision was closed using 
Vetbond and animals were given ketofen (IP 10 mg/kg) and allowed to recover over a heat pad. 




All assays were performed in the Pittsburgh Phenotyping Core and scored by an 
experimenter blind to treatment.  
Observation of Scratching Behavior  
All tests were performed in a blinded manner. Scratching behavior was observed using a 
previously reported method (Kardon et al. 2014). On the testing day, the mice were individually 
placed in the observation cage (12x9x14 cm) to permit acclimation for 30 minutes. Scratching 
behavior was videotaped for 30 minutes after administration of chloroquine. The temporal and 
total numbers of scratch bouts by the hind paws at various body sites during the first 30 minutes 
after intrathecal injection were counted.  
Hargreaves testing 
Animals were acclimated on a glass plate held at 30°C (Model 390 Series 8, IITC Life 
Science Inc.). A radiant heat source was applied to the hindpaw and latency to paw withdrawal 
was recorded(Hargreaves et al. 1988). 2 trials were conducted on each paw, with at least 5 min 
between testing the opposite paw and at least 10 min between testing the same paw. To avoid 
tissue damage, a cut off latency of 20 sec was set. Values from both paws were averaged to 
determine withdrawal latency.  
Stress-induced analgesia 
Mice were placed in a water bath maintained at 30C and forced to swim for 3 minutes. 
After the swim, mice were returned to their home cages and tested 30 minutes later for stress-
induced analgesia (Ibironke and Rasak 2013) to hotplate and capsaicin (described further in the 





Twenty minutes after the forced-swim test, mice were placed on a 55C hotplate. The 
latency to first nocifensive response (lick or jump) and total number of licks over a 60s period 
were measured. Values were averaged across two trials for each mouse. 
Von Frey testing 
Mechanical sensitivity was measured using the Chaplan up-down method of the von Frey 
test (Chaplan et al. 1994). Calibrated von Frey filaments (North Coast Medical Inc.) were 
applied to the plantar surface of the hindpaw. Lifting, shaking, and licking were scored as 
positive responses to von Frey stimulation. Average responses were obtained from each 
hindpaw, with 3 min between trials on opposite paws, and 5 min between trials on the same paw.  
Cold plantar assay 
Paw withdrawal to cold sensitivity was measured as previously described (Brenner et al. 
2015; Brenner, Golden, and Gereau 2012). Briefly, animals were acclimated to a 1/4” glass plate 
and crushed dry ice was packed into a modified 3 mL syringe and used as a probe. The dry ice 
probe was applied to the glass beneath the plantar hindpaw and the latency to withdrawal was 
recorded. Two trials were conducted on each hindpaw, with 3 min between trials on opposite 
paws, and 5 min between trials on the same paw. A cut off latency of 20 s was used to prevent 
tissue damage. Withdrawal latencies for each paw were determined by averaging values across 2 
trials per paw. 
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Tail immersion test  
Mice were habituated to mice restraints 15 minutes for 3 days before testing. Tails were 
immersed 3 cm into a water bath at 48°C, and the latency to tail flick was measured three times 
with a 1 minute interval between trials.  
Immunohistochemistry 
Mice were anesthetized with an intraperitoneal injection of urethane, transcardially 
perfused, and post-fixed at least four hours in 4% paraformaldehyde. 40um and 25um thick 
RVM and spinal cord sections were collected on a cryostat and slide-mounted for 
immunohistochemistry. Sections were blocked at room temperature for two hours in a 5% 
donkey serum, 0.2% triton, in phosphate buffered saline. Primary antisera was incubated for 14 
hours overnight at 4°C: rabbit anti-RFP (1:1K), chicken anti-GFP (1:1K), and mouse anti-NeuN 
(1:500). Sections were subsequently washed three times for 20 minutes in wash buffer (0.2% 
triton, in PBS) and incubated in secondary antibodies (Life Technologies, 1:500) at room 
temperature for two hours. Sections were then incubated in Hoechst (ThermoFisher, 1:10K) for 1 
minute and washed 3 times for 15 minutes in wash buffer, mounted and cover slipped.  
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in situ hybridization experiments, confocal images of tissue samples (3-4 
sections per mouse over 3-4 mice) were imaged and only cells whose nuclei were clearly visible 




All statistical analyses were performed using GraphPad Prism 8. Values are presented as 
mean +/- SEM. Statistical significance was assessed using tests indicated in applicable figure 
legends. Significance was indicated by p < 0.05. Sample sizes were based on pilot data and are 
similar to those typically used in the field. 
10.3 Results 
We tested whether microinjection of a kappa agonist, U69,593, could affect naive 
responses to nociceptive stimuli (Figure 27A). We found that U69,593 had a pro-nociceptive 
effect when microinjected into the RVM, leading to a reduction in the latencies to respond to 
cold and thermal stimuli (Figure 27B, C) as well as a reduction in mechanical thresholds (Figure 
27D). Consistent with previous experiments (Pan, Tershner, and Fields 1997), we found that 
microinjection of the kappa agonist did not affect latencies in response to tail flick (Figure 27E). 
These data support that, at least for some stimuli, kappa-sensitive neurons in the RVM tonically 
suppress responses to pain that can be potentiated with their temporary pharmacological 
inhibition. 
10.3.1 Chemogenetic inhibition of RVM-KOR neurons elicits nociception 
To follow up on this observation, we sought to chemogenetically inhibit RVM-KOR 
neurons using both hM4Di and KORD DREADDs (Figure 27F). We found that chemogenetic 
inhibition of RVM-KOR neurons with both hM4Di and KORD enhanced sensitivities to cold, 
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thermal, and mechanical stimuli, but not chloroquine-evoked itch (Figure 27G-J). In the tail flick 
assay, only chemogenetic inhibition with hM4Di, but not KORD, reduced latencies (Figure 
27K). Chemeogenetic inhibition of RVM-KOR neurons did not exacerbate hyperalgesia in an 
acute injury model with intraplantar capsaicin (Figure 24H-K) and had no effect on locomotor 
activity (Figure 24L). In agreement with our pharmacological inhibition of RVM-KOR neurons 
(Figure 27B-D), these experiments involving chemogenetics suggest that RVM-KOR neurons 





Figure 27. Pharmacological and chemogenetic inhibition of RVM-KOR neurons facilitates nociception. 
(A) Model to test whether microinjection of a kappa agonist could inhibit RVM-KOR neurons to facilitate 
nociception.  
(B-E) Microinjection of U69,593 into the RVM increased sensitivities to (B) cold plantar assay, (C) hargreaves 
assay, (D) von Frey assay, but with no effect on (E) tail flick assay. Data are mean + SEM with dots representing 
individual mice (n=8 saline, n=7 U69,593 treated animals). Asterisks indicate the results of unpaired t-test (ns 
p>0.05, * p<0.05, ** p<0.01). 
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(F) Model for how a chemogenetic strategy using both hM4Di (pink) and KORD (green) DREADDs could mimic 
the effects of pharmacological inhibition of RVM-KOR neurons. Representative images of the RVM and spinal 
cords following infection are shown. Scale bar = 50 μm. 
(G-K) Chemogenetic inhibition of RVM-KOR neurons with hM4Di (pink, left) and KORD (green, right) on (G) 
cold plantar assay, (H) hargreaves, (I) chloroquine-evoked itch, (J) von Frey assay, and (K) tail flick assay. Data are 
mean + SEM with dots representing individual mice (n=10 hM4Di control, n=11 hM4Di, n=7 KORD control, n=8 
KORD mice). Asterisks indicate the results of two-way repeated measures ANOVA with Bonferroni’s correction (ns 
p>0.05, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
10.3.2 RVM-KOR neurons are required for stress-induced analgesia 
To further test the roles of RVM-KOR neurons in the tonic inhibition of pain, next 
wanted to test their contributions to stress-induced analgesia. We used the forced swim model of 
stress-induced analgesia (Mogil 1995; Ibironke and Rasak 2013) and tested the contributions of 
RVM-KOR neurons to stress-induced analgesia to hotplate and intraplantar capsaicin (Figure 
28A). With chemogenetic activation of RVM-KOR neurons, we found that naive animals 
receiving hM3Dq and CNO exhibited similar total licking behaviors and latencies to hotplate 
that resembled control animals following forced swim test (Figure 28B, C). Furthermore, when 
we inhibited RVM-KOR with hM4Di and CNO, we found that mice no longer exhibited stress-
induced analgesia to intraplantar capsaicin and hotplate (Figure 28D-F). Together, these results 
suggest that RVM-KOR neurons are required for stress-induced analgesia. 
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Figure 28. RVM-KOR neurons are required for stress-induced analgesia. 
(A) Model to test stress-induced analgesia. Mice were forced to swim for 3 minutes and later tested on a hotplate or 
their responses to intraplantar capsaicin were quantified. 
(B-C) Chemogenetic activation of RVM-KOR neurons produces responses similar to stress-induced analgesia as 
measured by hotplate (B) total licks and (C) latencies. Data are mean + SEM with dots representing individual mice 
(n=14 control, n=15 hM3Dq mice). Asterisks indicate the results of two-way repeated measures ANOVA with 
Bonferroni’s correction (ns p>0.05, *** p<0.001, **** p<0.0001). 
(D-F) Chemogenetic inhibition of RVM-KOR neurons abolishes stress-induced analgesia as measured by (D) 
nocifensive responses to capsaicin, hotplate (E) total licks, and (F) latencies. Data are mean + SEM with dots 
representing individual mice (n=11 control, n=12 hMDi mice). Asterisks indicate the results of two-way repeated 




In our pharmacological experiments, we found that microinjection of the kappa agonist, 
U69,593, into the RVM, resulted in an increase in sensitivities to cold and thermal stimuli. This 
is consistent with previous studies that found that microinjection of U69,593 (at a similar dose 
and volume, scaled down to by weight from rat to mouse) reversed morphine-induced analgesia 
(Pan, Tershner, and Fields 1997; Meng et al. 2005) and precipitated mechanical allodynia in a 
chronic injury model (De Felice et al. 2011). These data support that RVM-KOR neurons 
tonically suppress nociception, which is facilitated with their temporary pharmacological 
inhibition. 
Notably, this is in contrast with another study which found that microinjection of the 
same kappa agonist into the RVM promoted anti-nociception to thermal stimuli in freely-
behaving rats (Ackley et al. 2001). The differences observed in our study may be attributed to 
two main factors: first, most of the prior literature pertaining to the descending modulation of 
pain centered upon studies in rats, whereas our studies were conducted in mice. There are 
important considerations regarding the physiological, behavioral, anatomical, and biochemical 
differences between rats and mice. Such differences may have contributed to our divergent 
findings. Secondly, the concentration and volume of the injection is important because, as we 
found in prior chapters, many RVM neurons express KOR, including those containing MOR. It 
is possible that kappa agonism in previous work may have inhibited the dual MOR/KOR-
expressing ON cells, thereby eliciting responses consistent with analgesia. In our experiments, 
we did not observe analgesia, suggesting that our agonism of KOR preferentially targeted OFF 
cells, but it may account for the differences observed in our study. In support of this possibility, 
it has been shown that U69,593 inhibits the ON cell burst (Meng et al. 2005), suggesting that 
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some ON cells also express the kappa opioid receptor. Still, it remains unknown how these 
mixed ON cells could modulate the activity of GABAergic, spinally-projecting RVM-KOR OFF 
cells. 
Extensive pharmacological studies into endogenous analgesic pathways have established 
that the CNS has the capacity to provide relief to chronic pain patients when engaged by 
alternative methods such as the placebo effect, stress, mindfulness, fear or pleasure (Fechir et al. 
2012; Kut et al. 2011; Sharon et al. 2016; Eippert et al. 2009). Our findings suggest that RVM-
KOR neurons participate in the state-dependence of pain modulation. In particular, we found that 
RVM-KOR neurons are required for the behavioral expression of stress-induced analgesia. Thus 
these neurons may provide a key entry-point into the body’s powerful endogenous pain-
modulatory system. RVM-KOR neurons may represent a target for the treatment of pain 
disorders.  
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11.0 Dynorphin input from the PAG modulates pain and itch 
11.1 Introduction 
In this section, we investigated potential inputs to RVM-KOR neurons. In particular, we 
test the contributions of dynorphin-PAG neurons in pain and itch as a possible pre-synaptic 
pathway to RVM-KOR neurons. This is due to two reasons: first, dynorphin is the endogenous 
peptide for the kappa opioid receptor (Kardon et al. 2014). Furthermore, the most well-studied 
region projecting to the RVM is the PAG. Lesioning and inactivation of the RVM (with local 
anesthetics) block the antinociceptive action of PAG (Behbehani and Fields 1979; Prieto, 
Cannon, and Liebeskind 1983; Gebhart 1982). Thus, the RVM is a necessary component within 
the descending modulatory circuit activated by stimulation of the PAG. On this basis, we wanted 
to test the contributions of possible dynorphinergic inputs from the PAG to the RVM. 
11.2 Methods 
Mice 
The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 background. KOR-Cre and Pdyn-Cre (Jax #027598) mice were used. Even 
numbers of male and female mice were used for all experiments. Mice were given free access to 
food and water and housed under standard laboratory conditions. The use of animals was 
approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh.  
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Pharmacologic agents 
Clozapine-N-oxide (Tocris) was dissolved in PBS and administered intraperitoneally 
(5mg/kg) or locally via cannula injection (1mmol in 300nl). nor-Binaltorphimine 
dihydrochloride (norBNI; Sigma, 100ng in 250nl) was dissolved in sterile saline and 
microinjected into the RVM. Chloroquine diphosphate salt (Sigma) was dissolved in 
physiological saline (100μg in 10μL) and administered intradermally. 
Intradermal injections 
For intradermal injection of chloroquine, hair was removed at least 24 hours before the 
experiment. Chloroquine (100μg in 10μL) was administered into the nape of the neck or calf, 
which could be subsequently visualized by the formation of a small bubble under the skin. These 
procedures were performed in awake mice.  
Stereotaxic injections and cannula implantation 
Animals were anesthetized with 2% isoflurane and placed in a stereotaxic head frame. A 
drill bit (MA Ford, #87) was used to create a burr hole and custom-made metal needle (33 gauge) 
loaded with virus was subsequently inserted through the hole to the injection site. Virus was 
infused at a rate of 100nL/min using a Hamilton syringe with a microsyringe pump (World 
Precision Instruments). Mice received 250-500 nL of virus (AAV2.hSyn.DIO.mCherry Addgene 
#50459; AAV2.hSyn.DIO.hM3D(Gq)-mCherry, Addgene #44361; 
AAVr.EF1a.DIOhChR2(H134R).eyfp-wpre-hghpa, Addgene 20298; AAVr-FLEX-tdTomato, 
Addgene 28306). The injection needle was left in place for an additional 15 min and then slowly 
withdrawn over another 15 min. Injections and cannula implantations were performed at the 
following coordinates for each brain region: RVM: AP -5.80 mm, ML 0.00 mm, DV -6.00 and 
vlPAG: AP -4.70 mm, ML ± 0.74 mm, DV: -2.75. For implantation of guide cannulas (P1 
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Technologies), implants were slowly lowered 0.300-0.500 mm above the site of injection and 
secured to the skull with a thin layer of Vetbond (3M) and dental cement. The incision was 
closed using Vetbond and animals were given ketofen (IP 10 mg/kg) and allowed to recover over 
a heat pad. Mice were given 4 weeks to recover prior to experimentation. 
Behavior 
All assays were performed in the Pittsburgh Phenotyping Core and scored by an 
experimenter blind to treatment.  
Observation of scratching behavior  
All tests were performed in a blinded manner. Scratching behavior was observed using a 
previously reported method (Kardon et al. 2014). On the testing day, the mice were individually 
placed in the observation cage (12x9x14 cm) to permit acclimation for 30 minutes. Scratching 
behavior was videotaped for 30 minutes after administration of chloroquine. The temporal and 
total numbers of scratch bouts by the hind paws at various body sites during the first 30 minutes 
after intrathecal injection were counted.  
Hargreaves testing 
Animals were acclimated on a glass plate held at 30°C (Model 390 Series 8, IITC Life 
Science Inc.). A radiant heat source was applied to the hindpaw and latency to paw withdrawal 
was recorded (Hargreaves et al. 1988). 2 trials were conducted on each paw, with at least 5 min 
between testing the opposite paw and at least 10 min between testing the same paw. To avoid 
tissue damage, a cut off latency of 20 sec was set. Values from both paws were averaged to 
determine withdrawal latency.  
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Von Frey testing 
Mechanical sensitivity was measured using the Chaplan up-down method of the von Frey 
test (Chaplan et al. 1994). Calibrated von Frey filaments (North Coast Medical Inc.) were 
applied to the plantar surface of the hindpaw. Lifting, shaking, and licking were scored as 
positive responses to von Frey stimulation. Average responses were obtained from each 
hindpaw, with 3 min between trials on opposite paws, and 5 min between trials on the same paw.  
Cold plantar assay 
Paw withdrawal to cold sensitivity was measured as previously described (Brenner et al. 
2015; Brenner, Golden, and Gereau 2012). Briefly, animals were acclimated to a 1/4” glass plate 
and crushed dry ice was packed into a modified 3 mL syringe and used as a probe. The dry ice 
probe was applied to the glass beneath the plantar hindpaw and the latency to withdrawal was 
recorded. Two trials were conducted on each hindpaw, with 3 min between trials on opposite 
paws, and 5 min between trials on the same paw. A cut off latency of 20 s was used to prevent 
tissue damage. Withdrawal latencies for each paw were determined by averaging values across 2 
trials per paw. 
Tail immersion test  
Mice were habituated to mice restraints 15 minutes for 3 days before testing. Tails were 
immersed 3 cm into a water bath at 48°C, and the latency to tail flick was measured three times 
with a 1 minute interval between trials.  
RNAscope in situ hybridization  
Multiplex fluorescent in situ hybridization was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 um-thick fresh-
frozen sections containing the RVM were fixed in 4% paraformaldehyde, dehydrated, treated 
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with protease for 15 minutes, and hybridized with gene-specific probes to mouse. Probes were 
used to detect tdTomato-C2 (#317041-C2), mCherry-C2 (#431201), Mm-Pdyn-C2 (#31877), 
Mm-Slc32a1-C3 (#319191), and Mm-Slc17a6-C3 (#319171). DAPI (#320858) was used to 
visualize nuclei. 3-plex positive (#320881) and negative (#320871) control probes were tested. 
Three to four z-stacked sections were quantified for a given mouse, and 3-4 mice were used per 
experiment. 
Immunohistochemistry 
Mice were anesthetized with an intraperitoneal injection of urethane, transcardially 
perfused, and post-fixed at least four hours in 4% paraformaldehyde. 40um and 25um thick 
RVM and spinal cord sections were collected on a cryostat and slide-mounted for 
immunohistochemistry. Sections were blocked at room temperature for two hours in a 5% 
donkey serum, 0.2% triton, in phosphate buffered saline. Primary antisera was incubated for 14 
hours overnight at 4°C: rabbit anti-RFP (1:1K), chicken anti-GFP (1:1K), and mouse anti-NeuN 
(1:500). Sections were subsequently washed three times for 20 minutes in wash buffer (0.2% 
triton, in PBS) and incubated in secondary antibodies (Life Technologies, 1:500) at room 
temperature for two hours. Sections were then incubated in Hoechst (ThermoFisher, 1:10K) for 1 
minute and washed 3 times for 15 minutes in wash buffer, mounted and cover slipped.  
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in situ hybridization experiments, confocal images of tissue samples (3-4 
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sections per mouse over 3-4 mice) were imaged and only cells whose nuclei were clearly visible 
by DAPI staining and exhibited fluorescent signal were counted.  
Statistical analysis 
All statistical analyses were performed using GraphPad Prism 8. Values are presented as 
mean +/- SEM. Statistical significance was assessed using tests indicated in applicable figure 
legends. Significance was indicated by p < 0.05. Sample sizes were based on pilot data and are 
similar to those typically used in the field. 
11.3 Results 
We injected Cre-dependent retrograde viral tracers into the RVM in Dyn-Cre mice to 
identify areas that could provide dynorphinergic inputs to the RVM (Figure 29A). We found 
robust labeling in many areas, including the parabrachial nucleus (PBN), dorsal reticular nucleus 
(Drt), and the agranular insular area (AIp); however, the most robust labeling was observed in 
the ventrolateral periaqueductal gray (vlPAG) (Figure 29A).  
We characterized RVM-projecting Dyn-PAG neurons using CTB and AAVr-DIO-tdt 
(Figure 29B) and found that 10.4 +/- 4.0% Dyn-PAG neurons project to the RVM. Using a 
complementary approach involving retrograde viral labeling and FISH, we found that this 
population represented 32.3 +/- 2.1% of RVM-projecting Dyn-PAG neurons. We found that 
these Slc17a6-expressing (glutamatergic) neurons comprised 99.3 +/- 0.7% of all RVM-
projecting PAG neurons (Figure 29C). We also found that Dyn-PAG neurons represented a 
population that was molecularly distinct from a recently described population of Tac1-PAG 
neurons (Gao et al. 2019) (Figure 30A-C). 
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Figure 29. Pdyn-PAG neurons provide input to the RVM and bidirectionally modulate pain. 
(A) Experimental strategy to trace dynorphinergic inputs to the RVM. Robust labeling was observed in the vlPAG 
of Dyn-Cre mice receiving AAVr-Ef1a-DIO-eYFP to the RVM. vlPAG: ventrolateral periaqueductal gray, PBN: 
parabrachial nucleus, AIp: agranular insular area, Drt: dorsal reticular nucleus. Scale bar = 50 μm. 
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(B) Approach to characterize dynorphin neurons projecting to the RVM. In one experiment, mice Dyn-Cre mice 
receiving Cre-dependent AAVr-DIO-tdt in the RVM and RVM-projecting neurons were further characterized using 
FISH. In a separate experiment, Dyn-Cre;tdt mice received CTB and back labeled CTB neurons were quantified. 
Scale bar = 50 μm. 
(C) Summary of RVM-projecting dynorphin-PAG neurons characterization. Data are mean + SEM with dots 
representing individual mice. 
(D) Experimental strategy to bidirectionally modulate pain behaviors following chemogenetic activation (purple) 
and inhibition (green) of Dyn-PAG neurons. Scale bar = 50 μm. 
(E-I) Chemogenetic activation with hM3Dq (purple, left) and inhibition with hM4Di (green, right) on (E) cold 
plantar assay, (F) hargreaves assay, (G) chloroquine-evoked itch, (H) von Frey assay, and (I) tail flick assay. Data 
are mean + SEM with dots representing individual mice (n=8 hM3Dq control, n=6 hM3Dq, n=7 hM4Di control, n=7 
hM4Di mice). Asterisks indicate the results of two-way repeated measures ANOVA with Bonferroni’s correction 
(ns p>0.05, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
(J) Experimental approach to selectively activate Dyn-PAG neurons containing hM3Dq by delivery of local CNO to 
the RVM. Chemogenetic activation facilitates responses to thermal and mechanical, but not cold testing. Data are 
mean + SEM with dots representing individual mice (n=7 control, n=9 hM3Dq mice). Asterisks indicate the results 
of unpaired t-test (ns p>0.05, * p<0.05). 
(K) Experimental approach to block input from Dyn-PAG neurons containing hM3Dq by delivery of local norBNI 
to the RVM. Pharmacological blockade of Dyn-PAG activation reverses thermal and mechanical, but not cold 
testing. Data are mean + SEM with dots representing individual mice (n=7 control, n=9 hM3Dq mice). Asterisks 
indicate the results of two-way repeated measures ANOVA with Bonferroni’s correction (ns p>0.05, * p<0.05, ** 




Figure 30. Further characterization of PAG neuronal cell types. 
(A) Experimental strategy to trace Tac1 inputs to the RVM. vlPAG: ventrolateral periaqueductal gray, PBN: 
parabrachial nucleus, AIp: agranular insular area, IF: interfascicular nucleus. Scale bar = 50 μm. 
(B) FISH characterization of Pdyn, Tac1, and Slc32a1 expression in the PAG. Scale bar = 50 μm. 
(C) Immunohistochemical characterization of Dyn;tdt neurons and TH (tyrosine hydroxylase) and Tph (tryptophan 
hydroxylase). Scale bar = 50 μm. 
11.3.1 Dynorphin-PAG neurons modulate itch and pain 
Recent work has revealed that specific manipulation of glutamatergic and GABAergic 
PAG neurons can bidirectionally modulate pain and itch (Samineni et al. 2017, 2019). We used 
chemogenetics to bidirectionally modulate the dynorphin population of PAG neurons using Cre-
dependent hM3Dq and hM4di in Dyn-Cre mice to activate and inhibit these neurons, 
respectively (Figure 29D). Mice received either AAV2-hSyn-DIO-hM3Dq-mCherry or AAV2-
hSyn-DIO-hM4Di-mCherry. We found that chemogenetic activation and inhibition with IP CNO 
bidirectionally modulated thresholds to cold plantar and hargreaves testing (Figure 29E, F) and 
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chloroquine-evoked itch (Figure 29G). Although chemogenetic activation reduced mechanical 
thresholds (Figure 29H), inhibition did not elevate thresholds above baseline (Figure 29H). 
Neither activation nor inhibition of Dyn-PAG neurons affected latencies to tail flick (Figure 29I). 
Overall, we found that activation of Dyn-PAG neurons facilitated pain, whereas inhibition of 
these neurons reduced sensitivities to cold, thermal, and itch responses.  
We confirmed that Dyn-PAG neurons facilitated pain through their input to the RVM by 
implanting cannulas in the RVM for the local delivery of CNO (Figure 29J). This allowed us to 
selectively activate RVM-projecting PAG neurons. We found that the selective chemogenetic 
activation of this pathway generally recapitulated our findings following IP CNO (Figure 29F, 
H) and facilitated sensitivity to thermal and mechanical testing (Figure 29J). 
11.3.2 Dynorphinergic pathways from the PAG to RVM modulates nociception 
To test more directly whether Dyn-PAG neurons could exert their effects through 
dynorphin signaling in the RVM, we used a pharmacological approach to block dynorphin input 
to the RVM following activation of Dyn-PAG neurons (Figure 29K). We found that IP CNO 
reduced latencies to hargreaves testing and mechanical thresholds in the von Frey assay. 
However, microinjection of norBNI prior to the administration of IP CNO blocked the 
development of thermal and mechanical hypersensitivity (Figure 29K). Thus, these data suggest 
that Dyn-PAG neurons facilitate pain through dynorphin signaling in the RVM. 
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11.4 Discussion 
Recent studies into the PAG using Cre drivers targeting Vgat (GABAergic) and Vglut2 
(glutamatergic) neurons have revealed that these two classes of neurons divergently modulate 
nociception. Through careful chemogenetic and optogenetic studies, Vgat neurons have been 
shown to be pain facilitating, whereas Vglut2 are anti-nociceptive (Samineni et al. 2019, 2017). 
Interestingly, these two populations of PAG neurons exhibit modality-specificity and are 
differentially engaged to modulate pain and itch: Vgat and Vglut2 neurons inhibit and facilitate 
itch, respectively (Samineni et al. 2019). Another cell type that has recently been examined using 
genetic approaches are Tac1-PAG neurons. Glutamatergic PAG neurons containing Tac1 have 
recently been shown to be involved in the facilitation of itch (Gao et al. 2019). Calcium imaging 
of this population found them to be active during itch behaviors. Chemogenetic activation and 
inhibition of Tac1 neurons identified that they are both sufficient and necessary for itch and their 
behavioral effects were mediated through glutamate signaling in the RVM. Interestingly, these 
neurons were not found to be involved in nociception (Gao et al. 2019).  
Here, we tested the role of dynorphin-PAG neurons in the modulation of pain and itch. In 
contrast to other recent work, we found that dynorphin neurons participate in the modulation of 
both itch and pain. Chemogenetic activation of these neurons facilitated both itch and pain, 
representing a departure from studies of Vgat/Vglut2 populations, which were found to 
differentially modulate itch and pain (Samineni et al. 2019, 2017). We also found that RVM-
projecting dynorphin-PAG neurons are overwhelmingly glutamatergic, which is consistent with 
previous investigations into Vglut2 and Tac1-PAG populations and their roles in facilitating itch. 
Lastly, our pharmacological blockade of dynorphinergic-PAG signaling to the RVM using 
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norBNI expands on prior work by demonstrating that the PAG functionally provides inputs to the 




Our study identifies the role of RVM-KOR neurons in the inhibition of pain and itch. 
Previous work has also implicated the role of RVM-KOR neurons as OFF cells (Pan, Tershner, 
and Fields 1997; Pan, Williams, and Osborne 1990; Pan, Hirakawa, and Fields 2000). However, 
depending on the assay tested and whether the animals were lightly anesthetized (Pan, Tershner, 
and Fields 1997; Pan, Williams, and Osborne 1990; Pan, Hirakawa, and Fields 2000) or awake 
(Ackley et al. 2001; Meng et al. 2005), there was controversy as to whether RVM neurons 
responsive to kappa agonists could be pro- or anti-nociceptive. Indeed, our neurochemical 
characterization of RVM-KOR neurons reveals that they comprise a heterogeneous population; 
yet our ability to capture and manipulate spinally-projecting RVM-KOR neurons identifies them 
as a unique and molecularly distinct subgroup of all RVM-KOR neurons. We found that the 
targeting of a small number of RVM-KOR neurons that project to the spinal cord was sufficient 
to produce anti-nociception and revealed that RVM-KOR neurons are required for stress-induced 
analgesia.  
A considerable amount of work has been conducted to examine how the RVM could 
contribute to the state-dependence of somatosensation, including nociception (Mason 2001; 
Mason, Gao, and Genzen 2007; Mason et al. 2001; Leung and Mason 1999; Foo and Mason 
2003; Hellman and Mason 2012). In support of this view, in our loss-of-function experiments, 
we found that RVM-KOR neurons are required for stress-induced analgesia. Our findings 
suggest that in addition to the inhibition of nociception, acute, and chronic pain, these RVM-
KOR neurons are also engaged in a state of stress. Such a protective mechanism may explain, for 
example, how firefighters are able perform their heroic duties, despite hazardous and extreme 
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conditions. Curiously, our experiments also uncovered the possible role of other KOR neurons in 
the brainstem that could drive profound and diverse functions in movement and arousal whose 
precise identities and roles remain to be further elucidated.  
Dynorphin signaling within the brain has been shown to be involved in myriad behaviors, 
including stress, addiction, analgesia (Chavkin 2011; Bruchas, Land, and Chavkin 2010). We 
found that the selective activation and inhibition of dynorphin neurons in the PAG facilitates and 
inhibits nociception, respectively. Using pharmacological approaches, we determined that these 
PAG neurons influence nociception through their release of dynorphin within the RVM. This 
finding, together with the observation that we and others have made that RVM neurons are 
sensitive to kappa agonism and antagonism, suggest that the descending modulation of pain is 
influenced by dynorphin signaling between the PAG and RVM. Identification of this 
dynorphinergic pathway may provide opportunities to take advantage of the body’s endogenous 
opioid system to manage pain. Approaches that make use of the powerful endogenous pain-
modulatory system can reduce the need for pharmacological treatments, such as opioids, with 
fewer side effects and improved outcomes for the treatment of pain disorders. 
12.1 Limitations 
12.1.1 A simplistic view of inputs to KOR RVM neurons 
We tested the contributions of dynorphin-PAG neurons in pain and itch as a possible pre-
synaptic pathway to RVM-KOR neurons because 1) dynorphin is the endogenous peptide for the 
kappa opioid receptor (Kardon et al. 2014) and 2) the PAG is a well-established source of input 
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to the RVM. We identified a dynorphinergic pathway from the PAG that modulates itch and 
pain, which we hypothesize directly engages RVM-KOR neurons. In our tracing studies, 
however, we also observed robust labeling of possible dynorphin inputs from other brain regions 
including the PBN and dorsal reticular nucleus. Our group has recently uncovered the role of 
dynorphin PBN neurons as a source for conveying nociceptive information between distinct 
subnuclei within the PBN (Chiang et al. 2020). Furthermore, activation of PBN terminals in the 
RVM has been found to inhibit OFF cells and activate ON cells, giving rise to pro-nociceptive 
phenotypes (Chen et al. 2017). Here, we also provide evidence that dynorphin neurons from 
several areas including the PAG, PBN, and dorsal reticular areas project to the RVM. Whether 
these represent distinct subpopulations of dynorphin neurons is not yet known, but given the 
importance of the PBN as the target of ascending nociceptive inputs, it is conceivable that these 
neurons may coordinate appropriate nocifensive responses through an RVM-dependent circuit. 
However, this possibility was not tested in our study. Analogous approaches that were used in 
our study to determine inputs from the PAG could also be used to characterize and manipulate a 
dynorphinergic PBN to RVM circuit in the future. 
We examined the role of dynorphin inputs because dynorphin is the endogenous peptide 
for the kappa opioid receptor. However, RVM neurons have been found to respond to numerous 
pharmacological agents, reflective of their receptor heterogeneity. Thus, RVM-KOR neurons 
may also receive inputs from other peptide ligands as well as fast transmitters, such as GABA 
and glutamate, which were not explicitly tested in our study. KOR and MOR have been shown, 
for instance, to overlap in the RVM (Gutstein et al. 1998). However, our FISH characterization 
revealed that spinally-projecting KOR neurons do not express MOR, suggesting that, at least 
among the descending neurons, these receptors mark distinct subpopulations. The use of 
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retrograde tracers, such as rabies virus, and Cre-dependent AAV helpers will more 
comprehensively reveal additional inputs to RVM-KOR neurons. Combined with neurochemical 
and electrophysiological approaches, these studies will reveal the nature of the cell types and 
transmitters involved in RVM-KOR signaling. 
Another limitation of our focus on dynorphin PAG neurons is the observation that these 
neurons are exclusively glutamatergic, whereas dynorphin activation of the kappa opioid 
receptor generally leads to the inhibition of KOR-expressing cells through Gai signaling. 
Although the PAG to RVM projection has been suggested to be excitatory, it has also been 
proposed that inhibitory output from the PAG helps maintain the GABA tone at the level of the 
RVM (Behbehani and Fields 1979; Morgan et al. 2008). However, most of the current evidence 
supports the hypothesis of local GABAergic tone in the PAG which regulates excitatory 
projections to the RVM (Reichling and Basbaum 1990; Cho and Basbaum 1991; Morgan et al. 
2008). Presently, it is unclear how these excitatory dynorphin neurons could modulate the 
activity of RVM-KOR cells. Our pharmacological blockade of dynorphin inputs to the RVM 
with norBNI, combined with the observation that chemogenetic manipulation of dynorphin-PAG 
neurons produces the opposite effect of RVM-KOR manipulation suggests that dynorphin-PAG 
neurons use dynorphin as their primary transmitter to inhibit RVM-KOR cells. Future 
electrophysiological recordings of RVM-KOR neurons with simultaneous manipulation of 
dynorphin-PAG neurons may further elucidate the nature of this circuit. 
Lastly, we did not examine the roles of dynorphin-PAG neurons beyond itch and pain. 
The PAG functions as a hub for many other aspects of physiology and behavior, including 
autonomic function, motivated behaviors, as well as nociception, which warrant further 
investigation (Silva and McNaughton 2019; Behbehani 1995; Koutsikou et al. 2015; Morgan and 
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Clayton 2005; Comoli, Ribeiro-Barbosa, and Canteras 2003; Dampney et al. 2013; Li et al. 
2018). 
12.1.2 Confounding motor and arousal findings 
In our study, we emphasize the role of spinally-projecting RVM-KOR neurons in the 
inhibition of itch and pain. However, considerable efforts have been conducted to characterize 
the roles of RVM neurons in myriad behaviors, including sleep, feeding, thermoregulation, 
sexual climax, movement, and behavioral arousal (discussed further in the future directions) 
(Mason 2001; Mason, Gao, and Genzen 2007; Mason et al. 2001; Leung and Mason 1999; Foo 
and Mason 2003; Hellman and Mason 2012) . In accordance with this idea, we also observed in 
our experiments that the non-specific activation of either local RVM-KOR interneurons and/or 
non-spinally-projecting RVM-KOR neurons appear to be involved in both locomotion (as 
determined using rotarod and openfield assays) and arousal (as determined by the lack of 
acoustic startle to loud sounds).  
Given the robust motor and arousal phenotypes, we were required to consider the 
possibility that either or both of these confounds could affect the interpretation of our 
somatosensory findings; for instance, because the mice were not moving in the openfield, one 
could conclude that they lacked the motor coordination to perform withdrawal reflexes and 
because mice were unresponsive to 115 dB presentations, then perhaps they would not scratch in 
response to intradermal chloroquine. These confounds necessitated the serial dilution of the viral 
titer used to capture fewer and fewer neurons with the goal of separating these variables. Because 
of technical limitations, and the apparent intermingling of these heterogeneous KOR-expressing 
cell types by FISH, it was not possible to simply restrict our viral targeting to sub-nuclei of the 
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RVM. Although there may be some organization (our very dilute titer was more circumscribed to 
the RMg and NGCa), only with the very dilute virus were we able to prevent the non-specific 
infection of other KOR-expressing brainstem neurons during needle reflux. Furthermore, given 
that nearly six cohorts of animals were generated by these dilutions, we were unable to perform 
motor, arousal, and somatosensory assays on all cohorts and only tested animals for pruritogen-
evoked scratching when we observed the loss of spinal innervation in the animals receiving very 
dilute titers. Due to these limitations, it is possible that even with the diluted titers used, we may 
have captured some neurons that modulate movement and arousal. Nevertheless, our 
complementary approach using a retrogradely-labeled virus, which allowed us to selectively 
manipulate only the spinally-projecting RVM-KOR neurons, yielded highly consistent results 
with respect to the inhibition of itch and pain behaviors. 
12.1.3 Molecular heterogeneity of KOR RVM neurons 
Our initial FISH characterization of RVM-KOR neurons using several genetic markers 
revealed that they constituted a diverse population. Although we were able to directly manipulate 
spinally-projecting RVM-KOR neurons and found that this population is exclusively 
GABAergic, it remains an open question the functions of the non-spinally-projecting KOR RVM 
neurons as well as the GABAergic spinally-projecting neurons that do not contain KOR. 
The role of inhibitory neurons, as a collective population, is still hotly contested; one 
study, using very similar approaches to those used in our study, uncovered the role of Vgat-RVM 
neurons in the facilitation of mechanical, but not heat pain; however, another study found Gad2-
RVM neurons (which comprise a subpopulation of Vgat neurons) to be involved in the inhibition 
of mechanical and theraml pain. Our manipulation of Gad2-RVM neurons is in agreement with 
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the latter group, where activation of these cells was also anti-nociceptive. We also found that the 
spinally-projecting RVM-KOR neurons are exclusively GABAergic and broadly inhibit pain and 
itch. Thus, it is likely that GABAergic neurons in the RVM span several functional subgroups 
and differences in behavioral findings may reflect the relative subpopulations that are captured 
with viral approach used. Nevertheless, technological advances involving intersectional genetic 
approaches provide several advantages that can allow us to continue to identify and directly 
manipulate unique RVM subpopulations in freely-behaving mice. 
12.1.4 Targeting of KOR RVM neurons 
We also did not report the injection or implantation site of every mouse that received a 
viral injection or a cannula surgery. Over four hundred animals, across six different Cre alleles, 
were used in this study and efficiency was prioritized over validation. Although this is an 
important limitation to the study, we will, in future experiments, validate the expression of fos 
within RVM-KOR neurons mice that received an anterograde hM3Dq virus in the RVM as well 
as in animals receiving AAV-retro into the spinal cord with cannula implantation in the RVM. 
We also used a high dose of CNO in most experiments (5 mg/kg IP and 0.3 nmol intracranial) 
and did not perform a dose-response analysis to determine the specificity of the agonist to the 
behaviors observed. However, some of the concerns of off-target effects of CNO (or its back-
metabolite, clozapine) are mitigated due to the use of control animals that received a control viral 
vector and were exposed to the same doses of IT, intracranial, and IP CNO. 
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12.2 Future Directions 
12.2.1 Role of KOR neurons beyond nociception 
In our study, we were surprised to find that the chemogenetic activation of KOR-
expressing RVM neurons affected motor and arousal states. Although the use of the KOR-Cre 
allele allowed us to selectively target KOR-expressing neurons in the brainstem, we found that 
many brainstem neurons expressed KOR and that these neurons, identified with FISH, 
represented a heterogenous group. Although we were able to selectively manipulate only the 
spinally-projecting RVM-KOR neurons and assess their contributions to itch and pain, it remains 
unknown the other functions of KOR-expressing brainstem neurons. Given the striking 
behavioral phenotypes, including the suppression of acoustic startle and locomotor deficits, we 
hypothesize that the non-spinally projecting RVM-KOR neurons may be involved in other 
homeostatic, motor, and arousal functions. Further dissection of RVM-KOR neurons, which may 
include a combination of optogenetics or retrograde targeting to isolate distinct pathways arising 
from the RVM may help to disentangle these complex functions. We found robust labeling 
within the reticular formation, the superior colliculus, the nucleus of the solitary tract, thalamic, 
and hypothalamic structures. It is possible that some, or a combination, of these targets could 
mediate the effects observed. Given the role of medullar neurons in the autonomic regulation, 
movement, and behavioral arousal (discussed in the introduction of this section), the use of 
additional assays may allow for the assessment of the contribution of RVM-KOR neurons in 
functions beyond pain. 
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12.2.2 Spinal circuits influenced by descending modulation 
The spinal cord represents the final target of the pain descending modulatory system. 
Electrical stimulation of the PAG and RVM induce analgesia that is spinally-mediated; this form 
of analgesia can be blocked by spinal cord delivery of agents such as lidocaine or modulating 
monoamine or adrenergic systems, hinting at an interaction between descending circuits and the 
spinal cord (Sandkühler, Fu, and Zimmermann 1987; Carstens et al. 1981; Rydenhag and 
Andersson 1981; Camarata and Yaksh 1985; Jensen and Yaksh 1984). Moreover, both the PAG 
and RVM have been reported to modulate spinal cord circuitry in a fiber-specific fashion. It has 
been shown that spinal cord neurons receiving C-type fiber inputs are preferentially suppressed 
during PAG or RVM stimulation (Heinricher et al. 2009; Hentall and Fields 1979; Waters and 
Lumb 2008; Koutsikou et al. 2007). These observations support that descending pathways target 
specific spinal neurons to modulate pain. 
Recent efforts have begun to elucidate the precise identities of spinal neurons that receive 
input from the RVM in the context of somatosensation. Optogenetic and chemogenetic 
manipulations of Vgat-Cre RVM neurons have suggested that GABAergic RVM neurons 
descend to presynaptically inhibit mechanosensory input onto spinal inhibitory enkephalinergic 
(Penk) interneurons (François et al. 2017). Thus, this model posits that descending GABAergic 
neurons could facilitate mechanical nociception through the process of disinhibition of Penk 
neurons in the dorsal horn. Alternatively, combined optogenetic and electrophysiological 
experiments in spinal cord slices have suggested that GABAergic RVM-spinal projection 
neurons inhibit GRPR-expressing neurons in the spinal cord (Liu et al. 2019), a population that 
has been heavily implicated in driving itch (Sun and Chen 2007). Together, these reports suggest 
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that GABAergic RVM neurons could facilitate pain through inhibition of Penk spinal neurons, 
and inhibit itch through inhibition of excitatory GRPR neurons.  
Given our finding that activation of GABAergic RVM-KOR neurons inhibits itch and 
pain, it is unlikely that Penk neurons are downstream of our circuit. However, we speculate that 
RVM-KOR neurons may inhibit itch through the inhibition of GRPR neurons. Nevertheless, we 
speculate that RVM-KOR neurons may engage many more subpopulations of spinal neurons due 
to their extensive innervation of many laminae of the spinal cord. Although we attribute our 
behavioral findings to an RVM-spinal circuit, it is unclear where in the spinal cord RVM-KOR 
neurons exert their influence; further work is necessary to determine precisely where and how 
RVM-KOR neurons elicit their antipruritic and anti-nociceptive effects. 
12.2.3 Plasticity of RVM pathways in the transition from acute to chronic pain 
Acutely, stress inhibits pain (Yilmaz et al. 2010) and stress-induced analgesia is thought 
to be mediated by the RVM (Shamsizadeh et al. 2014). Our findings support the idea that RVM 
neurons are required for stress-induced analgesia. Interestingly, chronic stress-induced 
hyperalgesia is also thought to be RVM-dependent (Jennings et al. 2014). Recent rodent work 
suggests that stress enhances the activity of GABAergic RVM neurons to inhibit the activity of 
spinal neurons producing enkephalins (François et al. 2017), thereby driving hyperalgesia. Still, 
it remains unclear how structural and functional changes occur within the RVM in the setting of 
chronic stress; characterization of plasticity in descending neural circuits could facilitate the 
development of improved, targeted therapies for chronic pain. Although we did not test this 
transition in our studies (and only examined stress-induced analgesia acutely), it would be 
interesting to determine which neurons may be differentially involved in the expression of 
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chronic stress-induced hyperalgesia, which may now be detected using in vivo microendoscopy 
in a chronic stress model.  
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Appendix introduction 
The following appendix contains additional information pertaining to other major 
projects and studies that I have worked on throughout my graduate studies. Appendix A features 
experiments to reveal the molecular identities of PBN neurons and the effect of general 
inhibition of PBN neurons that I conducted as a contributing author as part of a larger body of 
work examining PBN circuits for nocifensive behaviors. Appendix B highlights experiments 
aimed at characterizing a possible tool to understand RVM neurons that express the mu-opioid 
receptor. Appendix C features experiments that examine the role of delta-opioid receptor 
signaling in itch behaviors. Appendix D contains neurochemical studies of the kappa-opioid 
receptor in the spinal cord dorsal horn. Appendix E evaluates the role of NK1R neurons in the 
descending modulation of itch and pain. Lastly, Appendix F assesses the functional role of 
neurons in the periaqueductal gray containing the mu-opioid receptor. 
 
These, as well as additional projects, can be found in the following PubMed link: 
https://www.ncbi.nlm.nih.gov/myncbi/1-_4iDHumLdAx/bibliography/public/  
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Appendix A Neurochemical characterization of the PBN neurons and its role in nocifensive 
behaviors 
Appendix A.1 Introduction 
The lateral parabrachial nucleus (lPBN) participates in numerous homeostatic and 
nociceptive functions (Palmiter 2018; Carter et al. 2013; Carter et al. 2015; Han et al. 2015). 
Underlying its ability to coordinate physiological and behavioral changes are the diverse 
neuronal subpopulations within the PBN. Although a few of these populations have been 
ascribed to distinct functions, how well these markers define unique populations remains 
contested. As a part of my contribution to a larger study (Chiang et al. 2020), we used 
chemogenetics to globally inhibit PBN neurons to determine the role of the PBN in a variety of 
nociceptive assays. Furthermore, we performed fluorescent in situ hybridization of the PBN to 
evaluate the overlap among various markers of putative neuronal subpopulations.  
Appendix A.2 Methods 
RNAscope in situ hybridization 
Multiplex fluorescent in situ hybridization was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics#320850). Briefly, 18mm-thick fresh-
frozen sections containing the parabrachial nucleus were fixed in 4% paraformaldehyde, 
dehydrated, treated with protease for 15 minutes, and hybridized with gene-specific probes to 
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mouse Pdyn(#318771), Calca(#417961), Tac1(#410351), Fos(#316921), Slc32a1(#319191), and 
Slc17a6(#319171). DAPI (#320858) was used to visualize nuclei. 3-plex positive (#320881) and 
negative (#320871) control probes were tested. Two to three full-thickness z stacked sections 
were quantified for a given mouse, and 2 - 4 mice were used per experiment. 
Behavioral tests described below were performed in a blinded manner. 
Conditioned place aversion 
Mice were placed in a two-chamber plexiglass box for 20 minutes and allowed to freely 
roam between one of two sides differentiated by visual cues (spots versus stripes). For two 
conditioning days, mice were restricted to one of two sides and received either no stimulation or 
CNO for 20-minute periods in the morning and afternoon. On the test day, mice were placed 
back into the box and allowed to freely explore either chamber. The behavior was recorded and 
post hoc analysis performed to determine body position using the open source software 
Optimouse as described in RTPA. For Formalin-induced CPA, mice were conditioned to 2% 
10mL solution of formalin injected into either one hindpaw on the first day of conditioning and 
the contralateral hindpaw on the second day of conditioning. Control mice received no hindpaw 
injections. In experiments involving hM4D, mice were pretreated with CNO (5 mg/kg) 30 min 
prior to conditioning with formalin. 
Tail immersion test 
Mice were habituated to mice restraints 15 minutes for 5 days before testing. Tails were 
immersed 3 cm into a water bath at 48C or 55C, and the latency to tail flick was measured three 
times per temperature with a one-minute interval between trials. For optogenetic testing, mice 
were photostimulated for 10 s prior to tail immersion testing. 
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Appendix A.3 Results 
Transient inhibition of the lPBN significantly reduced jumping behaviors, the inhibition 
of the tail flick response, and conditioned place aversion to a noxious stimulus (Figures 1G-K). 
Collectively, these data suggest that activity in the lPBN is important to help an organism escape 
from a noxious stimulus and to learn avoidance. Fluorescent in-situ hybridization of the PBN 
confirmed that many of the previously identified neuronal populations (Palmiter 2018; Barik et 
al. 2018; Gao et al. 2019) are excitatory (based on expression of Vglut2) (Figure 2A-D, G, and 
H). Furthermore, we found that the neurons that expressed fos in response to an aversive 
stimulus were also excitatory (Figure 1E). Finally, we ablated Pdyn neurons and found a 
reduction in the expression of fos in Pdyn and CGRP, but not Tac1 neurons (Figure 3D-I), 





Appendix A Figure 1. lPBN Is Required for Numerous Behavioral Responses to Noxious Stimuli 
D) Strategy to inhibit the lPBN through inhibition of excitatory neurons. (E) The PWT was significantly increased 
following intraperitoneal (i.p.) injection of CNO (orange bar) in hM4D mice compared with mCherry controls in a 
model of capsaicin-induced mechanical hypersensitivity. Data are mean ± SEM (n = 10–11 mice per group). Two-
way RM ANOVA followed by Holm-Sidak post hoc test, ∗∗∗p < 0.001. (F) The PWT was significantly increased 
following i.p. injection of CNO (orange bar) in hM4D mice compared with mCherry controls in a model of CFA-
induced mechanical hypersensitivity. Testing was performed 7 days post-CFA treatment. Data are mean ± SEM (n = 
10–11 mice per group). Two-way RM ANOVA followed by Holm-Sidak post hoc test, ∗p < 0.05. (G) Escape 
behaviors from a 55°C plate increased significantly following i.p. injection of CNO in hM4D mice (red bars) 
compared with mCherry controls (gray bars). Data are mean ± SEM (n = 11–14 mice per group); ∗∗∗p < 0.001, 
∗∗∗∗p < 0.001 (Student’s t test). (H) Strategy to test for conditioned pain modulation (CPM) using intraplantar 
capsaicin (0.03%). (I) CPM was observed in mCherry control mice but not hM4D mice (n = 11–14 mice per group). 
∗∗∗∗p < 0.0001; not significant (ns), p > 0.05 (paired Student’s t test). (J) Protocol for conditioned place aversion 
(CPA). CNO was given 30 min prior to 2% intraplantar formalin on days 2 and 3, which was paired with one side of 
a two-chambered box differentiated by visual cues. (K) Formalin-induced CPA is observed in control mice but not 





Appendix A Figure 2. Characterization of PBN neurons by fluorescent in-situ hybridization 
(A – E) FISH was performed to characterize the neurochemical properties of Gad2 neurons for (A) Vgat, (B) 
Vglut2, (C) Calca, (D) Tac1, or (E) Fos following intraplantar capsaicin injection (0.03%; 10 µl; unilateral; tissue 
was collected 20 m after stimulation). (F) Visualization and quantification eYFP expression in dPBN and elPBN 
following stereotactic injection of Cre-dependent AAV encoding eYFP into GadCre mice. Data are mean and dots 
represent data points from individual animals (n = 4 - 5 mice). Scale bar = 100 µm. (G) Representative image and 
quantification of PdynCre-expressing neurons in the dPBN and elPBN as visualized by FISH (n = 4 mice). Scale 
bars, 100 μm; inset, 25 μm. (H) Representative image (left) and quantification (right) of the lPBN using dual FISH 
with probes targeting Pdyn and Vgat. Data are mean and dots represent data points from individual animals (n = 3 





Appendix A Figure 3. Deletion of PBN-Pdyn neurons reduces activity in response to painful stimuli 
(D) Strategy to ablate PdynCre lPBN neurons. (E) Representative images of co-localization of PdynCre and Fos in 
lPBN neurons following intraplantar capsaicin injection. (F) The proportion of Fos+ neurons that co-localized with 
PdynCre was significantly reduced in mice treated with capsaicin compared to control-treated mice (n = 5 mice per 
group). **** indicates p < 0.0001 (unpaired Student’s t-test). (G) The proportion of PdynCre neurons that co-
localized with Fos was reduced in mice treated with capsaicin compared to controltreated mice (unable to compare 
statistics as a result of complete or near complete loss of PdynCre neurons). (H) Representative images from 
multiplex FISH experiments for Fos (red), Calca (green, top) and Tac1 (pseudocolored green, bottom) between 
control vs. caspase-injected mice. (I) Ablation of PdynCre neurons in dPBN reduces the number of Fos expressing-
Calca neurons in elPBN following intraplantar injection of capsaicin. Data are mean with dots representing 
individual animals (n = 5 – 7 mice) * indicates p < 0.05; n.s. indicates p > 0.05 (unpaired Student’s t-test).  
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Appendix A.4 Discussion 
Overall, these experiments helped to contextualize the role of Pdyn neurons within the 
PBN and validate prior suspicions that transiently inhibiting the PBN would have robust effects 
on nocifensive behaviors. 
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Appendix B Validation of Oprm1-Cre in RVM 
Appendix B.1 Introduction 
Previous reports have provided strong evidence for the existence of morphine-sensitive, 
Oprm1-expressing neurons in the RVM that could facilitate pain (Heinricher et al. 2009; Cleary 
et al. 2008; Skinner et al. 1997; Basbaum and Fields 1984). These neurons have been termed 
ON-cells. However, these pharmacological manipulations may have off-target effects, given that 
Oprm1 is expressed in many RVM neuronal subpopulations (Pedersen et al. 2011; Cai et al. 
2014; François et al. 2017). Thus, prior studies have been unable to tease apart the underlying 
circuitry by which MOR+ spinal projections facilitate pain. With the development of viral and 
genetic tools to selectively visualize and manipulate the activity of Oprm1 RVM neurons, we 
sought to address new questions about the descending circuitry which facilitates pain.  
Appendix B.2 Methods 
RNAscope in situ hybridization  
Multiplex fluorescent in situ hybridization was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 um-thick fresh-
frozen sections containing the RVM were fixed in 4% paraformaldehyde, dehydrated, treated 
with protease for 15 minutes, and hybridized with gene-specific probes to mouse. Probes were 
used to detect Mm-tdt-C2 (#431201), Mm-Oprm1-C1 (#315841), and Mm-Slc17a6-C3 
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(#319171). DAPI (#320858) was used to visualize nuclei. 3-plex positive (#320881) and 
negative (#320871) control probes were tested. Three to four 16um z-stacked sections were 
quantified for a given mouse, and 3-4 mice were used per experiment. 
Immunohistochemistry 
Mice were anesthetized with an intraperitoneal injection of urethane, transcardially 
perfused, and post-fixed at least four hours in 4% paraformaldehyde. 40um and 25um thick 
RVM and spinal cord sections were collected on a cryostat and slide-mounted for 
immunohistochemistry. Sections were blocked at room temperature for two hours in a 5% 
donkey serum, 0.2% triton, in phosphate buffered saline. Primary antisera was incubated for 14 
hours overnight at 4°C: rabbit anti-RFP (1:1K). Sections were subsequently washed three times 
for 20 minutes in wash buffer (0.2% triton, in PBS) and incubated in secondary antibodies (Life 
Technologies, 1:500) at room temperature for two hours. Sections were then washed 3 times for 
15 minutes in wash buffer, mounted and cover slipped.  
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in situ hybridization experiments, confocal images of tissue samples (3-4 
sections per mouse over 3-4 mice) were imagined and only cells whose nuclei were clearly 
visible by DAPI staining and exhibited fluorescent signal were counted.  
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Appendix B.3 Results 
Using the recently developed Oprm1-Cre mouse (a gift from Dr. Richard Palmiter), I 
tested the potential of using this allele to target Oprm1 RVM neurons. I used fluorescent in-situ 
hybridization to validate this Cre allele (Figure 1) and a Cre-dependent virus to infect Oprm1 
neurons in the RVM (Figure 2). 
 
 
Appendix B Figure 1 Validation of Oprm1-Cre mice.  
(A) Oprm1-Cre crossed to a tdtTomato reporter. (B) Fluorescent in-situ hybridization of Oprm1 (green) and 
tdTomato (red). Arrows indicate neurons positive for both markers. Scale bar = 50 μm 
 
 
Appendix B Figure 2. Viral approach to target Oprm1 neurons in the RVM.  
(A) Strategy to infect the RVM. (B) Immunohistochemistry of infected RVM neurons. Scale bar = 50 μm. 
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Appendix B.4 Discussion 
The neurochemical characterization of the Oprm1-Cre allele suggests that it may be a 
promising tool to study the role of Oprm1 neurons in RVM signaling. 
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Appendix C Bi-directional modulation of delta signaling in itch 
Appendix C.1 Introduction 
Opioid peptides and their receptors are widely expressed throughout the peripheral and 
central nervous systems. Due to its role in regulating nociception, the opioid system has been the 
target of the most widely used analgesics. The four characterized opioid receptors subtypes 
include the mu, kappa, delta, orphanin receptors (Al-Hasani and Bruchas 2011). All four are G-
protein coupled receptors and exert their influence on inhibitory G-proteins (Dhawan et al. 
1996). 
Mu opioid receptor agonists, such as morphine, act on the mu opioid receptor (MOR) to 
inhibit pain signaling (Matthes et al. 1996) but it has also been documented in human as well as 
non-human models that MOR agonists are associated with itch (Ko 2015; Liu et al. 2011; 
Sukhtankar and Ko 2013; Ding et al. 2015; Thomas et al. 1992). Numerous prior studies have 
investigated MOR and KOR signaling using pharmacology. For instance, mu-opioid receptor 
(MOR) agonists have been shown to cause itch that is reversible with mu antagonists (Ko and 
Naughton 2000). Furthermore, it has previously been shown that kappa opioid receptor (KOR) 
agonists, when given systemically, can also mitigate pruritus induced by MOR signaling (Somrat 
et al. 1999; Charuluxananan et al. 2003; Ben-David et al. 2002).  
However, the role of delta opioid receptors (DORs) and their peptides in the modulation 
of itch is less clear. Indeed, delta opioid signaling has been shown to be a promising target for 
the treatment of pain (Custodio-Patsey et al. 2020; Vicente-Sanchez et al. 2016; Abdallah and 
Gendron 2018; Wang et al. 2018). Given the precedence that other opioid receptors modulate 
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itch as well as pain transmission, the role of delta signaling in itch, in particular, warrants further 
investigation. 
Previously, it was found that DOR agonists do not cause itch, and, conversely, DOR 
antagonists do not reverse itch (Ko et al. 2003; Thomas et al. 1992). However, the inverse of 
these experiments have never been tested. Given that KOR agonists inhibit itch, whereas KOR 
antagonists exacerbate itch (Kardon et al. 2014), we tested whether DOR signaling may work in 
a similar manner. That is, we performed experiments to test whether a DOR antagonist 
(naltrindole) could evoke spontaneous itch and whether a DOR agonist (SNC-80) could suppress 
itch caused by a pruritogen (chloroquine). 
Appendix C.2 Methods 
Mice 
The studies were performed in both male and female mice 8-10 weeks of age. All animals 
were of the C57Bl/6 wild-type mice acquired from Charles River (Strain #027). Even numbers of 
male and female mice were used for all experiments. Mice were given food and water ad libitum 
and housed under standard laboratory conditions. The use of animals was approved by the 
Institutional Animal Care and Use Committee of the University of Pittsburgh. 
Pharmacologic agents used in mice 
Naltrindole (Sigma #111469-81-9), SNC-80 (Tocris #0764), and chloroquine diphosphate 
salt (Sigma) were dissolved in physiological saline immediately prior to administration.  
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Intradermal and intrathecal Injections 
For intradermal injection of chloroquine, hair was clipped from the neck or calf of each 
mouse at least 24 hours before the experiment. Chloroquine (100 μg in 10 μL) was administered 
into the nape of the neck or calf, which could be subsequently visualized by the formation of a 
small bubble under the skin. For intrathecal injections, hair was clipped from the back of each 
mouse at least 24 hours before the experiment. All intrathecal injections were delivered 
(naltrindole, 15 pmol; SNC-80, 500 pmol) in a total volume of 5 μL using a 30-gauge needle 
attached to a luer-tip 25 μL Hamilton syringe. The needle was inserted into the tissue at a 45° 
angle through the fifth intervertebral space (L5 – L6). Solution was injected at a rate of 1 μL/s. 
The needle was held in position for 10 seconds and removed slowly to avoid any outflow of the 
solution. Only mice that exhibited a reflexive flick of the tail following puncture of the dura were 
included in behavioral analysis. These procedures were performed in awake, restrained mice.  
All behavioral tests described below were performed in a blinded manner. 
Observation of scratching behavior  
Scratching behavior was observed using a previously reported method(Kardon et al. 
2014). Mice were individually placed in the observation cage (12 x 9 x 14 cm) to acclimate for 
30 minutes. The mice were assigned to dosing conditions in a randomized manner. Scratching 
behavior was videotaped for 60 minutes after administration of naltrindole. For assessment of 
SNC-80 inhibition of itch SNC-80 was intrathecally administered 20 minutes prior to the 
intradermal chloroquine injection. In these experiments, only scratch bouts directed to the nape 
of the neck were counted over 30 minutes. The total numbers of scratch bouts by the hind paws 
were binned every minute and tallied cumulatively. The latency to the first scratch and the total 
time spent scratching were also quantified.  
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RNAscope in situ hybridization  
Multiplex fluorescent in situ hybridization was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 um-thick fresh-
frozen sections containing the RVM were fixed in 4% paraformaldehyde, dehydrated, treated 
with protease for 15 minutes, and hybridized with gene-specific probes to mouse. Probes were 
used to detect Mm-Npy-C2 (#313321-C2), Mm-Penk-C1 (#318761), Mm-Slc32a1-C3 (#319191-
C3), Mm-Oprd1-C2 (#427371-C2) and Mm-Oprk1-C1 (#31611). DAPI (#320858) was used to 
visualize nuclei. 3-plex positive (#320881) and negative (#320871) control probes were tested. 
Three to four 16um z-stacked sections were quantified for a given mouse, and 3-4 mice were 
used per experiment. 
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in situ hybridization experiments, confocal images of tissue samples (3-4 
sections per mouse over 3-4 mice) were imagined and only cells whose nuclei were clearly 
visible by DAPI staining and exhibited fluorescent signal were counted.  
Statistical analysis 
All statistical analyses were performed using GraphPad Prism 8. Values are presented as 
mean ± SEM. P values were determined by tests indicated in applicable figure legends. Sample 
sizes were based on pilot data and are similar to those typically used in the field. 
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Appendix C.3 Results 
We found that a low dose of naltrindole compared to doses commonly used in the field 
(Scherrer et al. 2009) was sufficient to cause itch behaviors (Figure 1A-E). The effect of DOR 
antagonism caused itch that was sustained (Figure 1A, B-D), and also decreased animals’ 
latency to scratch following an intrathecal injection of naltrindole (15 pmol) compared to 
controls (Figure 1E). When we pre-treated animals with intradermal chloroquine, we found that 
DOR agonism with SNC-80 (500 pmol) reduced the total number of scratch bouts over 30 
minutes and increased animals’ latencies to scratch (Figure 2A, B). These effects were also 
confirmed to occur dose-dependently (Figure 3D-F). Consistent with previous work (Scherrer et 
al. 2009), we also found that DOR agonism suppressed capsaicin-induced mechanical 
hypersensitivity (Figure 3G). 
When we examined the overlap of Penk, encoding for proenkephalin, the endogenous 
peptide for the delta-opioid receptor, we founde extensive overlap with Npy, a population of 
inhibitory spinal neurons implicated in the inhibition of itch (Bourane et al. 2015). We also 
found that Oprd1, encoding for the delta-opioid receptor, overlapped with Oprk1, the kappa-
opioid receptor, which has also been implicated in modulating itch at the spinal level (Figure 4). 
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Appendix C Figure 1. Antagonism of DOR causes itch. 
A, Effect of naltrindole (15 pmol) on itch as a time course B, and shown as a heat map. C, The number of scratch 
bouts D, and time spent scratching summated over a 60 minute period. E, Effect of naltrindole on the latency to the 
first observed scratch bout. Asterisks indicate the results of a two-tailed, unpaired t-test. * p < 0.05, ** p < 0.01. N = 
7 mice per group, with dots representing individual mice. 
 
 
Appendix C Figure 2. Agonism of DOR suppresses itch. 
A, Effect of SNC-80 (500 pmol) on suppressing chloroquine-induced itch totaled over a 30 minute period B, and on 
the latency to the first observed scratch bout. Asterisks indicate the results of a two-tailed, unpaired t-test. * p < 




Appendix C Figure 3. Dose-response effects of DOR agonism and antagonism on itch and mechanical 
hypersensitivity.  
A, Effect of naltrindole on alloknesis, B, chloqoruine-induced itch, C, and spontaneous itch. D, Effect of SNC-80 on 
chloroquine-induced itch, E, the latency to the first observed scratch bout, F, alloknesis, G, and mechanical 




Appendix C Figure 4. RNAscope analysis of Penk and DOR. 
 A, neurons expressing Penk co-localize with Npy. B, Oprd1 overlaps with Oprk1. N = 2-4 mice, with dots 
representing individual mice. 
Appendix C.4 Discussion 
Much like the previously established roles for MOR and KOR in itch, these results with 
bidirectional modulation of DOR-expression neurons in the neuraxis suggest now that DOR 
signaling could also be important for gating itch. Our pharmacological studies reveal that delta 
agonists inhibit chemical and possible mechanical itch, whereas delta antagonists elicit 
spontaneous as well as chemical and mechanical-evoked itch. Based on our RNAscope analysis, 
we speculate that Npy neurons that co-release proenkephalin may inhibit itch through 
downstream neurons containing the delta-opioid receptor. Given the overlap with the kappa-
opioid receptor, these neurons may be situated to modulate both mechanical and chemical itch 
through both the delta and kappa-opioid receptors. 
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Appendix D Neurochemical characterization of KOR spinal neurons 
Appendix D.1 Introduction 
Our lab has previously identified the role for spinal dynorphin signaling in itch (Snyder et 
al. 2018; Ross et al. 2010; Kardon et al. 2014). Dynorphin is the precursor peptide for dynorphin, 
a kappa opioid receptor (KOR) agonist (Kardon et al. 2014). KOR agonists, such as nalfurafine, 
nalbuphine, and butorphanol, have also been used for the therapeutic treatment of various forms 
of itch in humans (Phan et al. 2012; Lawhorn et al. 1991; Cowan et al. 2015; Kumagai et al. 
2010). Despite the clear roles for both dynorphin and other KOR agonists in the management of 
itch, KOR spinal circuitry remains poorly understood.  
Appendix D.2 Methods 
RNAscope in situ hybridization  
Multiplex fluorescent in situ hybridization was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 um-thick fresh-
frozen sections containing the RVM were fixed in 4% paraformaldehyde, dehydrated, treated 
with protease for 15 minutes, and hybridized with mouse-gene-specific probes. Probes were used 
to detect Mm-Oprm1-C1 (#315841), Mm-Oprk1-C1 (#316111), Mm-Npy-C2 (#313321-C2), 
Mm-Pdyn-C2 (#318771-C2), Mm-Pvalb-C2 (#421931-C2), Mm-Nos1-C2 (#437651-C2), Mm-
Slc31a1-C3 (#319191), Mm-Slc17a6-C3 (#319171). DAPI (#320858) was used to visualize 
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nuclei. 3-plex positive (#320881) and negative (#320871) control probes were tested. Three to 
four 16um z-stacked sections were quantified for a given mouse. 
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in situ hybridization experiments, confocal images of tissue samples (3-4 
sections per mouse over 3-4 mice) were imagined and only cells whose nuclei were clearly 
visible by DAPI staining and exhibited fluorescent signal were counted.  
Appendix D.3 Results 
To begin to understand KOR circuitry, we sought to neurochemically characterize KOR 
(Oprk1-expressing) neurons in the dorsal horn. Using fluorescent in-situ hybridization, we found, 
surprisingly, that a majority of KOR neurons expressed Slc32a1, the gene encoding Vgat, 
indicating that they are inhibitory neurons (Figure 1A-D). Among the inhibitory subset, nearly a 
third of these neurons also contained Pdyn (dynorphin) (Figure 1B, D). Further characterization 





Appendix D Figure 1. RNAscope characterization of Oprk1 in the dorsal horn. 
(A) Relative proportions of Oprk1 neurons and their expression of Slc17a6 (Vglut2) and Slc31a1 (Vgat). (B) Among 
Oprk1+, Slc32a1+ neurons, the relative proportions of other markers of inhibitory spina neurons; Pvalb: 
parvalbumin, Nos1: nNos, Pdyn: dynorphin, Npy: NPY. (C) A representative image of overlap between Oprk1 and 
Slc32a1. Scale bar = 50 μm. (D) Relative expression of the various inhibitory markers and Oprk1. 
 
 
Appendix D Figure 2. Overlap between Oprk1 and Oprm1. 
(A) Representative image of staining for Oprk1 and Oprm1. Scale bar = 50 μm. (B) Quantification A. 
Appendix D.4 Discussion 
These intriguing findings suggest that the majority of KOR neurons in the dorsal horn are 
not glutamatergic, which casts doubt on prior models for how KOR signaling produces itch 
(Munanairi et al. 2018). Additionally, many KOR neurons co-expressed Pdyn, the peptide that 
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binds to KOR, suggesting a possible mechanism for auto-regulation. These data shed light on the 
complexity of itch spinal circuitry and further experimentation is necessary to better understand 
the role of KOR in itch. 
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Appendix E NK1R RVM neurons in modulation of itch 
Appendix E.1 Introduction 
Pharmacological manipulations of neurons in the RVM containing NK1R have suggested 
that these neurons may respond to substance P release from SP (tachykinin) neurons in the PAG 
(Lagraize et al. 2010)). Microinjection of substance P into the RVM has been shown to have pro-
nociceptive effects. Conversely, infusion of NK1R antagonists in the RVM has been found to 
inhibit thermal thresholds and attenuate hypersensitivity to heat and mechanical stimuli 
following inflammatory injury (Lagraize et al. 2010; Hamity, White, and Hammond 2010; 
Pacharinsak et al. 2008).  
Pharmacological ablation of NK1R RVM neurons reduces hyperalgesia in both acute and 
chronic pain models (S G Khasabov and Simone 2013). However, the contributions of these 
neurons to itch has not been examined. Recently, PAG Tac1 neurons were found to facilitate itch 
through an RVM-spinal pathway (Gao et al. 2019). Neurochemically, NK1R neurons comprise 
roughly 8% of neurons in the RVM and have been found to overlap with Gad67, suggesting that 
they may be inhibitory neurons (T. Chen et al. 2013). Furthermore, only the Gad67+, NK1R+ 
neurons are thought to be spinally projecting (T. Chen et al. 2013). This suggests there are at 
least two neurochemically distinct NK1R subtypes, and whether these distinct subpopulations are 
pro-nociceptive is unclear. Lastly, given the precedent that Tac1-PAG neurons participate in the 
facilitation of itch, we wanted to test the role of NK1R-CreER RVM neurons in itch behaviors. 
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Appendix E.2 Methods 
Mice 
NK1R-CreER mice used were generated as previously described (Huang et al. 2016). The 
studies were performed in both male and female mice 8-10 weeks of age. All animals were of the 
C57Bl/6 background. Even numbers of male and female mice were used for all experiments. 
Mice were given free access to food and water and housed under standard laboratory conditions. 
The use of animals was approved by the Institutional Animal Care and Use Committee of the 
University of Pittsburgh. 
Pharmacologic agents 
Clozapine-N-oxide (Tocris) was dissolved in PBS and administered intraperitoneally 
(5mg/kg) or IT (50ug/kg). In CNO treated mice, experiments were conducted 30 minutes 
following the administration of CNO. Chloroquine diphosphate salt (Sigma) was dissolved in 
physiological saline (100μg in 10μL) and administered intradermally. 
Intradermal and Intrathecal Injections 
For intradermal injection of chloroquine, hair was removed at least 24 hours before the 
experiment. Chloroquine (100μg in 10μL) was administered into the nape of the neck, which 
could be subsequently visualized by the formation of a small bubble under the skin. Injections 
were delivered in a total volume of 10 μL using a 30-gauge needle attached to a luer-tip 25 μL 
Hamilton syringe. These procedures were performed in awake mice. 
Stereotaxic injections 
Animals were anesthetized with 2% isoflurane and placed in a stereotaxic head frame. A 
drill bit (MA Ford, #87) was used to create a burr hole and custom-made metal needle (33 gauge) 
loaded with virus was subsequently inserted through the hole to the injection site. Virus was 
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infused at a rate of 100nL/min using a Hamilton syringe with a microsyringe pump (World 
Precision Instruments). Mice received 250-500 nL of virus. The injection needle was left in place 
for an additional 15 min and then slowly withdrawn over another 15 min. Injections were 
performed at the following coordinates for the RVM: AP -5.80 mm, ML 0.00 mm, DV -6.00. 
The incision was closed using Vetbond and animals were given ketofen (IP 10 mg/kg) and 
allowed to recover over a heat pad. Mice were given 4 weeks to recover prior to experimentation. 
Behavior 
All assays were performed in the Pittsburgh Phenotyping Core and scored by an 
experimenter blind to treatment (infection with Cre-dependent hM3Dq or the control, mCherry, 
virus). 
Observation of Scratching Behavior 
All tests were performed in a blinded manner. Scratching behavior was observed using a 
previously reported method (Kardon et al. 2014). On the testing day, the mice were individually 
placed in the observation cage (12x9x14 cm) to permit acclimation for 30 minutes. Spontaneous 
behavior was videotaped for 60 minutes following habituation, the total numbers of scratch bouts 
by the hind paws at various body sites were counted. Scratching behavior was videotaped for 30 
minutes after administration of chloroquine. The total numbers of scratch bouts by the hind paws 
directed at the site of injection (nape of the neck) during the first 30 minutes after chloroquine 
injection were counted.  
Hargreaves testing 
Animals were acclimated on a glass plate held at 30°C (Model 390 Series 8, IITC Life 
Science Inc.). A radiant heat source was applied to the hindpaw and latency to paw withdrawal 
was recorded (Hargreaves et al. 1988). 2 trials were conducted on each paw, with at least 5 min 
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between testing the opposite paw and at least 10 min between testing the same paw. To avoid 
tissue damage, a cut off latency of 20 sec was set. Values from both paws were averaged to 
determine withdrawal latency. 
Von Frey testing 
Mechanical sensitivity was measured using the Chaplan up-down method of the von Frey 
test (Chaplan et al. 1994). Calibrated von Frey filaments (North Coast Medical Inc.) were 
applied to the plantar surface of the hindpaw. Lifting, shaking, and licking were scored as 
positive responses to von Frey stimulation. Average responses were obtained from each 
hindpaw, with 3 min between trials on opposite paws, and 5 min between trials on the same paw. 
RNAscope in situ hybridization 
Multiplex fluorescent in situ hybridization was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 16 um-thick fresh-
frozen sections containing the RVM were fixed in 4% paraformaldehyde, dehydrated, treated 
with protease for 15 minutes, and hybridized with gene-specific probes to mouse. Probes were 
used to detect Mm-TacR1-C1 (#428781) and Mm-Slc32a1-C3 (#319191). DAPI (#320858) was 
used to visualize nuclei. 3-plex positive (#320881) and negative (#320871) control probes were 
tested. Three to four z-stacked sections were quantified for a given mouse, and 3-4 mice were 
used per experiment. 
Immunohistochemistry 
Mice were anesthetized with an intraperitoneal injection of urethane, transcardially 
perfused, and post-fixed at least four hours in 4% paraformaldehyde. 40um and 25um thick 
RVM and spinal cord sections were collected on a cryostat and slide-mounted for 
immunohistochemistry. Sections were blocked at room temperature for two hours in a 5% 
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donkey serum, 0.2% triton, in phosphate buffered saline. Primary antisera was incubated for 14 
hours overnight at 4°C: rabbit anti-RFP (1:1K). Sections were subsequently washed three times 
for 20 minutes in wash buffer (0.2% triton, in PBS) and incubated in secondary antibodies (Life 
Technologies, 1:500) at room temperature for two hours. Sections were then incubated in 
Hoechst (ThermoFisher, 1:10K) for 1 minute and washed 3 times for 15 minutes in wash buffer, 
mounted and cover slipped. 
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x or 10x objectives. All images were quantified and analyzed 
using ImageJ. To quantify images in RNAscope in situ hybridization experiments, images of 
tissue samples (3-4 sections per mouse over 3 mice) were imaged and only cells whose nuclei 
were clearly visible by DAPI staining and exhibited fluorescent signal were counted. 
Statistical analysis 
All statistical analyses were performed using GraphPad Prism 8. Values are presented as 
mean +/- SEM. Statistical significance was assessed using a two-way, repeated measures 
ANOVA with Bonferroni’s correction. Significance was indicated by p < 0.05. Sample sizes 
were based on pilot data and are similar to those typically used in the field. 
Appendix E.3 Results 
 Using fluorescent in situ hybridization, we found that 75.6 +/- 4.9 of Tacr1-expressing 
neurons co-expressed Slc32a1, the gene for Vgat, indicating that a majority of NK1R neurons are 
GABAergic, and thus, inhibitory. Following viral infection with the Cre-dependent DREADD 
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(AAV2.hSyn.DIO.hM3Dq.mCherry), we chemogenetically activated NK1R-CreER neurons and 
tested mice for pain and itch-related behaviors. In mice receiving the hM3Dq DREADD virus, 
chemogenetic activation using CNO significantly reduced chloroquine evoked scratch bouts 
(Figure 1A) and spontaneous scratching behavior (Figure 1B), and also significantly reduced 
the von Frey mechanical withdrawal threshold (Figure 1C) with no effect on thermal withdrawal 
latency (Figure 1D). CNO had no effect in the control mice. We also observed mCherry 
expression in the RVM of virally-injected neurons (Figure 1E) and their descending innervation 




Appendix E Figure 1. Chemogenetic activation of RVM NK-1R expressing neurons inhibits itch related 
behavior.  
(A) CNO administration significantly reduced chloroquine evoked scratch bouts in DREADDs but not control 
vector mice (n = 5-7 males, 5-7 females). (B) CNO reduced spontaneous scratching in mice receiving DREADDs ( n 
= 5  males, 5 females). (C) CNO administration significantly reduced mechanical withdrawal thresholds in 
DREADDs but not control vector mice (n = 5-7 males, 5-7 females).  (D) CNO did not affect thermal withdrawal 
latency in any group (n = 5-7 males, 5-7 females). (E) mCherry expression (red) was robust at the site of injection in 





Appendix E.4 Discussion 
Previous work has established a possible pronociceptive role for substance P on NK1R-
RVM neurons (S G Khasabov and Simone 2013), and their descending spinal input has 
previously been identified (T. Chen et al. 2013).  We establish for the first time that activation of 
NK1R-RVM neurons inhibits spontaneous grooming and pruritogen-evoked itch. In this study, 
we also found that chemogenetic activation of NK1R-expressing RVM neurons facilitates 
mechanical nociception, consistent with previous work. However, we found that activation of 
these neurons had no effect on thermal nociception. Our results support the idea that NK1R-
RVM neurons modulate both itch and mechanical, but not heat pain. Nevertheless, whether these 
neurons are preferentially tuned to modulate pain or itch warrants further investigation. 
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Appendix F Neurons in the PAG expressing the mu-opioid receptor 
Appendix F.1 Introduction 
Supraspinal structures including the midbrain periaqueductal gray (PAG) represent 
highly organized anatomical systems for the inhibition and facilitation of pain. The PAG has 
been shown to modulate pain behaviors through a descending pathway involving the rostral 
ventromedial medulla (RVM) and spinal cord and is also a major component of the endogenous 
opioid analgesic system (Basbaum and Fields 1978).  
Pharmacological manipulations of the PAG have provided critical insight into the types 
of receptors that participate in the descending modulation of pain. For example, the injection of 
an mu-opioid receptor (MOR) agonist into the PAG results in elevation of sensory thresholds and 
analgesia (Lewis and Gebhart 1977; Carstens et al. 1990; Loyd, Wang, and Murphy 2008; Loyd, 
Morgan, and Murphy 2008; Yaksh 1997). Local microinjections of the mu-antagonist, naloxone, 
into the PAG or lesioning of the PAG have blocked the analgesic effects of systemic morphine 
(Vigouret et al. 1973; Tsou and Jang 1964; Zhang et al. 1998; Loyd, Wang, and Murphy 2008), 
underscoring the role of the PAG as a crucial site of action for the analgesic effects of 
systemically-administered opioids.  
Despite the clear role for opioidergic signaling within the PAG, the molecular and 
anatomical characterizations of neurons containing the mu-opioid receptor remain elusive. It has 
been proposed that inhibitory cells within the PAG express the mu-opioid receptor (Vaughan et 
al. 1997; Osborne et al. 1996), which implies that mu agonists may produce analgesia through 
the disinhibition of PAG output (Vaughan et al. 1997; Budai and Fields 1998; Heinricher et al. 
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2009). In support of this model, MOR-expressing PAG neurons have also been shown through 
immunohistochemistry to comprise a subset of GABAergic neurons, but do not appear to be 
those that project to the RVM (Commons et al. 2000; Reichling and Basbaum 1990; Kalyuzhny 
and Wessendorf 1998). Nevertheless, PAG neurons containing the mu-opioid receptor comprise 
over half of RVM-projecting cells (Commons et al. 2000), and these neurons are also presumed 
to be GABAergic. Presently, the effects of opioid microinjections within the PAG are thought to 
induce analgesia through inhibition of both local interneurons within the PAG as well as the 
inhibition of RVM-projecting PAG neurons. Thus, although there have been considerable 
advances to the understanding of opioidergic circuits in the PAG, how the direct manipulation of 
these circuits affects distinct somatosensory modalities warrants further investigation. The 
expansion of cell type-specific drivers, fluorescent tracers, and behavioral paradigms may now 
permit the detailed understanding of molecularly-defined PAG neurons and ascertain their 
precise contributions to somatosensation. 
Using combinatorial anatomical, optogenetic, and chemogenetic approaches, we 
delineate a supraspinal pathway for the modulation of pain and itch behaviors. We found that 
optogenetic activation of PBN projections to the PAG inhibits response to noxious thermal 
stimuli and activation of PAG-MOR afferents in the RVM facilitates jumping on the hotplate 
assay. Chemogenetic manipulations of PAG-MOR neurons unveiled surprising results; whereas 
activation of these neurons facilitated responses to noxious stimuli and jumping behaviors on the 
hotplate assay, opposing patterns were observed with respect to reflexive responses to sensory 
testing. These dichotomous findings across distinct types of sensory testing emphasize the 
contextual behavioral expression of nociception using reflexive and noxious paradigms. Lastly, 
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we uncovered the role for PBN projections in the PAG that modulate pain in an uninjured, post-
surgical state of latent sensitization. 
Appendix F.2 Methods 
Mice 
All animals were of the C57BL/6J background. The studies were performed in both male 
and female mice 8-10 weeks of age. Even numbers of male and female mice were used for all 
experiments and no clear sex differences were observed so data were pooled. Mice were given 
free access to food and water and housed under standard laboratory conditions. The use of 
animals was approved by the Institutional Animal Care and Use Committee of the University of 
Pittsburgh.  
Viral vectors 
All viruses are commercially available from UNC Vector Core and Addgene. 
AAV2.hSyn.DIO.hM4D(Gi)-mCherry, AAV2-hsyn-DIO-mCherry, AAV2-hsyn-DIO-
hM3D(Gq)-mCherry, AAV2/EF1a-DIO-hChR2(H134R)-eYFP, AAV2.EF1a.DIO.eYFP, 
pENN.AAV.hSyn.HI.eGFP-Cre.WPRE.SV40, and AAVr-hsyn-DIO-mCherry. 
Stereotaxic injections and optical fiber implantation 
Animals were anesthetized with 2% isoflurane and placed in a stereotaxic head frame. A 
drill bit (MA Ford, #87) was used to create a burr hole and a custom-made metal needle (33 
gauge) loaded with virus was subsequently inserted through the hole to the injection site. Virus 
was infused at a rate of 100 nL/min using a Hamilton syringe with a microsyringe pump (World 
Precision Instruments). Mice received 250-500 nL of virus. The injection needle was left in place 
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for an additional 5 min and then slowly withdrawn over another 5 min. Injections and cannula 
implantations were performed at the following coordinates for each brain region: RVM: AP -
5.80 mm, ML 0.00 mm, DV -6.00, PAG: AP -4.70 mm, ML ± 0.74 mm, DV: -2.75 at a 4° angle, 
and PBN: AP -5.11 mm, ML ± 1.25 mm, DV: -3.25. For implantation of optical fibers (Thor 
Labs: 1.25 mm ceramic ferrule 230 mm diameter), implants were slowly lowered 0.3 - 0.5 mm 
above the site of injection and secured to the skull with a thin layer of Vetbond (3M) and dental 
cement. The incision was closed using Vetbond, and animals were provided analgesics (ketofen, 
i.p. 10 mg/kg; buprenorphine, subcutaneous, 0.3mg/kg) and allowed to recover over a heat pad. 
Mice were given 4 weeks to recover prior to experimentation. 
Pharmacologic agents 
Clozapine-N-oxide (Tocris) was dissolved in PBS and administered intraperitoneally (5 
mg/kg). Capsaicin (0.1%) in 10% EtOH in PBS was injected 10 μL into the plantar hindpaw. 
Chloroquine diphosphate salt (Sigma) was dissolved in physiological saline (100 μg in 10 μL) 
and administered intradermally. Formalin (Sigma; 2% w/v) in saline was injected 10 μL into the 
plantar hindpaw. 
RNAscope in situ hybridization  
Multiplex fluorescent in situ hybridization (FISH) was performed according to the 
manufacturer’s instructions (Advanced Cell Diagnostics #320850). Briefly, 14 um-thick fresh-
frozen sections containing the RVM were fixed in 4% paraformaldehyde, dehydrated, treated 
with protease for 15 min, and hybridized with gene-specific probes to mouse. Probes were used 
to detect eYFP, Th, tdTomato-C2 (#317041-C2), mCherry-C2 (#431201), Mm-Oprm1-C1 
(#315841), Mm-Tac1-C1 (#517971), Mm-Tph2-C2 (#318691-C2), Mm-Fos-C3 (#498401-C3), 
Mm-Pdyn-C2 (#31877), Mm-Slc32a1-C3 (#319191), and Mm-Slc17a6-C3 (#319171). DAPI 
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(#320858) was used to visualize nuclei. 3-plex positive (#320881) and negative (#320871) 
control probes were tested. Three to four z-stacked sections were quantified for a given mouse, 
and 3-4 mice were used per experiment. 
Immunohistochemistry 
Mice were anesthetized with an intraperitoneal injection of urethane, transcardially 
perfused, and post-fixed at least 4 h in 4% paraformaldehyde. 40 μm and 25 μm thick brain 
sections were collected on a cryostat and slide-mounted for immunohistochemistry. Sections 
were blocked at room temperature for 2 h in a 5% donkey serum, 0.2% triton, in phosphate 
buffered saline. Primary antisera was incubated for 14 h overnight at 4° C: rabbit anti-RFP 
(1:1K), chicken anti-GFP (1:1K), and mouse anti-NeuN (1:500). Sections were subsequently 
washed three times for 20 min in wash buffer (0.2% triton, in PBS) and incubated in secondary 
antibodies (Life Technologies, 1:500) at room temperature for 2 h. Sections were then incubated 
in Hoechst (ThermoFisher, 1:10K) for 1 min and washed 3 times for 15 min in wash buffer, 
mounted and cover slipped.  
Fos experiments 
Mice received either optical stimulation or CNO as described for behavioral testing. 
Brain tissues were harvested 90 min after for immunohistochemistry. For optogenetically-
induced fos expression, mice were photostimulated for 20 minutes at a 3 s on, 2 s off stimulation 
pattern and subsequently perfused 90 minutes after the initial onset of photostimulation as noted 
for immunohistochemistry. 
Image acquisition and quantification 
Full-tissue thickness sections were imaged using either an Olympus BX53 fluorescent 
microscope with UPlanSApo 4x, 10x, or 20x objectives or a Nikon A1R confocal microscope 
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with 20X or 60X objectives. All images were quantified and analyzed using ImageJ. To quantify 
images in RNAscope in situ hybridization experiments, confocal images of tissue samples (3-4 
sections per mouse over 3-4 mice) were imaged and only cells whose nuclei were clearly visible 
by DAPI staining and exhibited fluorescent signal were counted.  
Behavior 
All assays were performed in the Pittsburgh Phenotyping Core and scored by an 
experimenter blind to treatment. For all chemogenetic behavioral experiments, CNO was 
administered (5 mg/kg IP) 30 minutes prior to the start of behavioral testing. Mice that were 
optogenetically tested were photostimulated with the following parameters: 10 mW laser power,  
20Hz stimulation frequency, and 5ms pulse duration. 
Observation of scratching behavior  
Scratching behavior was observed using a previously reported method (Kardon et al. 
2014). On the testing day, the mice were individually placed in the observation cage (12x9x14 
cm) to permit acclimation for 30 min. Scratching behavior was videotaped for 30 min after 
administration of chloroquine. The temporal and total numbers of scratch bouts by the hind paws 
at various body sites during this period were counted. For the experiments targeting the lumbar 
spinal cord, the amount of time spent biting following intradermal chloroquine was summated. 
Hargreaves testing 
Animals were acclimated on a glass plate held at 30°C (Model 390 Series 8, IITC Life 
Science Inc.). A radiant heat source was applied to the hindpaw and latency to paw withdrawal 
was recorded (Hargreaves et al. 1988). Two trials were conducted on each paw, with at least 5 
min between testing the opposite paw and at least 10 min between testing the same paw. To 
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avoid tissue damage, a cut off latency of 20 sec was set. Values from both paws were averaged to 
determine withdrawal latency.  
Tail-flick assay 
Mice were placed in custom-made mouse restraints and allowed to habituate 15 minutes 
before testing. Tails were immersed 3 cm into a water bath at 48° and 55° C, and the latency to 
tail-flick was measured three times with a 1 min interval between trials. For optogenetic testing, 
mice were photostimulated for 10 s prior to testing. Cut-offs times were implemented at 25 s 
(48°) and 5 s (55°C) to prevent tissue damage. 
Hotplate 
Mice were placed on a 55°C hotplate, and the latency to first nocifensive response (jump) 
and total number of jumps were measured over a 60 s period. Values were averaged across two 
trials for each mouse spaced several minutes apart. For optogenetic testing, mice were 
photostimulated for 10 s prior to testing. 
Openfield 
Spontaneous activity in the open field was conducted over 30 min in an automated 
Versamax Legacy open field apparatus for mice (Omnitech Electronics Incorporated, Columbus, 
OH). Distance traveled was measured by infrared photobeams located around the perimeter of 
the arenas interfaced to a computer running Fusion v.6 for Versamax software (Omnitech 
Electronics Incorporated) which monitored the location and activity of the mouse during testing. 
Activity plots were generated using the Fusion Locomotor Activity Plotter analyses module 




Acute injury models 
For formalin-induced injury, 10 μL of 2% formalin was injected into the intraplantar 
hindpaw. Mice were video recorded for 1 hr after formalin injection and time spent licking and 
lifting the paw was scored in 5-min bins. For capsaicin-induced injury, animals received 10 μL 
of intraplantar capsaicin (0.1% w/v in 10% ethanol diluted in saline) and the total time spent 
licking the injured paw was quantified over 20 minutes. Hargreaves and von Frey testing 
following capsaicin-induced injury occurred 20 min and 1 h after intraplantar injection. 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 8. Values are presented as 
mean +/- SEM. Statistical significance was assessed using tests indicated in applicable figure 
legends. Significance was indicated by p < 0.05. Sample sizes were based on pilot data and are 
similar to those typically used in the field. 
Appendix F.3 Results 
Activation of a descending circuit inhibits nociception 
Midbrain and brainstem structures, centered upon the PAG, have been shown to modulate 
nociception. In particular, we focused on inputs to the PAG from the PBN, which has been 
extensively documented in relaying nociceptive information from the spinal cord to supraspinal 
targets. The PBN has also been shown to engage descending pain modulatory systems (Lapirot et 
al. 2009; Roeder et al. 2016). Given the role of the PBN in integrating nociceptive information 
from the spinal cord, we sought to determine whether it could directly modulate nociception 
through a descending pathway. Consistent with previous reports, when we injected the retrograde 
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tracer, cholera toxin B (CTB) into the PAG, we identified extensive labeling of cell bodies 
within the PBN, highlighting that PBN neurons directly project to the PAG (Figure 1A). To 
follow up on this observation, we sought to neurochemically characterize PBN neurons that 
project to the PAG using a combination of retrograde tracing and multiplex fluorescent in situ 
hybridization (FISH). We injected AAVretro-hSyn-eGFP into the PAG of wild type mice and 
subsequently stained PBN sections containing eYFP and analyzed their expression of known 
markers of PBN populations that have previously been implicated in modulating pain behaviors 
including Tac1, Pdyn, and Penk. We identified that among the PBN neurons that project to the 
PAG, there was considerable overlap with Tac1 (19.4+/-3.5), but minimal overlap with Pdyn 
(1.6+/-1.6) and Penk (1.8+/-1.4) (Figure 1B).  
We next functionally assessed the role of PBN projections within the PAG using 
optogenetics. We introduced AAV2-EF1a-DIO-hChR2-eYFP into the PBN and implanted 
optical fibers within the PAG to directly stimulate PBN projections within the PAG (Figure 1C). 
Consistent with our previous findings, photostimulation of this pathway robustly inhibited 
reflexive responses in the tail flick assay (Figure 1D). This observation supports the role of the 
PBN in the central modulation of pain through a direct connection to the PAG. 
Direct projections by the PAG to the spinal cord are sparse (Basbaum and Fields 1979), 
but, instead, the PAG modulates nociception through projections to the RVM, which is generally 
considered the primary output of the pain-modulation system (Prieto, Cannon, and Liebeskind 
1983; Basbaum and Fields 1979; Gebhart 1982). Therefore, we then assessed the functional 
connection between the PAG and RVM using the same optogenetic approach in MOR-Cre mice. 
The optogenetic activation of PAG-MOR fibers in the RVM resulted in the robust induction of 
fos-expressing neurons in animals receiving channelrhodopsin compared to controls (Figure 1E). 
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Behaviorally, photostimulation of PAG-MOR fibers within the RVM resulted in heightened 
jumping responses on the hotplate test (Figure 1F). 
Molecular and anatomical characterization of PAG-MOR neurons 
Immunohistochemical and combined electrophysiological and pharmacological studies 
have highlighted the existence of neurons containing the mu-opioid receptor within the PAG 
[36,37,49,50]. For instance, microinjections of mu agonists such as morphine [51] and DAMGO 
[52] into the RVM inhibits withdrawal reflexes to noxious heat [51] and acts directly on PAG 
neurons containing the mu-opioid receptor. 
The circuitry and molecular identities of mu-sensitive PAG neurons remains unclear. 
Although it is thought that morphine may inhibit local GABAergic PAG neurons containing the 
mu-opioid receptor to mediate anti-nociception [50], a significant number of PAG neurons 
immunoreactive for the mu-opioid receptor have been shown to project directly to the RVM 
[36]. Furthermore, it also remains unknown whether these opioid-sensitive neurons comprise 
glutamatergic or GABAergic subpopulations of PAG neurons. We performed tracing analysis of 
PAG-MOR neurons using a Cre-dependent fluorescent reporter (Figure 2A). We identified 
projection targets in numerous structures throughout the forebrain and brainstem such as the 
anterior hypothalamus, ventral tegmental area, and RVM (Figure 2A). Given the important role 
of the PAG in the descending modulation of pain and its significant projections to the RVM, we 
focused on this particular pathway (Figure 2B). When we stained Oprm1-expressing neurons in 
the PAG, we found that these neurons extensively overlapped with both Slc32a1 (Vgat) and 
Slc17a6 (Vglut2) (Figure 2C). This observation supports the idea that PAG-MOR neurons 
comprise a heterogeneous population and that the glutamatergic and GABAergic subpopulations 
may contribute distinct roles in nociception. To characterize PAG-MOR neurons projecting to 
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the RVM, we injected complementary Cre-dependent and Cre-independent retrograde tracers in 
the RVM of MOR-Cre and wild type mice, respectively (Figure 2D). We then used FISH to 
characterize back labeled neurons in the PAG. In contrast to Oprm1 neurons within the PAG that 
expressed either Slc32a1 or Slc17a6, PAG-MOR neurons that project to the RVM were found to 
be exclusively glutamatergic by their expression of Slc17a6 and limited expression of Slc32a1 
(Figure 2E). On the basis of these findings, we propose that inhibitory PAG-MOR neurons may 
participate in the modulation of local circuitry within the PAG whereas excitatory PAG-MOR 
neurons project to other structures including the RVM (Figure 2F). 
PAG-MOR neurons modulate complex somatosensory behaviors 
Given the dramatic effects of pharmacological application of mu agonists within the 
PAG, we sought to test the contributions of PAG-MOR neurons directly. We used a 
chemogenetic approach to activate and inhibit PAG-MOR neurons by injection of 
AAV2.hSyn.DIO.hM3Dq-mCherry and AAV2.hSyn.DIO.hM4Di-mCherry, respectively, into 
the PAG of MOR-Cre mice. As a validation of these chemogenetic actuators, the chemogenetic 
activation of PAG-MOR neurons resulted in the induction of fos expression in the PAG (Figure 
3A). Consistent with our optogenetic activation of the population, the chemogenetic activation of 
PAG-MOR neurons also activated neurons in the RVM, as determined by fos expression (Figure 
3B). Neither activation nor inhibition of PAG-MOR neurons affected locomotor activity in an 
open field assay (Figure 3C), suggesting that the manipulation of these neurons does not 
influence locomotion. To examine the contribution of PAG-MOR neurons to nocifensive 
behaviors, we tested mice in several noxious pain assays, including hotplate (55 C) and injury 
models using intraplantar formalin and capsaicin. On the hotplate assay, the chemogenetic 
activation of PAG-MOR neurons facilitated jumping in naive animals (Figure 3D) and 
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chemogenetic inhibition attenuated jumping in capsaicin-injured animals (Figure 3E). However, 
neither chemogenetic activation nor inhibition influenced licking behaviors in an acute 
capsaicin-induced injury model (using 0.1% w/v capsaicin dissolved in 10% ethanol and saline) 
(Figure 3F). To assess the contribution of PAG-MOR neurons to a more persistent injury model, 
we injected mice with intraplantar formalin (2% w/v in saline) and quantified their licking 
behaviors targeted to the injured paw. We found that activation of PAG-MOR neurons modestly 
enhanced cumulative licking responses over the second phase of the formalin assay, although 
this trend was not found to be statistically significant (Figure 3H). In contrast, the inhibition of 
PAG-MOR neurons inclined toward a reduction in formalin-induced licking, yet this was also 
not found to be statistically significant. Together, our chemogenetic manipulations of PAG-MOR 
neurons robustly modulated jumping behaviors on a noxious hotplate, but did not significantly 
affect licking responses in acute injury models. 
Upon assessment of reflexive nociceptive behaviors, the chemogenetic manipulations of 
PAG-MOR neurons revealed striking complexity in contrast to the behaviors observed on the 
hotplate assay and with formalin and capsaicin-induced licking. For example, with intradermal 
injection of chloroquine into the nape of the neck, chemogenetic activation of PAG-MOR 
neurons with CNO robustly attenuated scratching responses compared to baseline (Figure 4A). 
In the von frey assay, chemogenetic activation and inhibition of PAG-MOR neurons 
bidirectionally modulated mechanical thresholds (Figure 4B). In both the von Frey and 
Hargreaves assays, activation of PAG-MOR neurons consistently inhibited thresholds (Figure 
4B, C), in contrast to its facilitation of responses to noxious stimuli, such as hotplate (Figure 3D). 
However, tail flick responses were not affected by either chemogenetic activation or inhibition of 
PAG-MOR neurons (Figure 4D, E). Curiously, for assays involving noxious stimulation, 
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activation of PAG-MOR neurons generally facilitated nocifensive responses (such as licking and 
jumping), however for reflexive nociceptive assays such as the von frey and Hargreaves test, 
chemogenetic excitation inhibited responses. The activation of PAG-MOR neurons also robustly 
attenuated chloroquine-induced scratching, representing a divergence from its facilitation of 
licking responses following capsaicin and formalin-induced injury.  
Modulation of latent sensitization by a brainstem circuit 
Endogenous opioid signaling has been shown to mask the behavioral expression of pain 
in a variety of chronic and inflammatory models of pain in a process known as latent 
sensitization of pain (Le Roy et al. 2011; Li, Angst, and Clark 2001; Corder et al. 2013). 
Following a noxious injury, animals exhibit a hyperalgesic state that is later masked by the 
upregulation of opioid signaling (Taylor and Corder 2014). However, the masking of 
hyperalgesia has been shown to be reversed following the application of opioid receptor 
antagonists, such as naloxone (Corder et al. 2013). We sought to test the contribution of the PAG 
in the latent sensitization of pain (Figure 5A). Consistent with previous findings, we established 
that the systemic administration of naloxone (10 mg/kg IP) in naive animals did not affect 
jumping behaviors (either latency to jump or total jumps) on the hotplate assay compared to 
saline (Figure B). In our optogenetic experiments, however, the administration of naloxone 
facilitated jumping behaviors in control mice compared to baseline (Figure 5C). Naloxone 
decreased control animals’ latency to jump and increased their total jumping behaviors (Figure 
5C). However, optogenetic photostimulation of PBN fibers within the PAG blocks the 
hyperalgesic effects of naloxone and results in the elevation of latencies to jump and reduces 
total jumps on the hotplate test (Figure 5C). The robust effects of naloxone in control animals in 
the absence of a prior injury (beyond the intracranial viral injection and implant) highlight the 
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role of compensatory endogenous opioids mechanisms that are engaged following cranial 
surgery. The striking attenuation of latent sensitization by optical stimulation of PBN terminals 
within the PAG suggests that this particular circuit is important for the modulation of opioidergic 




Appendix F Figure 1. A polysynaptic brainstem circuit for descending modulation 
Stereotaxic delivery of CTB in the PAG and back labeled cell bodies in the PBN. Representative images are shown. 
Scale bars = 50 um. 
Characterization of PBN neurons that project to the PAG using a retrogradely-labeled reporter (AAVr-eYFP) and 
FISH. Representative images are shown. Percentages of eYFP-expressing PBN neurons expressing Tac1 (19.4+/-
3.5), Pdyn (1.6+/-1.6), and Penk (1.8+/-1.4) and their relative overlap are shown. Data are mean + SEM with dots 
representing 5-8 PBN sections from 2-3 mice. Scale bars = 
Strategy to optogenetically activate PBN projections within the PAG. Scale bars = 200 um. 
The effect of optogenetically activating PBN projections to the PAG on the tail-flick assay at 48 C and 55 C. Data 
are mean + SEM with dots representing individual mice (n=7 control, n=9 ChR2 mice). P values indicate the results 
of 2-way repeated measures ANOVA with Holm-Sidak’s multiple comparisons test. 
Approach to optogenetically activate PAG projections within the RVM. The activation of this pathway induces the 
expression of fos in the RVM. Data are mean + SEM with dots representing individual mice (3 sections are averaged 
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for each animal). P value represents the result of two-tailed, unpaired t-test. Representative images from control and 
ChR2 mice. Scale bars = 200 um. 
The effect of optogenetic activation of PAG projections in the RVM on jumping behaviors on the hotplate assay 
(total jumps and latency to jump). Data are mean + SEM with dots representing individual mice. P value represents 




Appendix F Figure 2. Molecular and anatomic characterization of MOR neurons in the PAG. 
(A) Approach to visualize projections from PAG-MOR neurons using Cre-dependent tracers introduced into the 
PAG. Major downstream targets of PAG-MOR neurons throughout the brain and brainstem. Representative images 
are shown. Re: reuniens thalamic nucleus, BSTMPL: bed nucleus stria terminalis, medial posterolateral, PV: 
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paraventricular thalamic nucleus, CM: centromedial thalamic nucleus, Spfpc: subparafascicular thalamus, REth: 
retroethmoid intramedullar thalamic area, PR: prerubral thalamic area, RVM: rostral ventromedial medulla, AHA: 
anterior hypothalamic area, LA: lateroanterior nuclei, Bar: Barrington’s nucleus, Irt: intermediate reticular nucleus, 
LPGi: lateral paragigantocellular nucleus, VTA: ventral tegmental area, RRF: retrorubral field. Scale bar = 100 um. 
(B) Cartoon representation of PAG-MOR ascending and descending projections throughout the brain. 
(C) FISH characterization of Oprm1 PAG neurons with respect to excitatory (Slc17a6) and inhibitory (Slc32a1) 
markers. Scale bars = 100 um.  
(D) Cartoon depiction of two complementary approaches used to characterize descending projections of PAG-MOR 
neurons to the RVM. Retrograde tracers are introduced into the RVM of MOR-Cre or WT mice and labeled cell 
bodies in the PAG are characterized (using Oprm1, Slc17a6, and Slc32a1) using FISH. Representative images of 
PAG sections are shown. Scale bar = 50 um. 
(E) Quantification of (D). Data are mean + SEM with dots representing individual mice (n=3 mice, with an average 
of 3-4 sections per mouse). 
(F) Model for how divergent excitatory and inhibitory PAG neurons containing the mu-opioid receptor (MOR) 





Appendix F Figure 3. PAG-MOR neurons modulate nocifensive behaviors. 
(A) Approach to chemogenetically activate and inhibit PAG-MOR neurons involving the injection of Cre-dependent 
hM3Dq and hM4Di, respectively to the PAG. A representative image is shown. Scale bar = 50 um. 
(B) Induction of fos expression within the RVM following chemogenetic manipulation of PAG-MOR neurons. 
Representative images of RVM sections are shown. Scale bar = 50 um. Comparison of fos expression in the RVM. 
Data are mean + SEM with dots representing individual mice (n=7-8 mice per group, averaging 4 sections per 
mouse). P values indicate the results of one-way ANOVA with Dunnett’s multiple corrections test. 
(C-F) Effect of chemogenetic activation and inhibition on the (C) openfield, (D-E) hotplate test (D) without and (E) 
with capsaicin-induced injury, and (F) nocifensive licking behaviors following intraplantar capsaicin-induced injury. 
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Data are mean + SEM with dots representing individual mice (Control: 6-11, hM3Dq: 7-13, and hM4Di: 7-11 mice 
per group). P values indicate the results of one-way ANOVA with Dunnett’s multiple corrections test. 
(G-H) Effect of chemogenetic manipulations of PAG-MOR neurons on licking responses following intraplantar 
formalin. (G) Time course of licking responses binned every 5 min over 1 h. Data are (G) mean +/- SEM and (H) 
mean + SEM with dots representing individual mice (n=11-13 mice per group. P values indicate the results of one-




Appendix F Figure 4. PAG-MOR neurons modulate itch and reflexive pain behaviors. 
(A-E) Effect of chemogenetic manipulations of PAG-MOR neurons on (A) chloroquine-induced itch, (B) von Frey 
assay, (C) Hargreaves assay, and (D-E) tail flick assay at (D) 48 C (E) and 55 C. Data are mean + SEM with dots 
representing individual mice (Control: 6-7, hM3Dq: 8-9, and hM4Di: 7-8 mice per group). P values indicate the 




Appendix F Figure 5. Latent sensitization of pain is modulated by a PBN → PAG pathway 
(A) Model for compensatory endogenous opioid signaling between the PBN and PAG following injury. 
(B) Jumping behaviors among naive animals receiving saline or naloxone. Latency to jump and total jumps on a 
hotplate were quantified. Data are mean + SEM with dots representing individual mice (n=10 mice per group). P 
values indicate the results of two-tailed unpaired t-test. 
(C-D) Effect of optogenetic stimulation of PBN projections in the PAG in the presence of naloxone on hotplate 
jumping behaviors including (C) latency to jump and (D) total jumps. Data are mean + SEM with dots representing 
individual mice (n=7-9 mice per group). P values indicate the results of two-way repeated measures ANOVA with 
Holm-Sidak’s multiple comparisons test. 
Appendix F.4 Discussion 
It has recently been shown that the PAG contains at least two classes of neurons that 
divergently modulate nociception. In addition to their differences in sensitivity to 
pharmacological agents (Moreau and Fields 1986; Carstens, Stelzer, and Zimmermann 1988; 
Behbehani et al. 1990), PAG neurons can also be distinguished by their transmitter. GABAergic 
(Vgat), or inhibitory, neurons are thought to be pain facilitating, whereas glutamatergic (Vglut2), 
or excitatory, neurons are thought to be anti-nociceptive (Samineni et al. 2019, 2017; Aimone 
and Gebhart 1986; M. Jiang and Behbehani 2001). Interestingly, PAG neurons have recently 
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been shown to exhibit modality-specificity and are differentially engaged to modulate pain and 
itch (Samineni et al. 2019).  
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